

(A free translation of the original in Portuguese)

# **Raia Drogasil S.A.**

**Quarterly Information (ITR) at**

**June 30, 2021**

**and report on review of quarterly  
information**

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Contents

### Company information

Capital composition	1
---------------------	---

### Individual financial information

Balance sheet - assets	2
Balance sheet - liabilities and equity	3
Statement of income	4
Statement of comprehensive income	5
Statement of cash flow	6
<b>Statement of changes in equity</b>	
1/1/2021 to 6/30/2021	7
1/1/2020 to 6/30/2020	8
Statement of value added	9

### Consolidated financial information

Balance sheet - assets	10
Balance sheet - liabilities and equity	11
Statement of income	12
Statement of comprehensive income	13
Statement of cash flow	14
<b>Statement of changes in equity</b>	
1/1/2021 to 6/30/2021	15
1/1/2020 to 6/30/2020	16
Statement of value added	17
Comments on company performance	18
Notes to the quarterly information	38
Comments on business projections performance	103

### Opinions and representations

Report on special review - without exceptions	104
Opinion of supervisory board or equivalent body	106
Officers' representation on financial statements	107
Officers' representation on independent auditor's report	108

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Company information/capital composition

<b>Number of shares (units)</b>	<b>Current quarter 6/30/2021</b>
<b>Paid-up share capital</b>	
<b>Common shares</b>	1,651,930,000
<b>Preferred shares</b>	0
<b>Total</b>	1,651,930,000
<b>Treasury shares</b>	
<b>Common shares</b>	1,770,355
<b>Preferred shares</b>	0
<b>Total</b>	1,770,355

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

**Parent company financial information/balance sheet - assets**

**(R\$ thousand)**

<b>Code</b>	<b>Description</b>	<b>Current quarter 6/30/2021</b>	<b>Prior year 12/31/2020</b>
1	Total assets	13,745,504	13,543,969
1.01	Current assets	6,642,346	6,695,857
1.01.01	Cash and cash equivalents	242,088	855,257
1.01.03	Trade receivables	1,790,876	1,631,988
1.01.03.01	Customers	1,574,116	1,373,801
1.01.03.01.01	Checks receivable	926	1,449
1.01.03.01.02	Credit and debit cards	1,504,689	1,324,847
1.01.03.01.03	PBM - Medicine benefit program	49,823	29,483
1.01.03.01.04	Agreements with companies	18,954	18,530
1.01.03.01.05	(-) Provision for impairment of trade receivables	562	138
1.01.03.01.06	(-) Expected credit losses	-838	-646
1.01.03.02	Other receivables	216,760	258,187
1.01.03.02.01	Advances to employees	15,646	10,755
1.01.03.02.02	Returns to suppliers	14,802	11,984
1.01.03.02.03	Commercial agreements	151,831	208,109
1.01.03.02.04	Receivables from subsidiaries	343	185
1.01.03.02.05	Other	34,138	27,154
1.01.04	Inventory	4,468,364	4,112,842
1.01.04.01	Goods for resale	4,488,187	4,134,721
1.01.04.02	Materials	13,627	6,317
1.01.04.03	(-) Allowance for losses on goods	-33,450	-28,196
1.01.06	Recoverable taxes	82,239	59,288
1.01.06.01	Current recoverable taxes	82,239	59,288
1.01.07	Prepaid expenses	58,779	36,482
1.02	Non-current assets	7,103,158	6,848,112
1.02.01	Long-term receivables	559,811	528,458
1.02.01.04	Trade receivables	60,050	58,310
1.02.01.04.02	Other receivables	513	504
1.02.01.04.03	Receivables from subsidiaries	59,537	57,806
1.02.01.08	Prepaid expenses	6,356	6,454
1.02.01.10	Other non-current assets	493,405	463,694
1.02.01.10.04	Judicial deposits	24,145	25,753
1.02.01.10.05	Recoverable taxes	122,672	96,035
1.02.01.10.06	Credits of subsidiaries	346,588	341,906
1.02.02	Investments	181,307	78,266
1.02.02.01	Equity interest	181,307	78,266
1.02.02.01.02	Interests in subsidiaries	181,307	78,266
1.02.03	Property and equipment	5,124,109	5,012,605
1.02.03.01	Property and equipment in use	1,865,502	1,854,211
1.02.03.02	Right-of-use lease	3,258,607	3,158,394
1.02.04	Intangible assets	1,237,931	1,228,783
1.02.04.01	Intangible assets	1,237,931	1,228,783
1.02.04.01.02	Intangible assets	1,237,931	1,228,783

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Parent company financial information/balance sheet - liabilities and equity**

**(R\$ thousand)**

<b>Code</b>	<b>Description</b>	<b>Current quarter 6/30/2021</b>	<b>Prior year 12/31/2020</b>
2	Total liabilities and equity	13,745,504	13,543,969
2.01	Current liabilities	4,591,606	4,583,196
2.01.01	Social security and labor obligations	404,697	302,833
2.01.01.01	Social security obligations	70,848	64,706
2.01.01.02	Labor obligations	333,849	238,127
2.01.02	Trade payables	2,520,141	2,943,379
2.01.02.01	Domestic suppliers	2,520,141	2,943,379
2.01.03	Tax obligations	148,464	130,457
2.01.03.01	Federal tax obligations	52,807	42,668
2.01.03.01.01	Income tax and social contribution payable	25,071	6,873
2.01.03.01.02	Other federal tax obligations	27,736	35,795
2.01.03.02	State tax obligations	88,868	83,081
2.01.03.03	Municipal tax obligations	6,789	4,708
2.01.04	Borrowing	582,340	497,751
2.01.04.01	Borrowing	106,287	342,701
2.01.04.01.01	In local currency	106,287	342,701
2.01.04.02	Debentures	476,053	155,050
2.01.04.02.01	Debentures	476,053	155,050
2.01.05	Other obligations	849,457	640,219
2.01.05.02	Other	849,457	640,219
2.01.05.02.01	Dividends and interest on capital	83,506	16,492
2.01.05.02.04	Rentals	131,936	69,322
2.01.05.02.06	Other payables	62,120	52,481
2.01.05.02.07	Lease liabilities	571,895	501,924
2.01.06	Provision	86,507	68,557
2.01.06.01	Provision for tax, social security, labor and civil contingencies	36,470	32,646
2.01.06.01.05	Provision for legal claims	36,470	32,646
2.01.06.02	Other provisions	50,037	35,911
2.01.06.02.06	Provisions for sundry obligations	50,037	35,911
2.02	Non-current liabilities	4,488,437	4,597,647
2.02.01	Borrowing	934,332	1,122,250
2.02.01.01	Borrowing	300,000	100,150
2.02.01.01.01	In local currency	300,000	100,150
2.02.01.02	Debentures	634,332	1,022,100
2.02.01.02.01	Debentures	634,332	1,022,100
2.02.02	Other obligations	3,442,702	3,327,225
2.02.02.02	Other	3,442,702	3,327,225
2.02.02.02.03	Tax recovery program (REFIS)	67,344	12,908
2.02.02.02.04	Payables to Subsidiary's shareholders	35,934	46,448
2.02.02.02.05	Lease liabilities	2,993,189	2,926,026
2.02.02.02.06	Payables of subsidiaries	346,235	341,843
2.02.03	Deferred taxes	49,222	72,772
2.02.03.01	Deferred income tax and social contribution	49,222	72,772
2.02.04	Provision	62,181	75,400
2.02.04.01	Provision for tax, social security, labor and civil contingencies	61,138	70,822
2.02.04.01.05	Provision for legal claims	61,138	70,822
2.02.04.02	Other provisions	1,043	4,578
2.02.04.02.04	Provision for losses on Investments	1,043	4,578
2.03	Equity	4,665,461	4,363,126
2.03.01	Paid-up share capital	2,500,000	2,500,000
2.03.02	Capital reserves	152,448	148,029
2.03.02.07	Capital reserves	152,448	148,029
2.03.04	Revenue reserves	1,664,172	1,733,650
2.03.04.01	Legal reserve	178,353	178,353
2.03.04.02	Statutory reserve	1,278,952	1,278,952
2.03.04.08	Proposed additional dividends	0	69,478
2.03.04.10	Tax incentive reserve	206,867	206,867
2.03.05	Retained earnings (accumulated deficit)	333,425	0
2.03.06	Carrying value adjustments	15,416	-18,553

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

**Parent company financial information/statement of income**

**(R\$ thousand)**

Code	Description	SCE*-	SCE*-	SCE*-	SCE*-
		01/04/2021 to 6/30/2021	1/1/2021 to 6/30/2021	4/1/2020 to 6/30/2020	1/1/2020 to 6/30/2020
3.01	Net sales revenue	5,567,062	10,894,263	4,221,166	8,931,057
3.01.01	Gross sales revenue	5,904,315	11,554,765	4,444,624	9,382,478
3.01.02	Taxes on sales	-284,102	-563,175	-189,180	-382,729
3.01.03	Rebates	-53,151	-97,327	-34,278	-68,692
3.02	Cost of sales and/or services	-3,801,860	-7,510,250	-2,920,832	-6,209,473
3.03	Gross profit	1,765,202	3,384,013	1,300,334	2,721,584
3.04	Operating income/expenses	-1,338,908	-2,642,521	-1,179,736	-2,360,288
3.04.01	Selling expenses	-1,192,978	-2,328,510	-1,019,249	-2,039,551
3.04.02	General and administrative expenses	-198,768	-383,122	-161,304	-310,047
3.04.04	Other operating income	59,786	77,925	32,167	33,506
3.04.05	Other operating expenses	-6,673	-8,798	-33,234	-46,955
3.04.06	Equity in the results of investees	-275	-16	1,884	2,759
3.05	Profit before finance results and taxes	426,294	741,492	120,598	361,296
3.06	Finance results	-80,430	-151,758	-72,370	-145,856
3.06.01	Finance income	12,916	23,502	14,000	28,889
3.06.02	Finance costs	-93,346	-175,260	-86,370	-174,745
3.07	Profit before income tax and social contribution	345,864	589,734	48,228	215,440
3.08	Income tax and social contribution	-93,109	-162,683	-3,553	-47,444
3.08.01	Current	-117,622	-186,191	-30,937	-87,967
3.08.02	Deferred	24,513	23,508	27,384	40,523
3.09	Profit from continuing operations	252,755	427,051	44,675	167,996
3.11	Profit for the period	252,755	427,051	44,675	167,996
3.99	Earnings per share - (Reais/share)				
3.99.01	Basic earnings per share - R\$				
3.99.01.01	Common shares	0.15319	0.25894	0.02711	0.10193
3.99.02	Basic earnings per share - R\$				
3.99.02.01	Common shares	0.15251	0.25828	0.02699	0.10148

\*SCE – Statement of Changes in Equity

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Parent company financial information/statement of comprehensive income**

**(R\$ thousand)**

<b>Code</b>	<b>Description</b>	<b>SCE*- 4/1/2021 to 6/30/2021</b>	<b>SCE*- 1/1/2021 to 6/30/2021</b>	<b>SCE*- 4/1/2020 to 6/30/2020</b>	<b>SCE*- 1/1/2020 to 6/30/2020</b>
4.01	Profit for the period	252,755	427,051	44,675	167,996
4.03	Comprehensive income for the period	252,755	427,051	44,675	167,996

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

**Parent company financial information/statement of cash flow - indirect method**

**(R\$ thousand)**

Code	Description	SCE - 1/1/2021 to 6/30/2021	SCE - 1/1/2020 to 6/30/2020
6.01	Net cash provided by operating activities	289,036	4,787
6.01.01	Cash from operations	1,402,213	945,362
6.01.01.01	Profit before income tax and social contribution	589,734	215,440
6.01.01.02	Depreciation and amortization	627,810	564,418
6.01.01.03	Share-based compensation plan, net	4,375	7,991
6.01.01.04	Interest on additional stock option	1,370	2,418
6.01.01.05	Result on disposal of property and equipment and intangible assets	8,909	1,225
6.01.01.06	Provision for (reversal of) legal claims	27,135	6,060
6.01.01.07	Provision for (reversal of) inventory losses	5,254	20,590
6.01.01.08	Provision for (reversal of) impairment of trade receivables	1,742	-192
6.01.01.09	Provision for (reversal of) store closures	-3,785	-1,198
6.01.01.10	Interest expenses	29,015	30,190
6.01.01.11	Amortization of transaction costs of debentures	2,388	1,705
6.01.01.12	Equity in the results of subsidiaries	16	-2,759
6.01.01.13	Interest expenses – leases	114,669	108,625
6.01.01.15	Gain on business combination	0	220
6.01.01.16	Discounts on property rental	-6,419	-9,371
6.01.02	Changes in assets and liabilities	-811,842	-720,259
6.01.02.01	Trade receivables and other receivables	-202,057	-96,121
6.01.02.02	Inventory	-360,776	-265,420
6.01.02.03	Other current assets	-1,740	-25,621
6.01.02.04	Long-term receivables	-29,621	-11,995
6.01.02.05	Trade payables	-426,671	-462,317
6.01.02.06	Salaries and social charges	101,864	117,300
6.01.02.07	Taxes and contributions	48,893	1,415
6.01.02.08	Other liabilities	-4,348	13,262
6.01.02.09	Rentals payable	62,614	9,238
6.01.03	Other	-301,335	-220,316
6.01.03.01	Interest paid	-28,844	-24,621
6.01.03.02	Income tax and social contribution paid	-157,822	-87,070
6.01.03.03	Interest paid – leases	-114,669	-108,625
6.02	Net cash used in investing activities	-391,188	-290,759
6.02.01	Investments in associated companies	-72,580	-3,289
6.02.03	Purchases of property and equipment and intangible assets	-319,283	-286,395
6.02.04	Proceeds from sale of property and equipment	675	8
6.02.05	Cash from merged company	0	-1,083
6.03	Net cash used in financing activities	-511,017	233,091
6.03.01	Borrowing	299,010	696,392
6.03.02	Repayments of borrowing	-406,787	-116,862
6.03.04	Interest on capital and dividends paid	-83,658	-107,605
6.03.05	Leases paid	-319,582	-238,834
6.05	Increase (decrease) in cash and cash equivalents	-613,169	-52,881
6.05.01	Cash and cash equivalents at the beginning of the period	855,257	294,863
6.05.02	Cash and cash equivalents at the end of the period	242,088	241,982



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

**Parent company financial information/statement of changes in equity - 1/1/2021 to 6/30/2021**

**(R\$ thousand)**

Code	Description	Paid-up share capital	Capital reserves, options granted and treasury shares	Revenue reserves	Retained earnings/ accumulated deficit	Other comprehensive income	Equity
5.01	Opening balance	2,500,000	148,029	1,733,650	0	-18,553	4,363,126
5.03	Adjusted opening balance	2,500,000	148,029	1,733,650	0	-18,553	4,363,126
5.04	Equity transactions with owners	0	4,419	-69,478	-93,708	34,052	-124,715
5.04.07	Interest on capital	0	0	0	-94,000	0	-94,000
5.04.08	Interest on capital of 2019 approved at the AGM of March 23, 2020	0	0	-69,478	0	0	-69,478
5.04.09	Interest on capital expired	0	0	0	292	0	292
5.04.10	Restricted share plan - Vesting period	0	4,392	0	0	0	4,392
5.04.11	Restricted share plan - Delivery	0	-6,095	0	0	0	-6,095
5.04.12	Goodwill on sales of shares	0	-1,348	0	0	0	-1,348
5.04.13	Treasury shares - Delivery - RD	0	7,444	0	0	0	7,444
5.04.14	Restricted shares - 4Bio	0	-47	0	0	0	-47
5.04.15	Treasury shares - Delivery - 4Bio	0	73	0	0	0	73
5.04.17	Investment adequacy adjustment	0	0	0	0	34,052	34,052
5.05	Total comprehensive income	0	0	0	427,050	0	427,050
5.05.01	Profit for the period	0	0	0	427,050	0	427,050
5.06	Internal changes in equity	0	0	0	83	-83	0
5.06.02	Realization of revaluation reserve	0	0	0	124	-124	0
5.06.03	Taxes on realization of revaluation reserve	0	0	0	-41	41	0
5.07	Closing balance	2,500,000	152,448	1,664,172	333,425	15,416	4,665,461

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Parent company financial information/statement of changes in equity - 1/1/2020 to 6/30/2020**

**(R\$ thousand)**

<b>Code</b>	<b>Description</b>	<b>Paid-up share capital</b>	<b>Capital reserves, options granted and treasury shares</b>	<b>Revenue reserves</b>	<b>Retained earnings/ accumulated deficit</b>	<b>Other comprehensive income</b>	<b>Equity</b>
5.01	Opening balance	2,500,000	129,768	1,413,627	0	-18,382	4,025,013
5.03	Adjusted opening balance	2,500,000	129,768	1,413,627	0	-18,382	4,025,013
5.04	Equity transactions with owners	0	8,045	-41,643	-95,716	0	-129,314
5.04.07	Interest on capital	0	0	0	-96,000	0	-96,000
5.04.08	Interest on capital of 2018 approved at the AGM of April 10, 2019	0	0	-41,643	0	0	-41,643
5.04.09	Interest on capital expired	0	0	0	284	0	284
5.04.10	Restricted share plan – Vesting period	0	7,991	0	0	0	7,991
5.04.11	Restricted share plan - Delivery	0	-11,958	0	0	0	-11,958
5.04.12	Goodwill on sales of shares	0	817	0	0	0	817
5.04.13	Treasury shares – Delivery - RD	0	11,141	0	0	0	11,141
5.04.14	Restricted shares - 4Bio	0	8	0	0	0	8
5.04.15	Treasury shares - Delivery - 4Bio	0	46	0	0	0	46
5.05	Total comprehensive income	0	0	0	167,996	0	167,996
5.05.01	Profit for the period	0	0	0	167,996	0	167,996
5.06	Internal changes in equity	0	0	0	86	-86	0
5.06.02	Realization of revaluation reserve	0	0	0	130	-130	0
5.06.03	Taxes on realization of revaluation reserve	0	0	0	-44	44	0
5.07	Closing balance	2,500,000	137,813	1,371,984	72,366	-18,468	4,063,695

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Parent company financial information/statement of value added**

**(R\$ thousand)**

Code	Description	SCE -	
		1/1/2021 to 6/30/2021	1/1/2020 to 6/30/2020
7.01	Revenue	11,465,165	9,316,052
7.01.01	Sales of products and services	11,457,439	9,313,786
7.01.03	Revenue from construction of own assets	7,321	2,294
7.01.04	Provision for/reversal of impairment of trade receivables	405	-28
7.02	Inputs acquired from third parties	-7,576,657	-6,253,730
7.02.01	Cost of sales and services	-6,863,017	-5,608,257
7.02.02	Materials, energy, outsourced services and other	-713,640	-645,473
7.03	Gross value added	3,888,508	3,062,322
7.04	Retentions	-611,102	-550,675
7.04.01	Depreciation, amortization and depletion	-611,102	-550,675
7.05	Net value added generated by the entity	3,277,406	2,511,647
7.06	Value added received through transfer	45,027	34,577
7.06.01	Equity in the results of subsidiaries	-17	2,758
7.06.02	Finance income	40,812	32,785
7.06.03	Other	4,232	-966
7.07	Total value added to distribute	3,322,433	2,546,224
7.08	Distribution of value added	3,322,433	2,546,224
7.08.01	Personnel	1,107,087	970,911
7.08.01.01	Direct remuneration	868,840	753,587
7.08.01.02	Benefits	164,776	154,222
7.08.01.03	Unemployment compensation fund	73,471	63,102
7.08.02	Taxes and contributions	1,542,034	1,193,349
7.08.02.01	Federal	412,683	277,763
7.08.02.02	State	1,109,318	897,720
7.08.02.03	Municipal	20,033	17,866
7.08.03	Providers of capital	246,261	213,968
7.08.03.01	Interest	174,806	174,296
7.08.03.02	Rentals	71,455	39,672
7.08.04	Stockholders and the Company	427,051	167,996
7.08.04.01	Interest on capital	94,000	96,000
7.08.04.03	Profits reinvested/loss for the period	333,051	71,996

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Consolidated financial information/balance sheet - assets

(R\$ thousand)

Code	Description	Current quarter 6/30/2021	Prior year 12/31/2020
1	Total assets	14,018,263	13,828,088
1.01	Current assets	7,011,312	7,020,490
1.01.01	Cash and cash equivalents	266,685	880,357
1.01.03	Trade receivables	1,990,674	1,816,456
1.01.03.01	Customers	1,770,670	1,555,434
1.01.03.01.01	Checks receivable	185,893	168,677
1.01.03.01.02	Credit and debit cards	1,518,058	1,340,675
1.01.03.01.03	PBM - Medicine benefit program	50,023	29,483
1.01.03.01.04	Agreements with companies	18,954	18,530
1.01.03.01.05	(-) Provision for impairment of receivables	622	138
1.01.03.01.06	(-) Expected credit losses	-2,880	-2,069
1.01.03.02	Other receivables	220,004	261,022
1.01.03.02.01	Advances to employees	15,689	11,023
1.01.03.02.02	Returns to suppliers	14,802	11,984
1.01.03.02.03	Commercial agreements	155,296	210,795
1.01.03.02.04	Other	34,217	27,220
1.01.04	Inventory	4,603,133	4,225,408
1.01.04.01	Goods for resale	4,622,956	4,247,287
1.01.04.02	Materials	13,627	6,317
1.01.04.03	(-) Allowance for losses on goods	-33,450	-28,196
1.01.06	Recoverable taxes	91,047	61,531
1.01.06.01	Current recoverable taxes	91,047	61,531
1.01.06.01.01	Taxes on profit	4,508	5,435
1.01.06.01.02	Other recoverable taxes	86,539	56,096
1.01.07	Prepaid expenses	59,773	36,738
1.02	Non-current assets	7,006,951	6,807,598
1.02.01	Long-term receivables	550,873	525,424
1.02.01.04	Trade receivables	3,513	3,502
1.02.01.04.02	Other receivables	3,513	3,502
1.02.01.07	Deferred taxes	37,899	36,261
1.02.01.07.01	Deferred income tax and social contribution	37,899	36,261
1.02.01.08	Prepaid expenses	6,356	6,454
1.02.01.10	Other non-current assets	503,105	479,207
1.02.01.10.03	Judicial deposits	26,753	25,753
1.02.01.10.04	Recoverable taxes	129,764	111,548
1.02.01.10.05	Credits of subsidiaries	346,588	341,906
1.02.02	Investments	8,096	0
1.02.02.01	Equity interests	8,096	0
1.02.02.01.04	Interests in jointly-controlled subsidiaries	8,096	0
1.02.03	Property and equipment	5,131,680	5,020,465
1.02.03.01	Property and equipment in use	1,870,331	1,859,220
1.02.03.02	Right-of-use lease	3,261,349	3,161,245
1.02.04	Intangible assets	1,316,302	1,261,709
1.02.04.01	Intangible assets	1,316,302	1,261,709
1.02.04.01.02	Intangible assets	1,316,302	1,261,709

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Consolidated financial information/balance sheet - liabilities and equity**

**(R\$ thousand)**

<b>Code</b>	<b>Description</b>	<b>Current quarter 6/30/2021</b>	<b>Prior year 12/31/2020</b>
2	Total liabilities and equity	14,018,263	13,828,088
2.01	Current liabilities	4,827,509	4,801,303
2.01.01	Social security and labor obligations	413,458	309,160
2.01.01.01	Social security obligations	72,022	65,593
2.01.01.02	Labor obligations	341,436	243,567
2.01.02	Trade payables	2,682,595	3,106,938
2.01.02.01	Domestic suppliers	2,682,595	3,106,938
2.01.03	Tax obligations	151,859	138,671
2.01.03.01	Federal tax obligations	54,365	43,221
2.01.03.01.01	Income tax and social contribution payable	26,174	6,873
2.01.03.01.02	Other federal tax obligations	28,191	36,348
2.01.03.02	State tax obligations	90,678	90,742
2.01.03.03	Municipal tax obligations	6,816	4,708
2.01.04	Borrowing	622,706	531,204
2.01.04.01	Borrowing	146,653	376,154
2.01.04.01.01	In local currency	146,653	376,154
2.01.04.02	Debentures	476,053	155,050
2.01.04.02.01	Debentures	476,053	155,050
2.01.05	Other obligations	857,938	645,907
2.01.05.02	Other	857,938	645,907
2.01.05.02.01	Dividends and interest on capital	83,506	16,492
2.01.05.02.04	Rentals	131,936	69,322
2.01.05.02.06	Lease liabilities	69,204	56,775
2.01.05.02.07	Lease liabilities	573,292	503,318
2.01.06	Provision	98,953	69,423
2.01.06.01	Provision for tax, social security, labor and civil contingencies	46,998	32,835
2.01.06.01.05	Provision for legal claims	46,998	32,835
2.01.06.02	Other provisions	51,955	36,588
2.01.06.02.06	Provisions for sundry obligations	51,955	36,588
2.02	Non-current liabilities	4,493,865	4,601,164
2.02.01	Borrowing	934,332	1,122,250
2.02.01.01	Borrowing	300,000	100,150
2.02.01.01.01	In local currency	300,000	100,150
2.02.01.02	Debentures	634,332	1,022,100
2.02.01.02.01	Debentures	634,332	1,022,100
2.02.02	Other obligations	3,446,542	3,329,086
2.02.02.02	Other	3,446,542	3,329,086
2.02.02.02.03	Tax recovery program (REFIS)	69,709	13,188
2.02.02.02.04	Payables to Subsidiary's stockholder	35,934	46,448
2.02.02.02.06	Lease liabilities	2,994,664	2,927,607
2.02.02.02.07	Payables of subsidiaries	346,235	341,843
2.02.03	Deferred taxes	50,810	74,428
2.02.03.01	Deferred income tax and social contribution	50,810	74,428
2.02.04	Provision	62,181	75,400
2.02.04.01	Provision for tax, social security, labor and civil contingencies	61,138	70,822
2.02.04.01.05	Provision for legal claims	61,138	70,822
2.02.04.02	Other provisions	1,043	4,578
2.02.04.02.04	Provision for losses on investments	1,043	4,578
2.03	Consolidated equity	4,696,889	4,425,621
2.03.01	Paid-up share capital	2,500,000	2,500,000
2.03.02	Capital reserves	152,448	148,029
2.03.02.07	Capital reserves	152,448	148,029
2.03.04	Revenue reserves	1,664,172	1,733,650
2.03.04.01	Legal reserve	178,353	178,353
2.03.04.02	Statutory reserve	1,278,952	1,278,952
2.03.04.07	Proposed additional dividends	206,867	206,867
2.03.04.08	Tax incentive reserve	0	69,478
2.03.05	Retained earnings (accumulated deficit)	333,425	0
2.03.06	Carrying value adjustments	15,416	-18,553
2.03.09	Noncontrolling interests	31,428	62,495

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Consolidated financial information/statement of income

(R\$ thousand)

Code	Description	SCE*-	SCE*-	SCE*-	SCE*-
		4/1/2021 to 6/30/2021	1/1/2021 to 6/30/2021	4/1/2020 to 6/30/2020	1/1/2020 to 6/30/2020
3.01	Net sales revenue	5,868,264	11,488,316	4,469,774	9,419,646
3.01.01	Gross sales revenue	6,245,162	12,224,670	4,721,872	9,928,193
3.01.02	Taxes on sales	-315,153	-624,864	-212,057	-427,956
3.01.03	Rebates	-61,745	-111,490	-40,041	-80,591
3.02	Cost of sales and/or services	-4,071,213	-8,049,412	-3,149,652	-6,657,673
3.03	Gross profit	1,797,051	3,438,904	1,320,122	2,761,973
3.04	Operating income/expenses	-1,363,631	-2,687,390	-1,197,994	-2,398,019
3.04.01	Selling expenses	-1,209,285	-2,357,584	-1,031,431	-2,065,774
3.04.02	General and administrative expenses	-205,760	-396,254	-165,514	-318,738
3.04.04	Other operating income	59,786	77,925	32,167	33,506
3.04.05	Other operating expenses	-6,886	-8,476	-33,216	-47,013
3.04.06	Equity in the results of subsidiaries	-1,486	-3,001	0	0
3.05	Profit before finance income (costs) and taxes	433,420	751,514	122,128	363,954
3.06	Finance results	-82,158	-154,693	-72,884	-147,111
3.06.01	Finance income	13,491	24,203	14,936	30,795
3.06.02	Finance costs	-95,649	-178,896	-87,820	-177,906
3.07	Profit before income tax and social contribution	351,262	596,821	49,244	216,843
3.08	Income tax and social contribution	-97,480	-166,810	-3,027	-46,590
3.08.01	Current	-120,842	-192,025	-30,937	-87,967
3.08.02	Deferred	23,362	25,215	27,910	41,377
3.09	Profit from continuing operations	253,782	430,011	46,217	170,253
3.11	Consolidated profit for the period	253,782	430,011	46,217	170,253
3.11.01	Attributable to owners of the Company	252,755	427,051	44,675	167,996
3.11.02	Attributable to noncontrolling interests	1,027	2,960	1,542	2,257
3.99	Earnings per share - (Reais/share)				
3.99.01	Basic earnings per share - R\$				
3.99.01.01	Common shares	0.15319	0.25894	0.02711	0.10193
3.99.02	Basic earnings per share - R\$				
3.99.02.01	Common shares	0.15251	0.25828	0.02699	0.10148

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

### Consolidated financial information/statement of comprehensive income

(R\$ thousand)

Code	Description	SCE*- 4/1/2021 to 6/30/2021	SCE*- 1/1/2021 to 6/30/2021	SCE*- 4/1/2020 to 9/30/2020	SCE*- 1/1/2020 to 9/30/2020
4.01	Consolidated profit for the period	253,782	430,011	46,217	170,253
4.03	Consolidated comprehensive income for the period	253,782	430,011	46,217	170,253
4.03.01	Attributable to owners of the Company	252,755	427,051	44,675	167,996
4.03.02	Attributable to noncontrolling interests	1,027	2,960	1,542	2,257

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

### Consolidated financial information/statement of cash flow - indirect method

(R\$ thousand)

Code	Description	SCE - 1/1/2021 to 6/30/2021	SCE - 1/1/2020 to 9/30/2020
6.01	Net cash provided by operating activities	270,587	10,522
6.01.01	Cash from operations	1,485,077	952,210
6.01.01.01	Profit before income tax and social contribution	596,821	216,843
6.01.01.02	Depreciation and amortization	629,907	566,805
6.01.01.03	Share-based compensation plan	4,336	8,010
6.01.01.04	Interest on additional stock option	1,370	2,418
6.01.01.05	Result on disposal of property and equipment and intangible assets	8,906	1,225
6.01.01.06	Provision for (reversal of) legal claims	94,349	6,060
6.01.01.07	Provision for (reversal of) inventory losses	5,254	20,590
6.01.01.08	Provision for (reversal of) impairment of trade receivables	2,655	-154
6.01.01.09	Provision for (reversal of) store closures	-3,785	-1,198
6.01.01.10	Interest expenses	31,518	30,304
6.01.01.11	Amortization of transaction costs of dividends	2,388	1,705
6.01.01.12	Interest expenses – leases	3,001	0
6.01.01.14	Gains acquired in business combination	114,776	108,753
6.01.01.15	Equity in the results of subsidiaries	0	220
6.01.01.16	Discounts on property rental	-6,419	-9,371
6.01.02	Changes in assets and liabilities	-912,276	-721,244
6.01.02.01	Trade receivables and other receivables	-215,256	-129,227
6.01.02.02	Inventory	-382,979	-283,838
6.01.02.03	Other current assets	-66,179	-23,021
6.01.02.04	Long-term receivables	8,575	-11,070
6.01.02.05	Trade payables	-428,165	-419,054
6.01.02.06	Salaries and social charges	103,699	118,754
6.01.02.07	Taxes and contributions	43,973	2,973
6.01.02.08	Other liabilities	-38,558	14,001
6.01.02.09	Rentals payable	62,614	9,238
6.01.03	Other	-302,214	-220,444
6.01.03.01	Interest paid	-29,616	-24,621
6.01.03.02	Income tax and social contribution paid	-157,822	-87,070
6.01.03.03	Interest paid – leases	-114,776	-108,753
6.02	Net cash used in investing activities	-379,455	-290,741
6.02.01	Purchases of property and equipment and intangible assets	-14,605	-3,289
6.02.02	Proceeds from sale of property and equipment	13,275	0
6.02.03	Purchases of property and equipment and intangible assets	-364,508	-287,460
6.02.04	Loans granted to subsidiaries	675	8
6.02.06	Cash from merged company	-14,292	0
6.03	Net cash used in financing activities	-504,804	247,409
6.03.01	Borrowing	339,010	711,420
6.03.02	Repayments of borrowing	-439,716	-116,862
6.03.04	Leases paid	-83,658	-107,605
6.03.05	Leases paid	-320,440	-239,544
6.05	Increase (decrease) in cash and cash equivalents	-613,672	-32,810
6.05.01	Cash and cash equivalents at the beginning of the period	880,357	299,226
6.05.02	Cash and cash equivalents at the end of the period	266,685	266,416



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

**Consolidated financial information/statement of changes in equity - 1/1/2021 to 6/30/2021**

**(R\$ thousand)**

Code	Description	Paid-up share capital	Capital reserves, options granted and treasury shares	Revenue reserves	Retained earnings/ accumulated deficit	Other comprehensive income	Equity	Noncontrolling interests	Consolidated equity
5.01	Opening balance	2,500,000	148,029	1,733,650	0	-18,553	4,363,126	62,495	4,425,621
5.03	Adjusted opening balance	2,500,000	148,029	1,733,650	0	-18,553	4,363,126	62,495	4,425,621
5.04	Equity transactions with owners	0	4,419	-69,478	-93,708	34,052	-124,715	-34,027	-158,742
5.04.07	Interest on capital	0	0	0	-94,000	0	-94,000	0	-94,000
5.04.08	Interest on capital of 2019 approved at the AGM of March 23, 2020	0	0	-69,478	0	0	-69,478	0	-69,478
5.04.09	Interest on capital expired	0	0	0	292	0	292	0	292
5.04.10	Restricted share plan - Vesting period	0	4,392	0	0	0	4,392	0	4,392
5.04.11	Restricted share plan - Delivery	0	-6,095	0	0	0	-6,095	0	-6,095
5.04.12	Goodwill on sales of shares	0	-1,348	0	0	0	-1,348	0	-1,348
5.04.13	Treasury shares - Delivery - RD	0	7,444	0	0	0	7,444	0	7,444
5.04.14	Restricted shares - 4Bio	0	-47	0	0	0	-47	0	-47
5.04.15	Treasury shares - Delivery - 4Bio	0	73	0	0	0	73	0	73
5.04.17	Investment adequacy adjustment	0	0	0	0	34,052	34,052	-34,027	25
5.05	Total comprehensive income	0	0	0	427,050	0	427,050	2,960	430,010
5.05.01	Profit for the period	0	0	0	427,050	0	427,050	2,960	430,010
5.06	Internal changes in equity	0	0	0	83	-83	0	0	0
5.06.02	Realization of revaluation reserve	0	0	0	124	-124	0	0	0
5.06.03	Taxes on realization of revaluation reserve	0	0	0	-41	41	0	0	0
5.07	Closing balance	2,500,000	152,448	1,664,172	333,425	15,416	4,665,461	31,428	4,696,889

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

**Consolidated financial information/statement of changes in equity - 1/1/2020 to 6/30/2020**

**(R\$ thousand)**

Code	Description	Paid-up share capital	Capital reserves, options granted and treasury shares	Revenue reserves	Retained earnings/ accumulated deficit	Other comprehensive income	Equity	Noncontrolling interests	Consolidated equity
5.01	Opening balance	2,500,000	129,768	1,413,627	0	-18,382	4,025,013	51,405	4,076,418
5.03	Adjusted opening balance	2,500,000	129,768	1,413,627	0	-18,382	4,025,013	51,405	4,076,418
5.04	Equity transactions with owners	0	8,045	-41,643	-95,716	0	-129,314	0	-129,314
5.04.07	Interest on capital	0	0	0	-96,000	0	-96,000	0	-96,000
5.04.08	Interest on capital of 2018 approved at the AGM of April 10, 2019	0	0	-41,643	0	0	-41,643	0	-41,643
5.04.09	Interest on capital expired	0	0	0	284	0	284	0	284
5.04.10	Restricted share plan – Vesting period	0	7,991	0	0	0	7,991	0	7,991
5.04.11	Restricted share plan - Delivery	0	-11,958	0	0	0	-11,958	0	-11,958
5.04.12	Goodwill on sales of shares	0	817	0	0	0	817	0	817
5.04.13	Treasury shares - Delivery - RD	0	11,141	0	0	0	11,141	0	11,141
5.04.14	Restricted shares - 4Bio	0	8	0	0	0	8	0	8
5.04.15	Treasury shares - Delivery - 4Bio	0	46	0	0	0	46	0	46
5.05	Total comprehensive income	0	0	0	167,996	0	167,996	2,257	170,253
5.05.01	Profit for the period	0	0	0	167,996	0	167,996	2,257	170,253
5.06	Internal changes in equity	0	0	0	86	-86	0	0	0
5.06.02	Realization of revaluation reserve	0	0	0	130	-130	0	0	0
5.06.03	Taxes on realization of revaluation reserve	0	0	0	-44	44	0	0	0
5.07	Closing balance	2,500,000	137,813	1,371,984	72,366	-18,468	4,063,695	53,662	4,117,357

## Comments on company performance

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

## Consolidated financial information/statement of value added

(R\$ thousand)

Code	Description	SCE - 1/1/2021 to 6/30/2021	SCE - 1/1/2020 to 6/30/2020
7.01	Revenue	12,120,355	9,849,828
7.01.01	Sales of products and services	12,113,240	9,847,600
7.01.02	Other income	7,329	2,294
7.01.04	Provision for/reversal of impairment of trade receivables	-214	-66
7.02	Inputs acquired from third parties	-8,130,644	-6,714,798
7.02.01	Cost of sales and services	-7,401,262	-6,055,995
7.02.02	Materials, energy, outsourced services and other	-729,382	-658,803
7.03	Gross value added	3,989,711	3,135,030
7.04	Retentions	-613,057	-553,062
7.04.01	Depreciation, amortization and depletion	-613,057	-553,062
7.05	Net value added generated by the entity	3,376,654	2,581,968
7.06	Value added received through transfer	45,295	33,735
7.06.01	Equity in the results of subsidiaries	-1,228	0
7.06.02	Finance income	42,291	34,701
7.06.03	Other	4,232	-966
7.07	Total value added to distribute	3,421,949	2,615,703
7.08	Distribution of value added	3,421,949	2,615,703
7.08.01	Personnel	1,126,200	986,457
7.08.01.01	Direct remuneration	880,343	762,702
7.08.01.02	Benefits	171,475	159,865
7.08.01.03	Unemployment compensation fund	74,382	63,890
7.08.02	Taxes and contributions	1,612,574	1,241,362
7.08.02.01	Federal	421,469	280,243
7.08.02.02	State	1,170,829	943,017
7.08.02.03	Municipal	20,276	18,102
7.08.03	Providers of capital	251,298	217,631
7.08.03.01	Interest	179,028	177,221
7.08.03.02	Rentals	72,270	40,410
7.08.04	Stockholders and the Company	431,877	170,253
7.08.04.01	Interest on capital	94,000	96,000
7.08.04.03	Profits reinvested/loss for the period	332,039	71,996
7.08.04.04	Noncontrolling interests in retained earnings	5,838	2,257

## Comments on company performance

São Paulo, August 10, 2021. **RD – People, Health and Well-being** (Raia Drogasil S.A. – B3: RADL3) announces today its results for the 2nd quarter of 2021 (2Q21). The Company's parent company and consolidated interim financial statements for the periods ended June 30, 2021 and 2020 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards - General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the interim financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of 2020.

Since 2019, our financial statements have been prepared in accordance with IFRS 16. In order to better represent the economics of the business, the figures in this report are presented under IAS 17 / CPC 06, the previous reporting standard. Reconciliation with IFRS 16 can be found on pages 12 and 13.

### QUARTERLY HIGHLIGHTS:

- › **PHARMACIES: 2,374 units in operation (62 openings and 7 closures)**
- › **MARKET SHARE: 1.1 percentage point increase, with gains in every region**
- › **GROSS REVENUE: R\$ 6.2 billion, 32.3% growth vs. the 2Q20 and 40.6% vs. the 2Q19**
- › **CONTRIBUTION MARGIN\*: 10.8%, 81% of growth and 2.9 p.p. of margin expansion**
- › **ADJUSTED EBITDA: R\$ 497.1 million, an 8.0% EBITDA margin and 114% growth**
- › **ADJUSTED NET INCOME: R\$ 232.0 million, 3.7% of net margin and 276% growth**
- › **CASH FLOW: R\$ 302.1 million negative free cash flow, R\$ 387.3 million total cash consumption**
- › **HEALTH PLATFORM: Announcement of Vitat, new platform for the promotion of integral health**

\* Margin before corporate overhead (gross profit – selling expenses)

RADL3

**R\$ 26.70/share**

NUMBER OF SHARES

**1,651,930,000**

MARKET CAP

**R\$ 44,107 (million)**

CLOSING

**August 9<sup>th</sup>, 2021**

IR CONTACTS:

**Eugênio De Zagottis**

**Fernando Spinelli**

**André Stolfi**

**Igor Spricigo**

SITE: [ir.rd.com.br](http://ir.rd.com.br)

E-MAIL: [ri@rd.com.br](mailto:ri@rd.com.br)


Summary	2Q20	3Q20	4Q20	1Q21	2Q21
<i>(R\$ thousand)</i>					
# of Pharmacies	2,159	2,220	2,299	2,319	2,374
Organic Openings	55	64	82	40	62
Closures	0	(3)	(3)	(20)	(7)
4Bio	3	3	4	4	4
# of Stores - Pharmacies + 4Bio	2,162	2,223	2,303	2,323	2,378
Headcount (EoP)	42,115	43,223	44,631	45,532	47,208
Pharmacist Count (EoP)	8,414	8,658	8,788	9,088	9,346
# of Tickets (000)	52,308	60,298	67,098	65,660	66,911
Gross Revenue	4,721,872	5,384,230	5,868,052	5,979,508	6,245,163
Gross Profit	1,320,122	1,494,996	1,634,213	1,641,852	1,797,052
% of Gross Revenues	28.0%	27.8%	27.8%	27.5%	28.8%
Adjusted EBITDA	231,811	397,159	430,843	415,855	497,115
% of Gross Revenues	4.9%	7.4%	7.3%	7.0%	8.0%
Adjusted Net Income	61,688	172,871	213,672	177,947	232,022
% of Gross Revenues	1.3%	3.2%	3.6%	3.0%	3.7%
Net Income	60,210	174,717	198,492	188,789	266,443
% of Gross Revenues	1.3%	3.2%	3.4%	3.2%	4.3%
Free Cash Flow	(437,520)	351,792	425,112	(131,972)	(302,106)

## Comments on company performance

### PHARMACY DEVELOPMENT

We opened 62 new pharmacies in the 2Q21 and closed 7, ending the quarter with 2,374 units in operation, in addition to 4 4Bio locations. We reiterate our gross openings guidance of 240 pharmacies per year for both 2021 and 2022.


At the end of the period, 31.3% of our pharmacies were still in the process of maturation and had not yet reached their full potential both in terms of revenue and profitability.



Of the 7 pharmacies closed in the 2Q21, 3 were still in the maturation process and represent corrections of mistakes that are to be expected in a large-scale expansion such as RD's. The remaining 4 closures were mature units driven by the optimization of our pharmacy portfolio, including 3 for relocation, with positive return expectations associated to them.


We continued diversifying our pharmacy network in the quarter, both geographically and demographically, with 76% of our openings in the last twelve months outside of the state of São Paulo, our native market. We also increased our capillarity, extending our presence to 436 cities, 59 more than in the 2Q20. Finally, while 67% of our units have popular or hybrid formats, 90% of the openings in the last twelve months belong to these clusters, increasing our reach into the expanded middle class.

## Comments on company performance



\* Premium and super premium pharmacies are grouped together, as well as popular and super popular units. Openings exclude the Onofre acquisition.

Lastly, we signed contracts to enter the states of Acre, Roraima and Amapá, expanding our presence to all states in Brazil by the end of 2021.



Our national share totaled 14.1%, a 1.1 percentage point increase when compared to the 2Q20, leveraged by our organic expansion and also by our digital transformation.

We increased our market share in the quarter in all six regions where we operate, with the Midwest region being our main highlight, with a market share of 16.9%, a 2.6 percentage point gain vs. the 2Q20.

We also recorded strong gains in the Northeast region, where we reached a market share of 9.4%, a 1.2 percentage point gain, and in the North, where we registered a market share of 5.5%, an increase of 1.1 percentage point.

## Comments on company performance

Finally, we recorded a market share of 9.3% in the South, an increase of 1.0 percentage point, a market share of 9.7% in the Southeast (excluding São Paulo), an increase of 0.6 percentage point and a market share of 25.9% in São Paulo, an increase of 0.4 percentage point vs. the 2Q20.

### DIGITAL HEALTH TRANSFORMATION


Our digital health transformation is based on three complementary pillars: the New Pharmacy, which combines a health hub with a digital and omnichannel experience, the Marketplace, and the Integral Health Platform. Together, these three businesses will allow us to take care of the health and well-being of our customers and, at the same time, leverage the frequency of interaction, the engagement and the spending of our more than 40 million customers.

In the 2Q21, the digital channel penetration in the New Pharmacy reached 8.9%, stemming from our commercial and operational efforts to enhance our omnichannel experience. It is important to highlight that 84% of our digital transactions were fulfilled by our pharmacies, which have delivered in under 4 hours with high economic efficiency.

Ship-from-store deliveries were made available in 405 cities, which represent 93% of those where RD operates pharmacies, complementing our *Neighborhood Delivery* and *Click & Collect* options that were already available at 100% of our locations.

We recorded 11.8 million cumulative app downloads since the 1Q19. Our apps have a sales conversion rate of approximately 10%, a level well above other digital channels, and prove to be essential for increasing customer frequency, engagement, loyalty and spending.

The digitalization of the relationship with our customers is key to our long-term strategy. Customers who use our digital channels increase their loyalty, engagement and frequency, resulting in an increase in their spending by an average of 20% to 25%, making their digitalization a fundamental driver of long-term value creation.



Finally, we've also advanced in the offering of health-related services by performing 1.9 million COVID-19 tests in the 1H21 alone (3.0 million since may/2020), as well as the application of flu shots and the offering of other health services to our customers. Finally, a total of 108.0 thousand COVID-19 immunizations have been performed for free at our stores during the quarter in partnership with 14 Brazilian municipalities.

We have also advanced in the development of our marketplace, which is in its initial stage of development. We already offer over 40 thousand SKUs from approximately 160 sellers in the marketplace, and we are preparing its roll-out to Drogasil, since it is currently operational only at Raia.

Lastly, we have launched in July **Vitat**, our Integral Health Platform. **Vitat** combines a portal with ample content health and wellness content, an app focused on the promotion of integral health, and the **Vitat Space**, an evolution of our health hubs which aims to offer a broader healthcare journey in the pharmacies.

The **Vitat** app started with 25 different programs focused on healthy eating, exercises, sleep, mental health and health promotion. It will also offer medical, nutritional, psychological and physical teleconsultations. In addition, the app will also allow the monitoring of the customer's


## Comments on company performance

history through a unified health wallet and the scheduling of services at the **Vitat Space**. All programs currently available are free.


The **Vitat Space** offers quick tests, monitoring of clinical parameters and orientation from trained pharmacists, which are integrated with the app's health programs. The **Vitat Space** will also be connected to the **Healthy Life Space**, which will focus on products that offer healthier and more sustainable choices, including our private label brands, thus complementing the health and well-being journey of the customers of Raia and Drogasil. By the end of 2021, RD plans to implement the **Vitat Space** as well as the **Healthy Life Space** in 20 stores. By 2022, all Droga Raia and Drogasil pharmacies will be connected to the **Vitat** app.

### GROSS REVENUES

Our consolidated revenue totaled R\$ 6,245 million, a 32.3% growth vs. the 2Q20. We recorded a same-store sales growth of 26.2% at our pharmacies, with 23.5% for mature stores, including a positive calendar effect of 0.1%.




Our revenue growth in the 2Q21 was favored by the atypical decrease in sales registered in the 2Q20 due to the strict social isolation verified in that quarter. In order to provide a better understanding of our structural sales performance, without the transitory effects of the peaks and valleys in growth caused by the pandemic, we provide below our quarterly growth over a cumulative two-year period.



We recorded in the quarter a two-year cumulative top-line growth of 40.6% over the 2Q19, with 23.1% for same-store sales and 15.1% for mature stores, including a negative calendar effect of 0.3%. Our two-year mature-store growth was 4.7 percentage points higher than the accumulated inflation recorded in the period, adjusted for the calendar effect, allowing for a significant gain in operating leverage and underscoring the structural growth of the Company.




## Comments on company performance



OTC was the highlight of the quarter growing 42.6% and gaining 1.5 percentage point in the mix vs. the 2Q20. The increase of OTC in the sales mix continues to be driven mainly by products related to the pandemic, such as masks, vitamins and COVID-19 tests. In addition, Branded Rx grew 32.7%, with its participation in the sales mix in line with the previous year. Lastly, Generics grew 32.4% and lost 0.1 percentage point in the mix, while HPC grew 24.8% and lost 1.5 percentage points in the mix.

## GROSS PROFIT

Our gross profit totaled R\$ 1,797.1 million, with a gross margin of 28.8%, a 0.8 percentage point increase versus the 2Q20, mainly due to the inflationary gains on inventories stemming from the 2021 price cap increase, which was above the historical average, and by the fact that in 2020 the increase was postponed by two months, coming into effect only in June. We also recorded a 0.1 percentage point expansion due to the Net Present Value (NPV) adjustment, a non-cash effect stemming from higher interest rates when compared to the same period last year, and a pressure of 0.1 percentage point from higher inventory losses.




## Comments on company performance

### SELLING EXPENSES


Selling expenses in the quarter totaled R\$ 1,119.8 million, equivalent to 17.9% of gross revenue, a 2.1 percentage point dilution over the same period of the previous year. We had recorded a drop in sales performance in the 2Q20 due to the pandemic, with a decrease in mature store sales, resulting in a considerable loss of operating leverage that raised the level of expenses in the comparison base. On the other hand, we registered a robust structural sales performance in the 2Q21, with a calendar-adjusted bi-annual mature stores growth 4.7 percentage points above the period's inflation.

We've recorded a dilution of 1.5 percentage point in personnel expenses, 0.2 percentage point in rentals, 0.2 percentage point in transportation expenses and 0.1 percentage point in utilities expenses, amongst other effects that generated a combined dilution of 0.1 percentage point.



### CONTRIBUTION MARGIN


Our contribution margin totaled R\$ 677,3 million, an increase of 81% versus the 2Q20. This represented 10.8% of gross revenue, a margin increase of 2.9 percentage points over the 2Q20 stemming from the 0.8 percentage point expansion in gross margin and the 2.1 percentage point dilution in selling expenses.



## Comments on company performance

### GENERAL & ADMINISTRATIVE EXPENSES

General and administrative expenses amounted to R\$ 180.2 million in the 2Q21, equivalent to 2.9% of gross revenue, a 0.1 percentage point dilution when compared to the same period of last year. We recorded a 0.2 percentage point pressure in personnel expenses, more than offset by dilutions of 0.2 percentage point in labor contingencies and 0.1 percentage point in institutional marketing expenses.




It is important to mention that the temporary drop in sales recorded in 2Q20 resulted in a higher-than-normal level of general and administrative expenses relative to revenues. However, even with the normalization of demand, the 0.4 percentage point increase in digital-related expenses (squads, software licenses, support teams, infrastructure and third-party services, among others) recorded in the 2Q21 have limited our G&A dilution.

## Comments on company performance

### EBITDA

Our adjusted EBITDA totaled R\$ 497.1 million in the quarter, an increase of 114% when compared to the 2Q20. We recorded an adjusted EBITDA margin of 8.0%, corresponding to a 3.1 percentage point expansion.



New pharmacies opened in the year, as well as those in the opening process, reduced the EBITDA by R\$ 9.0 million in the 2Q21. Therefore, considering only the 2,272 units in operation since the end of 2020 and full logistics, general and administrative expenses, the consolidated adjusted EBITDA would have totaled R\$ 506.1 million, equivalent to 8.2% of gross revenue.

### EBITDA RECONCILIATION AND NON-RECURRING EXPENSES


EBITDA Reconciliation	2Q21	2Q20
<i>(R\$ million)</i>		
<b>Net Income</b>	<b>266.4</b>	<b>60.2</b>
(+) Income Tax	104.0	10.2
(+) Equity Equivalence	1.5	0.0
(+) Financial Result	26.9	20.2
<b>EBIT</b>	<b>398.8</b>	<b>90.6</b>
(+) Depreciation and Amortization	150.4	138.9
<b>EBITDA</b>	<b>549.3</b>	<b>229.6</b>
(-) INSS, PIS and COFINS Credits from Previous Years	(58.0)	(32.0)
(+) Asset Write-offs	6.1	0.2
(+) Donations	0.3	25.9
(+) Consulting, Advisory and Restructuring Expenses		8.0
(+) Provisions for Inventory Losses from previous periods		(0.1)
(+) Other non-recurring / non-operating net expenses	(0.5)	0.2
<b>Non-recurring / non-operating Expenses</b>	<b>(52.2)</b>	<b>2.2</b>
<b>Adjusted EBITDA</b>	<b>497.1</b>	<b>231.8</b>

In the 2Q21, we recorded R\$ 52.2 million in non-recurring gains, of which R\$ 58.0 million refer to PIS and COFINS credits from previous years, resulting from a legal decision that determined the removal of the ICMS tax from the PIS and COFINS calculation, and R\$ 0.5 million in other non-recurring/non-operating revenues. We also recorded R\$6.1 million related to asset write-off expenses, mainly due to store closures, and R\$ 0.3

## Comments on company performance

million related to donations.

### DEPRECIATION, NET FINANCIAL EXPENSES AND INCOME TAXES




Depreciation expenses amounted to R\$ 150.4 million in the 2Q21, equivalent to 2.4% of gross revenues, a 0.5 percentage point dilution when compared to the same period of last year.

Net financial expenses represented 0.4% of gross revenue, in line with the 2Q20. Of the R\$ 26.9 million recorded in the quarter, R\$ 17.9 million refer to the actual financial interest accrued on financial liabilities, equivalent to 0.3% of gross revenue and stable when compared to the 2Q20. We've also recorded R\$ 8.3 million in financial expenses which refers to the NPV adjustment and R\$ 0.7 million which refers to the interest on the option to acquire the remaining 15% of 4Bio.

Lastly, we booked R\$ 86.3 million in income taxes, equivalent to 1.4% of gross revenue, a 1.2 percentage point increase.

## Comments on company performance


### NET INCOME



Our adjusted net income totaled R\$ 232.0 million in the quarter, an increase of 276%. We recorded a net margin of 3.7%, an expansion of 2.4 percentage point versus the 2Q20.

### CASH CYCLE

Our cash cycle in the 2Q21 was 68.8 days, a reduction of 11.3 days when compared to the same period of the previous year. Our inventories decreased by 16.0 days, while accounts payable decreased by 4.5 days. Finally, receivables were 0.2 day above the level of the 2Q20.



\* Adjusted for discounted receivables.

## Comments on company performance

### CASH FLOW

We recorded a negative free cash flow of R\$ 302.1 million and a total cash consumption of R\$ 387.3 million in the 2Q21. Our operating cash flow consumed R\$ 70.3 million.

<b>Cash Flow</b>	<b>2Q21</b>	<b>2Q20</b>
<i>(R\$ million)</i>		
<b>Adjusted EBIT</b>	<b>346.7</b>	<b>92.9</b>
NPV Adjustment	(6.9)	(1.8)
Non-Recurring Expenses	52.2	(2.2)
Income Tax (34%)	(133.3)	(30.2)
Depreciation	150.4	138.9
Others	20.6	5.0
<b>Resources from Operations</b>	<b>429.7</b>	<b>202.6</b>
Cash Cycle*	(647.4)	(532.1)
Other Assets (Liabilities)**	147.4	43.3
<b>Operating Cash Flow</b>	<b>(70.3)</b>	<b>(286.3)</b>
<b>Investments</b>	<b>(231.8)</b>	<b>(151.3)</b>
<b>Free Cash Flow</b>	<b>(302.1)</b>	<b>(437.5)</b>
Interest on Equity	(83.6)	(107.0)
Income Tax Paid over Interest on Equity	(6.3)	(5.4)
Net Financial Expenses***	(18.6)	(17.5)
Income Tax (Tax benefit over financial expenses and interest on equity)	23.3	22.6
<b>Total Cash Flow</b>	<b>(387.3)</b>	<b>(544.8)</b>

\*Includes adjustments to discounted receivables.

\*\*Includes NPV adjustments.

\*\*\*Excludes NPV adjustments.

Resources from operations totaled R\$ 429.7 million, equivalent to 6.9% of gross revenue, while we recorded a working capital consumption of R\$ 500.0 million, due to the seasonal working capital peak that happens in the second quarter when compared to the regular level at the end of the year.

Of the R\$ 231.8 million invested in the quarter, R\$ 89.3 million corresponded to new pharmacy openings, R\$ 37.3 million to the renovation or expansion of existing units and R\$ 105.2 million to investments in infrastructure.

Net financial expenses totaled R\$ 18.6 million in the 2Q21, excluding the NPV adjustments. These were more than fully offset by the R\$ 23.3 million in tax shield related to the net financial expenses and to the interest on equity accrued in the period, which shall be paid in the following quarters.

We accrued R\$ 50.0 million in interest on equity in the 2Q21 versus R\$ 49.0 million in the 2Q20, reflecting a payout of 18.8% over the Net Income, through the full usage of the legal interest on equity limit.

### INDEBTEDNESS

We ended the 2Q21 with an adjusted net financial debt of R\$ 1,332.8 million, versus R\$ 1,508.9 million in the same period of 2020. This equals an adjusted net debt to EBITDA ratio of 0.8x, 0.4x lower than the same period of the previous year.

Our adjusted net debt includes R\$ 35.9 million in liabilities related to the exercise of the put option granted and/or call option obtained for the acquisition of the remaining 15% minority stake of 4Bio.

Finally, we have concluded the acquisition of an additional 30% of 4Bio through the exercise of the first tranche of the call/put option, reaching an 85% voting interest in the company. The 2nd call/put option on the 15% remaining shares will be exercisable in 2024, and the estimated valuation of 4Bio will be revisited yearly to reflect changes in the financial outlook of the Company.

## Comments on company performance


Net Debt	2Q21	1Q21	4Q20	3Q20	2Q20
<i>(R\$ million)</i>					
Short-term Debt	622.7	206.7	531.2	536.5	537.4
Long-term Debt	934.3	1,426.2	1,122.2	1,195.5	1,191.1
<b>Total Gross Debt</b>	<b>1,557.0</b>	<b>1,632.8</b>	<b>1,653.5</b>	<b>1,732.0</b>	<b>1,728.4</b>
(-) Cash and Equivalents	266.7	734.4	880.4	600.2	266.4
<b>Net Debt</b>	<b>1,290.4</b>	<b>898.4</b>	<b>773.1</b>	<b>1,131.8</b>	<b>1,462.0</b>
Discounted Receivables	6.6	-	-	-	2.4
Put/Call options to acquire 4Bio (estimated)	35.9	47.1	46.4	45.8	44.5
<b>Adjusted Net Debt</b>	<b>1,332.8</b>	<b>945.5</b>	<b>819.5</b>	<b>1,177.6</b>	<b>1,508.9</b>
Adjusted Net Debt / EBITDA	0.8x	0.6x	0.6x	0.9x	1.2x

Our gross debt totaled R\$ 1,557.0 million, of which 71.4% corresponds to the debentures issued in 2017, 2018 and 2019, to the Certificate of Real Estate Receivables issued in 2019 and to the commercial papers issued in 2020 and 28.6% corresponds to other credit lines. Of our total debt, 60.0% is long-term, while 40.0% relates to its short-term parcels. We ended the quarter with a total cash position (cash and marketable securities) of R\$ 266.7 million.

## TOTAL SHAREHOLDER RETURNS

Our share price decreased by 1.4% in the quarter, 10.1 percentage points below the IBOVESPA, which grew by 8.7%. Since the IPO of Drogasil, we achieved a cumulative share appreciation of 2,106.2% versus a return of only 133.1% for the IBOVESPA. Including the payment of interest on equity, we generated an average annual total return to shareholders of 25.1%.

Considering the IPO of Raia in December of 2010, the cumulative return amounted to 748.2% versus an increase of only 86.5% of the IBOVESPA. Considering the payment of interest on equity, this resulted in an average annual total return to shareholders of 22.9%. Lastly, our shares recorded an average daily trading volume of R\$ 143.7 million in the quarter.



## IFRS 16

Since 2019, our financial statements have been prepared in accordance with IFRS 16. In order to preserve historic comparability, the figures in this report are presented under IAS 17 / CPC 06, the previous reporting standard, which we believe best represents the economic performance of our operations.

Financial statements in both IAS 17 and IFRS 16 are also available at our website [ir.rd.com.br](http://ir.rd.com.br), under Interactive Spreadsheets.



## Comments on company performance

Income Statement (R\$ million)	2Q21		Change
	IAS 17	IFRS 16	Δ 2Q21
<b>Gross Revenue</b>	<b>6,245.2</b>	<b>6,245.2</b>	<b>0.0</b>
<b>Gross Profit</b>	<b>1,797.1</b>	<b>1,797.1</b>	<b>0.0</b>
Gross Margin	28.8%	28.8%	0.0%
Selling Expenses	(1,119.8)	(923.8)	195.9
G&A	(180.2)	(179.8)	0.4
<b>Total Expenses</b>	<b>(1,299.9)</b>	<b>(1,103.6)</b>	<b>196.4</b>
as % of Gross Revenue	20.8%	17.7%	-3.1%
<b>Adjusted EBITDA</b>	<b>497.1</b>	<b>693.5</b>	<b>196.4</b>
as % of Gross Revenue	8.0%	11.1%	3.1%
Non-Recurring Expenses / Revenues	52.2	52.9	0.7
Depreciation and Amortization	(150.4)	(311.5)	(161.0)
Financial Results	(26.9)	(82.2)	(55.3)
Equity Equivalence	(1.5)	(1.5)	0.0
Income Tax	(104.0)	(97.5)	6.5
<b>Net Income</b>	<b>266.4</b>	<b>253.8</b>	<b>(12.7)</b>
as % of Gross Revenue	4.3%	4.1%	-0.2%

Balance Sheet (R\$ million)	2Q21		Change
	IAS 17	IFRS 16	Δ 2Q21
<b>Assets</b>	<b>10,757.4</b>	<b>14,018.3</b>	<b>3,260.9</b>
<b>Current Assets</b>	<b>7,011.3</b>	<b>7,011.3</b>	<b>0.0</b>
Taxes Receivable	91.0	91.0	0.0
Other Accounts Receivable	220.0	220.0	(0.0)
<b>Non-Current Assets</b>	<b>3,746.1</b>	<b>7,007.0</b>	<b>3,260.9</b>
Other Credits	356.9	356.5	(0.5)
Investments	8.1	8.1	(0.0)
Property, Plant and Equipment	1,870.3	5,131.7	3,261.3
<b>Liabilities and Shareholder's Equity</b>	<b>10,757.4</b>	<b>14,018.3</b>	<b>3,260.9</b>
<b>Current Liabilities</b>	<b>4,321.5</b>	<b>4,827.5</b>	<b>506.1</b>
Financial Leases	0.0	573.3	573.3
Dividend and Interest on Equity	133.3	83.5	(49.8)
Other Accounts Payable	270.5	253.1	(17.4)
<b>Non-Current Liabilities</b>	<b>1,597.6</b>	<b>4,493.9</b>	<b>2,896.3</b>
Financial Leases	0.0	2,994.7	2,994.7
Income Tax and Social Charges Deferred	149.2	50.8	(98.4)
<b>Shareholder's Equity</b>	<b>4,838.4</b>	<b>4,696.9</b>	<b>(141.5)</b>
Income Reserves	1,780.4	1,664.2	(116.2)
Accrued Income	358.6	333.4	(25.2)
Equity Adjustments	3.8	3.8	0.0
Non Controller Interest	31.5	31.4	(0.0)

## Comments on company performance

Cash Flow (R\$ million)	2Q21		Change
	IAS 17	IFRS 16	Δ 2Q21
<b>Adjusted EBIT</b>	<b>346.7</b>	<b>382.0</b>	<b>35.3</b>
NPV Adjustment	(6.9)	(6.9)	0.0
Non-Recurring Expenses	52.2	52.9	0.7
Income Tax (34%)	(133.3)	(145.5)	(12.3)
Depreciation	150.4	311.5	161.0
Rental Expenses	0.0	(197.1)	(197.1)
Others	20.6	32.9	12.3
<b>Resources from Operations</b>	<b>429.7</b>	<b>429.7</b>	<b>0.0</b>
Cash Cycle*	(647.4)	(647.4)	0.0
Other Assets (Liabilities)**	147.4	147.4	0.0
<b>Operating Cash Flow</b>	<b>(70.3)</b>	<b>(70.3)</b>	<b>0.0</b>
<b>Investments</b>	<b>(231.8)</b>	<b>(231.8)</b>	<b>0.0</b>
<b>Free Cash Flow</b>	<b>(302.1)</b>	<b>(302.1)</b>	<b>0.0</b>
Interest on Equity	(83.6)	(83.6)	0.0
Net Financial Expenses***	(18.6)	(18.6)	0.0
Income Tax (Tax benefit over financial expenses and interest on equity)	23.3	23.3	0.0
<b>Total Cash Flow</b>	<b>(387.3)</b>	<b>(387.3)</b>	<b>0.0</b>

\*Includes adjustments to discounted receivables.

\*\*Includes NPV adjustments

\*\*\*Excludes NPV adjustments

### 2Q21 Results Conference Calls – August 11<sup>th</sup>, 2021

#### Portuguese

at 10:00 am (BRT)

Link:

<https://live.atmodigital.com/register/a/rdresultados>

#### English

at 12:00 pm (BRT)

Link:

<https://live.atmodigital.com/register/a/rdresultados>

For more information, please contact our Investor Relations department.

E-mail: [ri@rd.com.br](mailto:ri@rd.com.br)

**Comments on company performance**

---

<b>Consolidated Adjusted Income Statement</b> <i>(R\$ thousand)</i>	<u>2Q20</u>	<u>2Q21</u>
<b>Gross Revenue</b>	<b>4,721,872</b>	<b>6,245,163</b>
Taxes, Discounts and Returns	(252,098)	(376,898)
<b>Net Revenue</b>	<b>4,469,774</b>	<b>5,868,265</b>
Cost of Goods Sold	(3,149,652)	(4,071,213)
<b>Gross Profit</b>	<b>1,320,122</b>	<b>1,797,052</b>
Operational (Expenses) Revenues		
Sales	(945,308)	(1,119,754)
General and Administrative	(143,003)	(180,183)
<b>Operational Expenses</b>	<b>(1,088,312)</b>	<b>(1,299,937)</b>
<b>EBITDA</b>	<b>231,811</b>	<b>497,115</b>
Depreciation and Amortization	(138,934)	(150,430)
<b>Operational Earnings before Financial Results</b>	<b>92,877</b>	<b>346,685</b>
Financial Expenses	(35,124)	(40,397)
Financial Revenue	14,936	13,492
<b>Financial Expenses/Revenue</b>	<b>(20,187)</b>	<b>(26,906)</b>
Equity Equivalence	0	(1,486)
<b>Earnings before Income Tax and Social Charges</b>	<b>72,690</b>	<b>318,293</b>
Income Tax and Social Charges	(11,002)	(86,271)
<b>Net Income</b>	<b>61,688</b>	<b>232,022</b>

**Comments on company performance**

---

<b>Consolidated Income Statement</b> <i>(R\$ thousand)</i>	<u>2Q20</u>	<u>2Q21</u>
<b>Gross Revenue</b>	<b>4,721,872</b>	<b>6,245,163</b>
Taxes, Discounts and Returns	(252,098)	(376,898)
<b>Net Revenue</b>	<b>4,469,774</b>	<b>5,868,265</b>
Cost of Goods Sold	(3,149,652)	(4,071,213)
<b>Gross Profit</b>	<b>1,320,122</b>	<b>1,797,052</b>
Operational (Expenses) Revenues		
Sales	(945,308)	(1,119,754)
General and Administrative	(143,003)	(180,183)
Other Operational Expenses, Net	(2,240)	52,153
<b>Operational Expenses</b>	<b>(1,090,552)</b>	<b>(1,247,784)</b>
<b>EBITDA</b>	<b>229,571</b>	<b>549,268</b>
Depreciation and Amortization	(138,934)	(150,430)
<b>Operational Earnings before Financial Results</b>	<b>90,637</b>	<b>398,838</b>
Financial Expenses	(35,124)	(40,397)
Financial Revenue	14,936	13,492
<b>Financial Expenses/Revenue</b>	<b>(20,187)</b>	<b>(26,906)</b>
Equity Equivalence	0	(1,486)
<b>Earnings before Income Tax and Social Charges</b>	<b>70,450</b>	<b>370,446</b>
Income Tax and Social Charges	(10,240)	(104,003)
<b>Net Income</b>	<b>60,210</b>	<b>266,443</b>

**Comments on company performance**

---

<b>Assets</b>	<b>2Q20</b>	<b>2Q21</b>
<i>(R\$ thousand)</i>		
<b>Current Assets</b>		
Cash and Cash Equivalents	266,416	266,685
Accounts Receivable	1,330,446	1,770,670
Inventories	4,114,635	4,603,133
Taxes Receivable	140,053	90,999
Other Accounts Receivable	233,490	220,028
Anticipated Expenses	54,925	59,773
	<u>6,139,964</u>	<u>7,011,289</u>
<b>Non-Current Assets</b>		
Deposit in Court	30,595	26,752
Taxes Receivable	71,494	129,764
Income Tax and Social Charges deferred	19,678	37,899
Other Credits	340,901	356,934
Investments	3,289	8,097
Property, Plant and Equipment	1,780,196	1,870,331
Intangible	1,253,664	1,316,302
	<u>3,499,817</u>	<u>3,746,079</u>
<b>ASSETS</b>	<u>9,639,782</u>	<u>10,757,368</u>

**Comments on company performance**

<b>Liabilities and Shareholder's Equity</b> <i>(R\$ thousand)</i>	<u><b>2Q20</b></u>	<u><b>2Q21</b></u>
<b>Current Liabilities</b>		
Suppliers	2,232,219	2,682,595
Loans and Financing	537,353	622,705
Salaries and Social Charges Payable	415,427	413,459
Taxes Payable	119,333	151,859
Dividend and Interest on Equity	109,951	133,309
Provision for Lawsuits	28,870	46,998
Other Accounts Payable	<u>170,099</u>	<u>270,529</u>
	<u><b>3,613,253</b></u>	<u><b>4,321,454</b></u>
<b>Non-Current Liabilities</b>		
Loans and Financing	1,191,067	934,332
Provision for Lawsuits	72,545	61,138
Income Tax and Social Charges deferred	162,925	149,170
Other Accounts Payable	<u>389,209</u>	<u>452,921</u>
	<u><b>1,815,746</b></u>	<u><b>1,597,560</b></u>
<b>Shareholder's Equity</b>		
Common Stock	2,500,000	2,500,000
Capital Reserves	137,813	152,448
Revaluation Reserve	11,762	11,595
Income Reserves	1,429,597	1,780,379
Accrued Income	108,150	358,641
Equity Adjustments	(30,230)	3,821
Non Controller Interest	<u>53,691</u>	<u>31,469</u>
	<u><b>4,210,782</b></u>	<u><b>4,838,354</b></u>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<u><b>9,639,782</b></u>	<u><b>10,757,368</b></u>

## Comments on company performance

<b>Cash Flow</b> <i>(R\$ thousand)</i>	<b>2Q20</b>	<b>2Q21</b>
<b>Earnings before Income Tax and Social Charges</b>	<b>70,450</b>	<b>339,384</b>
<b>Adjustments</b>		
Depreciation and Amortization	138,933	150,430
Compensation plan with restricted shares, net	4,533	5,666
Interest over additional stock option	1,226	694
P,P&E and Intangible Assets residual value	233	872
Provisioned Lawsuits	2,976	39,979
Provisioned Inventory Loss	(2,610)	2,753
Provision for Doubtful Accounts	(85)	1,885
Provisioned Store Closures	0	5,068
Interest Expenses	17,829	17,686
Debt Issuance Costs Amortization	991	1,127
Equity Equivalence Result	0	1,486
Gains from business combination	(29)	0
Provision for Estimated Losses on other Assets	234,447	0
Discount on rentals		(4,546)
	<b>234,447</b>	<b>562,484</b>
<b>Assets and Liabilities variation</b>		
Clients and Other Accounts Receivable	161,169	(37,625)
Inventories	(179,298)	(91,494)
Other Short Term Assets	(15,532)	(39,770)
Long Term Assets	(6,976)	(718)
Suppliers	(553,015)	(511,744)
Salaries and Social Charges	121,906	93,444
Taxes Payable	(36,496)	47,221
Other Liabilities	11,530	(28,794)
Rents Payable	(118)	45,322
<b>Cash from Operations</b>	<b>(262,383)</b>	<b>38,326</b>
Interest Paid	(17,809)	(9,318)
Income Tax and Social Charges Paid	(43,064)	(96,079)
<b>Net Cash from (invested) Operational Activities</b>	<b>(323,256)</b>	<b>(67,071)</b>
<b>Investment Activities Cash Flow</b>		
Cash acquired from business combination	0	13,275
P,P&E and Intangible Acquisitions	(151,252)	(230,645)
P,P&E Sale Payments	0	209
Investments in Associates	0	(332)
Cash from incorporated company	0	(14,292)
<b>Net Cash from Investment Activities</b>	<b>(151,252)</b>	<b>(231,785)</b>
<b>Financing Activities Cash Flow</b>		
Funding	411,599	39,954
Payments	(97,362)	(125,229)
Share Buyback	0	0
Interest on Equity and Dividends Paid	(107,020)	(83,618)
<b>Net Cash from Funding Activities</b>	<b>207,217</b>	<b>(168,893)</b>
<b>Cash and Cash Equivalents net increase</b>	<b>(267,291)</b>	<b>(467,749)</b>
<b>Cash and Cash Equivalents in the beginning of the period</b>	<b>533,707</b>	<b>734,434</b>
<b>Cash and Cash Equivalents in the end of the period</b>	<b>266,416</b>	<b>266,685</b>



## Raia Drogasil S.A.

Individual and Consolidated  
Interim Financial Information  
At June 30, 2021



## Raia Drogasil S.A.

### Parent Company and Consolidated Interim Financial Information

At June 30, 2021

---

#### Contents

##### Individual and Consolidated Interim Financial Information

Balance sheet.....	4
Statement of income .....	5
Statement of comprehensive income .....	6
Statement of changes in equity.....	7
Statement of cash flows .....	8
Statement of value added .....	9

##### Notes to the individual and consolidated interim financial information

<a href="#">1.</a> Operations .....	47
<a href="#">2.</a> Presentation of quarterly information .....	48
<a href="#">3.</a> New accounting procedures, amendments to and interpretation of standards .....	49
<a href="#">4.</a> Significant accounting practices .....	51
<a href="#">5.</a> Cash and cash equivalents.....	51
<a href="#">6.</a> Trade receivables.....	51
<a href="#">7.</a> Inventories .....	52
<a href="#">8.</a> Recoverable taxes.....	53
<a href="#">9.</a> Investments .....	55
<a href="#">10.</a> Property, plant and equipment and intangible assets .....	60
<a href="#">11.</a> Employees benefits.....	68
<a href="#">12.</a> Trade payables.....	68
<a href="#">13.</a> Borrowings, debentures and promissory notes .....	69
<a href="#">14.</a> Leases.....	74

---

## Raia Drogasil S.A.

### Parent Company and Consolidated Interim Financial Information

At June 30, 2021

---

<a href="#">15.</a>	Provision for contingencies and judicial deposits.....	79
<a href="#">16.</a>	Arbitration asset/liability.....	81
<a href="#">17.</a>	Income tax and social contribution .....	82
<a href="#">18.</a>	Earnings per share .....	85
<a href="#">19.</a>	Equity .....	86
<a href="#">20.</a>	Net sales revenue .....	89
<a href="#">21.</a>	Information on the nature of expenses recognized in the statement of income .....	90
<a href="#">22.</a>	Other operating income/expenses.....	91
<a href="#">23.</a>	Finance income and costs.....	92
<a href="#">24.</a>	Financial instruments and risk management policy .....	93
<a href="#">25.</a>	Transactions with related parties .....	98
<a href="#">26.</a>	Insurance coverage.....	101
<a href="#">27.</a>	Non-cash transactions .....	101
<a href="#">28.</a>	Events after the reporting period .....	101

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Raia Drogasil S.A.

### Balance sheet

June 30, 2021

All amounts in thousands of reais

Assets	Note	Parent Company		Consolidated		Liabilities and equity	Note	Parent Company		Consolidated	
		Jun/2021	Dec/2020	Jun/2021	Dec/2020			Jun/2021	Dec/2020	Jun/2021	Dec/2020
<b>Current assets</b>											
Cash and cash equivalents	5	242,088	855,257	266,685	880,357	Trade payables	12	2,520,141	2,943,379	2,682,595	3,106,938
Trade receivables	6	1,574,116	1,373,801	1,770,670	1,555,434	Borrowings	13	582,340	497,751	622,706	531,204
Inventories	7	4,468,364	4,112,842	4,603,133	4,225,408	Leases payable	14	571,895	501,924	573,292	503,318
Recoverable taxes	8	82,239	59,288	91,047	61,531	Salaries and social charges	-	404,697	302,833	413,458	309,160
Other current assets	-	216,760	258,187	220,004	261,022	Taxes and contributions	-	123,393	123,584	125,685	131,798
Prepaid expenses	-	58,779	36,482	59,773	36,738	Dividends and interest on equity	-	83,506	16,492	83,506	16,492
						Income tax and social contribution	-	25,071	6,873	26,174	6,873
						Provision for legal claims	15	36,470	32,646	46,998	32,835
						Other current liabilities	-	244,093	157,714	253,095	162,685
		<b>6,642,346</b>	<b>6,695,857</b>	<b>7,011,312</b>	<b>7,020,490</b>			<b>4,591,606</b>	<b>4,583,196</b>	<b>4,827,509</b>	<b>4,801,303</b>
<b>Non-current assets</b>											
Judicial deposits	15	24,145	25,753	26,753	25,753	Borrowings	13	934,332	1,122,250	934,332	1,122,250
Arbitration restricted asset	16	346,588	341,906	346,588	341,906	Leases payable	14	2,993,189	2,926,026	2,994,664	2,927,607
Recoverable taxes	8	122,672	96,035	129,764	111,548	Provision for legal claims	15	61,138	70,822	61,138	70,822
Deferred income tax and social contribution	17b	-	-	37,899	36,261	Deferred income tax and social contribution	17b	49,222	72,772	50,810	74,428
Amounts receivable from subsidiary	-	59,537	57,806	3,000	-	Payables to subsidiary's shareholder	9a	35,934	46,448	35,934	46,448
Other non-current assets	-	6,869	6,958	6,869	9,956	Arbitration liability	16	346,235	341,843	346,235	341,843
Investments	9	181,307	78,266	8,096	-	Provisions for losses on investments	9	1,043	4,578	1,043	4,578
Property and equipment	10a	1,865,502	1,854,211	1,870,331	1,859,220	Other non-current liabilities	-	67,344	12,908	69,709	13,188
Right-of-use lease	14	3,258,607	3,158,394	3,261,349	3,161,245			<b>4,488,437</b>	<b>4,597,647</b>	<b>4,493,865</b>	<b>4,601,164</b>
Intangible assets	10b	1,237,931	1,228,783	1,316,302	1,261,709			<b>9,080,043</b>	<b>9,180,843</b>	<b>9,321,374</b>	<b>9,402,467</b>
		<b>7,103,158</b>	<b>6,848,112</b>	<b>7,006,951</b>	<b>6,807,598</b>	<b>Total liabilities</b>					
						<b>Equity</b>	19				
						Attributable to owners of the Company					
						Share capital	-	2,500,000	2,500,000	2,500,000	2,500,000
						Capital reserves	-	152,448	148,029	152,448	148,029
						Revenue reserves	-	1,664,172	1,664,172	1,664,172	1,664,172
						Retained earnings	-	333,425	-	333,425	-
						Proposed additional dividend	-	-	69,478	-	69,478
						Equity adjustment	-	15,416	(18,553)	15,416	(18,553)
								<b>4,665,461</b>	<b>4,363,126</b>	<b>4,665,461</b>	<b>4,363,126</b>
						Noncontrolling interests	-	-	-	31,428	62,495
						<b>Total equity</b>		<b>4,665,461</b>	<b>4,363,126</b>	<b>4,696,889</b>	<b>4,425,621</b>
<b>Total assets</b>		<b>13,745,504</b>	<b>13,543,969</b>	<b>14,018,263</b>	<b>13,828,088</b>	<b>Total liabilities and equity</b>		<b>13,745,504</b>	<b>13,543,969</b>	<b>14,018,263</b>	<b>13,828,088</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Raia Drogasil S.A.

### Statement of income

Three and six-month periods ended June 30, 2021

All amounts in thousands of reais, except earnings per capital share

	Note	Parent Company				Consolidated			
		2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20
Net sales revenue	20	5,567,062	10,894,263	4,221,166	8,931,057	5,868,264	11,488,316	4,469,775	9,419,646
Cost of sales	21	(3,801,860)	(7,510,250)	(2,920,832)	(6,209,473)	(4,071,213)	(8,049,412)	(3,149,652)	(6,657,673)
<b>Gross profit</b>		<b>1,765,202</b>	<b>3,384,013</b>	<b>1,300,334</b>	<b>2,721,584</b>	<b>1,797,051</b>	<b>3,438,904</b>	<b>1,320,123</b>	<b>2,761,973</b>
<b>Operating (expenses) income</b>									
Selling expenses	21	(1,192,978)	(2,328,510)	(1,019,249)	(2,039,551)	(1,209,285)	(2,357,584)	(1,031,431)	(2,065,774)
General and administrative expenses	21	(198,768)	(383,122)	(161,304)	(310,047)	(205,760)	(396,254)	(165,515)	(318,738)
Other operating (income)/expenses	22	53,113	69,127	(1,067)	(13,449)	52,900	69,449	(1,049)	(13,507)
Equity in the results of subsidiaries	9	(275)	(16)	1,884	2,759	(1,486)	(3,001)	-	-
		<b>(1,338,908)</b>	<b>(2,642,521)</b>	<b>(1,179,736)</b>	<b>(2,360,288)</b>	<b>(1,363,631)</b>	<b>(2,687,390)</b>	<b>(1,197,995)</b>	<b>(2,398,019)</b>
<b>Profit before finance results</b>		<b>426,294</b>	<b>741,492</b>	<b>120,598</b>	<b>361,296</b>	<b>433,420</b>	<b>751,514</b>	<b>122,128</b>	<b>363,954</b>
<b>Finance income (costs)</b>									
Finance income	23	12,916	23,502	14,000	28,889	13,491	24,203	14,936	30,795
Finance costs	23	(93,346)	(175,260)	(86,370)	(174,745)	(95,649)	(178,896)	(87,820)	(177,906)
		<b>(80,430)</b>	<b>(151,758)</b>	<b>(72,370)</b>	<b>(145,856)</b>	<b>(82,158)</b>	<b>(154,693)</b>	<b>(72,884)</b>	<b>(147,111)</b>
<b>Profit before income tax and social contribution</b>		<b>345,864</b>	<b>589,734</b>	<b>48,228</b>	<b>215,440</b>	<b>351,262</b>	<b>596,821</b>	<b>49,244</b>	<b>216,843</b>
Income tax and social contribution									
Current	-	(117,622)	(186,191)	(30,937)	(87,967)	(120,842)	(192,025)	(30,937)	(87,967)
Deferred	-	24,513	23,508	27,384	40,523	23,362	25,215	27,910	41,377
	17	<b>(93,109)</b>	<b>(162,683)</b>	<b>(3,553)</b>	<b>(47,444)</b>	<b>(97,480)</b>	<b>(166,810)</b>	<b>(3,027)</b>	<b>(46,590)</b>
<b>Profit for the period</b>		<b>252,755</b>	<b>427,051</b>	<b>44,676</b>	<b>167,996</b>	<b>253,782</b>	<b>430,011</b>	<b>46,217</b>	<b>170,253</b>
<b>Attributable to:</b>									
Owners of the Company	-	252,755	427,051	44,675	167,996	252,755	427,051	44,676	167,996
Noncontrolling interests	-	-	-	-	-	1,027	2,960	1,541	2,257
		<b>252,755</b>	<b>427,051</b>	<b>44,675</b>	<b>167,996</b>	<b>253,782</b>	<b>430,011</b>	<b>46,217</b>	<b>170,253</b>
Basic earnings per share	18	0.15319	0.25894	0.02711	0.10193	0.15319	0.25894	0.02711	0.10193
Diluted earnings per share	18	0.15251	0.25828	0.02699	0.10148	0.15251	0.25828	0.02699	0.10148

The accompanying notes are an integral part of this interim financial information.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Raia Drogasil S.A.

### Statement of comprehensive income

Three and six-month periods ended June 30, 2021

All amounts in thousands of reais, except earnings per capital share

	Note	Parent Company				Consolidated			
		2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20
<b>Profit for the period</b>		<b>252,755</b>	<b>427,051</b>	<b>44,675</b>	<b>167,996</b>	<b>253,782</b>	<b>430,011</b>	<b>46,217</b>	<b>170,253</b>
<b>Components of comprehensive income</b>	-								
Other comprehensive income	-	-	-	-	-	-	-	-	-
<b>Total comprehensive income for the period</b>		<b>252,755</b>	<b>427,051</b>	<b>44,675</b>	<b>167,996</b>	<b>253,782</b>	<b>430,011</b>	<b>46,217</b>	<b>170,253</b>
<b>Attributable to:</b>									
Owners of the Company	-	252,755	427,051	44,675	167,996	252,755	427,051	44,675	167,996
Noncontrolling interests	-	-	-	-	-	1,027	2,960	1,542	2,257
<b>Total</b>		<b>252,755</b>	<b>427,051</b>	<b>44,675</b>	<b>167,996</b>	<b>253,782</b>	<b>430,011</b>	<b>46,217</b>	<b>170,253</b>

The accompanying notes are an integral part of this interim financial information.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Raia Drogasil S.A.

### Statement of changes in equity Six-month periods ended June 30, 2021 and 2020 All amounts in thousands of reais

	Attributable to owners of the Company														
	Capital reserves					Revenue reserves					Carrying value adjustments				
	Share capital	Special restatement	Goodwill on issue / sale of shares	Treasury shares	Restricted shares and other	Legal	Statutory	Tax incentives	Retained earnings	Proposed additional dividends	Revaluation reserve	Transactions with noncontrolling interests	Total	Noncontrolling interests	Total equity
<b>At December 31, 2019</b>	<b>2,500,000</b>	<b>10,191</b>	<b>135,739</b>	<b>(38,141)</b>	<b>21,980</b>	<b>154,131</b>	<b>1,080,636</b>	<b>137,216</b>	<b>-</b>	<b>41,643</b>	<b>11,848</b>	<b>(30,230)</b>	<b>4,025,013</b>	<b>51,406</b>	<b>4,076,419</b>
Dividend for 2019 approved at the Annual General Meeting (AGM) of March 23, 2020	-	-	-	-	-	-	-	-	-	(41,643)	-	-	(41,643)	-	(41,643)
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	86	-	(86)	-	-	-	-
Interest on capital expired	-	-	-	-	-	-	-	-	284	-	-	-	284	-	284
Restricted share plan - Vesting period	-	-	-	-	7,999	-	-	-	-	-	-	-	7,999	-	7,999
Restricted share plan - Delivery	-	-	817	11,141	(11,958)	-	-	-	-	-	-	-	-	-	-
Restricted shares - delivery of 4Bio shares	-	-	-	46	-	-	-	-	-	-	-	-	46	-	46
Profit for the period	-	-	-	-	-	-	-	-	167,996	-	-	-	167,996	2,257	170,253
Allocation of profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest on capital proposed	-	-	-	-	-	-	-	-	(96,000)	-	-	-	(96,000)	-	(96,000)
<b>At June 30, 2020</b>	<b>2,500,000</b>	<b>10,191</b>	<b>136,556</b>	<b>(26,954)</b>	<b>18,021</b>	<b>154,131</b>	<b>1,080,636</b>	<b>137,216</b>	<b>72,366</b>	<b>-</b>	<b>11,762</b>	<b>(30,230)</b>	<b>4,063,708</b>	<b>53,663</b>	<b>4,115,830</b>
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	85	-	(85)	-	-	-	-
Interest on capital expired	-	-	-	-	-	-	-	-	289	-	-	-	289	-	289
Restricted share plan - Vesting period	-	-	-	-	10,218	-	-	-	-	-	-	-	10,218	-	10,218
Restricted share plan - delivered	-	-	357	673	(1,030)	-	-	-	-	-	-	-	-	-	-
Profit for the period	-	-	-	-	-	-	-	-	316,448	-	-	-	316,448	8,832	325,280
Allocation of profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal reserve	-	-	-	-	-	24,222	-	-	(24,222)	-	-	-	-	-	-
Statutory reserve	-	-	-	-	-	-	198,316	-	(198,316)	-	-	-	-	-	-
Tax incentive reserve	-	-	-	-	-	-	-	69,650	(69,650)	-	-	-	-	-	-
Interest on capital proposed	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
- R\$ 0,011701207 per share	-	-	-	-	-	-	-	-	(27,522)	-	-	-	(27,522)	-	(27,522)
Interest on capital proposed	-	-	-	-	-	-	-	-	(69,478)	69,478	-	-	-	-	-
<b>At December 31, 2020</b>	<b>2,500,000</b>	<b>10,191</b>	<b>136,913</b>	<b>(26,283)</b>	<b>27,209</b>	<b>178,353</b>	<b>1,278,952</b>	<b>206,866</b>	<b>-</b>	<b>69,478</b>	<b>11,677</b>	<b>(30,230)</b>	<b>4,363,126</b>	<b>62,495</b>	<b>4,425,621</b>
Interest on capital for 2020 approved at the AGM of March 9, 2021	-	-	-	-	-	-	-	-	-	(69,478)	-	-	(69,478)	-	(69,478)
Interest on capital expired	-	-	-	-	-	-	-	-	292	-	-	-	292	-	292
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	83	-	(83)	-	-	-	-
Restricted share plan - Vesting period	-	-	-	-	4,345	-	-	-	-	-	-	-	4,345	-	4,345
Restricted share plan - Delivery	-	-	(1,348)	7,444	(6,096)	-	-	-	-	-	-	-	-	-	-
Restricted shares - delivery of 4Bio shares	-	-	-	73	-	-	-	-	-	-	-	-	73	-	73
Adjustment in percentage of interest - 4Bio	-	-	-	-	-	-	-	-	-	-	34,052	34,052	(34,027)	25	
Profit for the period	-	-	-	-	-	-	-	-	427,051	-	-	-	427,051	2,960	430,011
Allocation of profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest on capital proposed	-	-	-	-	-	-	-	-	(94,000)	-	-	-	(94,000)	-	(94,000)
<b>At June 30, 2021</b>	<b>2,500,000</b>	<b>10,191</b>	<b>135,565</b>	<b>(18,766)</b>	<b>25,458</b>	<b>178,353</b>	<b>1,278,952</b>	<b>206,866</b>	<b>333,428</b>	<b>-</b>	<b>11,594</b>	<b>3,822</b>	<b>4,665,461</b>	<b>31,428</b>	<b>4,696,889</b>

The accompanying notes are an integral part of this interim financial information.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Raia Drogasil S.A.

### Statements of cash flows

Six-month periods ended June 30, 2021 and 2020

All amounts in thousands of reais

	Note	Parent Company		Consolidated	
		Jun/21	Jun/20	Jun/21	Jun/20
<b>Cash flows from operating activities</b>					
Profit before income tax and social contribution	-	<b>589,734</b>	<b>215,440</b>	<b>596,821</b>	<b>216,843</b>
<b>Adjustments</b>					
Depreciation and amortization	21	627,810	564,418	629,907	566,805
Compensation plan with restricted shares, net	-	4,375	7,991	4,336	8,010
Interest on additional stock option	-	1,370	2,418	1,370	2,418
Loss (profit) on sale/write-off of property and equipment and intangible assets	-	8,909	1,225	8,906	1,225
Provision for legal claims	15	27,135	6,060	94,349	6,060
Provision for inventory losses	-	5,254	20,590	5,254	20,590
(Reversal of) provision for impairment of trade receivables	-	1,742	(192)	2,655	(154)
(Reversal of) provision for drugstore closures	-	(3,785)	(1,198)	(3,785)	(1,198)
(Reversal) provision for estimated losses on Other Assets	-	-	220	-	220
Interest expenses – borrowings	13	29,015	30,190	31,518	30,304
Interest expenses – leases	14	114,669	108,625	114,776	108,753
Amortization of transaction costs of debentures and promissory notes	13	2,388	1,705	2,388	1,705
Equity in the results of subsidiaries	9	16	(2,759)	3,001	-
Discounts on property rental	21	(6,419)	(9,371)	(6,419)	(9,371)
		<b>1,402,213</b>	<b>945,362</b>	<b>1,485,077</b>	<b>952,210</b>
<b>Changes in assets and liabilities</b>		<b>(811,842)</b>	<b>(720,259)</b>	<b>(912,276)</b>	<b>(721,244)</b>
Trade and other receivables	-	(202,057)	(96,121)	(215,256)	(129,227)
Inventories	-	(360,776)	(265,420)	(382,979)	(283,838)
Other current assets	-	(1,740)	(25,621)	(66,179)	(23,021)
Long-term receivables	-	(29,621)	(11,995)	8,575	(11,070)
Trade payables	-	(426,671)	(462,317)	(428,165)	(419,054)
Salaries and social charges	-	101,864	117,300	103,699	118,754
Taxes and contributions	-	48,893	1,415	43,973	2,973
Other obligations	-	(4,348)	13,262	(38,558)	14,001
Rentals payable	-	62,614	9,238	62,614	9,238
<b>Cash provided by operations</b>		<b>590,371</b>	<b>225,103</b>	<b>572,801</b>	<b>221,595</b>
Interest paid	13	(28,844)	(24,621)	(29,616)	(24,621)
Income tax and social contribution paid	-	(157,822)	(87,070)	(157,822)	(87,070)
Interest paid – leases	14	(114,669)	(108,625)	(114,776)	(108,753)
<b>Net cash provided by operating activities</b>		<b>(301,335)</b>	<b>(220,316)</b>	<b>(302,214)</b>	<b>(220,444)</b>
<b>Cash flows from investing activities</b>					
Investments in associated and subsidiary companies	-	(72,580)	(3,289)	(14,605)	(3,289)
Cash acquired in business combination	-	-	-	13,275	-
Net assets acquired in business combination	-	-	-	(14,292)	-
Purchases of property and equipment and intangible assets	-	(319,283)	(286,395)	(364,508)	(287,460)
Proceeds from sale of property and equipment	-	675	8	675	8
Loans granted to subsidiary	-	-	(1,083)	-	-
<b>Net cash used in investing activities</b>		<b>(391,188)</b>	<b>(290,759)</b>	<b>(379,455)</b>	<b>(290,741)</b>
<b>Cash flows from financing activities</b>					
Borrowings taken	13	299,010	696,392	339,010	711,420
Repayment of borrowings	13	(406,787)	(116,862)	(439,716)	(116,862)
Leases paid	-	(319,582)	(238,834)	(320,440)	(239,544)
Interest on capital and dividends paid	-	(83,658)	(107,605)	(83,658)	(107,605)
<b>Net cash provided by / (used in) financing activities</b>		<b>(511,017)</b>	<b>233,091</b>	<b>(504,804)</b>	<b>247,409</b>
Increase (decrease) cash and cash equivalents		<b>(613,169)</b>	<b>(52,881)</b>	<b>(613,672)</b>	<b>(32,810)</b>
Cash and cash equivalents at January 1	5	855,257	294,863	880,357	299,226
<b>Cash and cash equivalents at June 30</b>	5	<b>242,088</b>	<b>241,982</b>	<b>266,685</b>	<b>266,416</b>

The accompanying notes are an integral part of this interim financial information.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Raia Drogasil S.A.

### Statement of value added Three and six-month periods ended June 30, 2021 All amounts in thousands of reais

	Parent Company				Consolidated			
	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20
<b>Revenue</b>	<b>5,854,703</b>	<b>11,465,165</b>	<b>4,424,859</b>	<b>9,316,052</b>	<b>6,186,498</b>	<b>12,120,355</b>	<b>4,696,556</b>	<b>9,849,828</b>
Gross sales and services	5,851,163	11,457,439	4,410,348	9,313,786	6,183,476	12,113,240	4,681,831	9,847,600
Other income	3,058	7,321	528	2,294	3,066	7,329	528	2,294
Provision for (reversal of) impairment of trade receivables	482	405	13,983	(28)	(44)	(214)	14,197	(66)
<b>Inputs acquired from third parties</b>	<b>(3,839,548)</b>	<b>(7,576,657)</b>	<b>(2,995,441)</b>	<b>(6,252,602)</b>	<b>(4,117,497)</b>	<b>(8,130,644)</b>	<b>(3,229,756)</b>	<b>(6,713,670)</b>
Cost of sales and services	(3,477,766)	(6,863,017)	(2,648,607)	(5,608,257)	(3,746,660)	(7,401,262)	(2,877,235)	(6,055,994)
Materials, energy, outsourced services and other	(361,782)	(713,640)	(346,834)	(644,345)	(370,837)	(729,382)	(352,520)	(657,675)
<b>Gross value added</b>	<b>2,015,155</b>	<b>3,888,508</b>	<b>1,429,418</b>	<b>3,063,450</b>	<b>2,069,001</b>	<b>3,989,711</b>	<b>1,466,800</b>	<b>3,136,158</b>
Depreciation and amortization	(310,454)	(611,102)	(273,943)	(550,675)	(311,329)	(613,057)	(275,144)	(553,062)
<b>Net value added generated by the entity</b>	<b>1,704,701</b>	<b>3,277,406</b>	<b>1,155,475</b>	<b>2,512,775</b>	<b>1,757,672</b>	<b>3,376,654</b>	<b>1,191,656</b>	<b>2,583,096</b>
<b>Value added received through transfer</b>	<b>32,411</b>	<b>45,027</b>	<b>17,285</b>	<b>34,577</b>	<b>34,323</b>	<b>45,295</b>	<b>16,342</b>	<b>33,734</b>
Equity in the results of subsidiaries	(276)	(17)	1883	2758	287	(1,228)	(1)	(1)
Finance income	29,842	40,812	15686	32,785	31,191	42,291	16,627	34,701
Other	2,845	4,232	(284)	(966)	2,845	4,232	(284)	(966)
<b>Total value added to distribute</b>	<b>1,737,112</b>	<b>3,322,433</b>	<b>1,172,760</b>	<b>2,547,352</b>	<b>1,791,995</b>	<b>3,421,949</b>	<b>1,207,998</b>	<b>2,616,830</b>
<b>Distribution of value added</b>								
<b>Personnel</b>	<b>578,342</b>	<b>1,107,087</b>	<b>491,681</b>	<b>970,910</b>	<b>588,996</b>	<b>1,126,200</b>	<b>499,472</b>	<b>986,455</b>
Direct remuneration	457,235	868,840	380,599	753,586	463,479	880,343	385,253	762,699
Benefits	83,939	164,776	81,054	154,222	87,861	171,475	83,768	159,866
Unemployment compensation fund	37,168	73,471	30,028	63,102	37,656	74,382	30,451	63,890
<b>Taxes and contributions</b>	<b>775,688</b>	<b>1,542,034</b>	<b>538,139</b>	<b>1,194,478</b>	<b>813,635</b>	<b>1,612,574</b>	<b>562,300</b>	<b>1,242,492</b>
Federal	199,667	412,683	105,448	278,892	206,581	421,469	106,607	281,373
State	566,380	1,109,318	423,765	897,720	597,258	1,170,829	446,676	943,017
Municipal	9,641	20,033	8,926	17,866	9,796	20,276	9,017	18,102
<b>Providers of capital</b>	<b>130,327</b>	<b>246,261</b>	<b>98,264</b>	<b>213,968</b>	<b>133,715</b>	<b>251,298</b>	<b>100,010</b>	<b>217,631</b>
Interest	93,144	174,806	86,233	174,296	96,113	179,028	87,587	177,221
Rentals	37,183	71,455	12,031	39,672	37,602	72,270	12,423	40,410
<b>Interest on capital and dividends</b>	<b>252,755</b>	<b>427,051</b>	<b>44,676</b>	<b>167,996</b>	<b>255,649</b>	<b>431,877</b>	<b>46,217</b>	<b>170,253</b>
Interest on capital	50,000	94,000	49,000	96,000	50,000	94,000	49,000	96,000
Retained earnings for the period	202,755	333,051	(4,324)	71,996	201,743	332,039	(4,324)	71,996
Noncontrolling interests in retained earnings	-	-	-	-	3,906	5,838	1,541	2,257
<b>Value added distributed and retained</b>	<b>1,737,112</b>	<b>3,322,433</b>	<b>1,172,760</b>	<b>2,547,352</b>	<b>1,791,995</b>	<b>3,421,949</b>	<b>1,207,998</b>	<b>2,616,830</b>

The accompanying notes are an integral part of this interim financial information.



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 1. Operations

Raia Drogasil S.A. ("Company" or "Raia Drogasil" or "Parent Company") is a publicly-held company with its headquarters at Av. Corifeu de Azevedo Marques, 3.097, São Paulo – SP, listed on the Novo Mercado ("New Market") listing segment of B3 S.A. - Brasil, Bolsa, Balcão, under ticker RADL3.

Raia Drogasil S.A. and its subsidiaries (together "Consolidated" or "Group") are mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. The Group conducts its sales through 2,378 drugstores (2,303 drugstores - 2020), distributed in 24 Brazilian states (24 states - 2020), as presented below:

State	Consolidated	
	Jun/21	Dec/20
<b>Southeast region</b>	<b>1,502</b>	<b>1,482</b>
São Paulo	1,110	1,108
Minas Gerais	179	169
Rio de Janeiro	163	156
Espírito Santo	50	49
<b>Northeast region</b>	<b>318</b>	<b>297</b>
Pernambuco	79	75
Bahia	74	71
Ceará	53	46
Maranhão	23	18
Sergipe	21	20
Alagoas	20	20
Paraíba	19	19
Rio Grande do Norte	15	14
Piauí	14	14
<b>South region</b>	<b>260</b>	<b>243</b>
Paraná	129	127
Rio Grande do Sul	66	59
Santa Catarina	65	57
<b>Midwest region</b>	<b>229</b>	<b>219</b>
Goiás	92	87
Distrito Federal	78	77
Mato Grosso do Sul	30	29
Mato Grosso	29	26
<b>North region</b>	<b>69</b>	<b>62</b>
Pará	42	42
Tocantins	12	11
Amazonas	10	7
Rondônia	5	2
<b>Total</b>	<b>2,378</b>	<b>2,303</b>

Raia Drogasil's drugstores, as well as the Group's e-commerce demands, are supplied by eleven distribution centers located in nine states: São Paulo, Rio de Janeiro, Minas Gerais, Paraná, Goiás, Pernambuco, Bahia, Ceará and Rio Grande do Sul.

The subsidiary 4Bio Medicamentos S.A. ("4Bio" or "Subsidiary") markets its products through telesales and the delivery is made directly to the customer's location or through its four call centers in the states of São Paulo, Tocantins and Pernambuco.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 2. Presentation of quarterly information

In conformity with Rule 505/2006 issued by the CVM, authorization to issue this interim financial information (ITR) was granted by the Company's Board of Directors on August 6, 2021.

The interim financial information is presented in thousands of Brazilian reais (R\$), which is the Group's functional and presentation currency.

The individual and consolidated interim financial information for the period ended June 30, 2021 has been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian General Technical Accounting Standards (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the interim financial information, which is consistent with the information used by management.

The individual interim financial information is disclosed together with the consolidated interim financial information, which includes the interim financial information of the Company and its subsidiaries 4Bio, Vitat and RD Ventures FIP and has been prepared in accordance with consolidation practices and applicable legal provisions.

The accounting practices adopted by the subsidiaries were applied uniformly and consistently with those adopted by the Company. Where applicable, all transactions, balances, income and expenses between the subsidiary and the Company are fully eliminated in the consolidated quarterly information.

The interim financial information includes accounting estimates and requires management to exercise its judgment in the process of applying the Company's accounting policies regarding provision for inventory losses, provision for expected credit losses, appreciation of financial instruments, recoverable taxes, the amortization and depreciation periods for property and equipment and intangible assets, estimate of impairment of intangible assets with indefinite useful life, provision for legal claims, fair value measurement of financial liabilities, determination of provision for taxes, recognition of revenues from commercial agreements, among others. The significant estimates and judgments are disclosed in Note 4(w) to the financial statements for the year ended December 31, 2020.

The presentation of the individual and consolidated statements of value added is required by the Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies, while it is not required by IFRS. Therefore, under the IFRS, the presentation of such statements is considered supplementary information, and not part of the set of the interim financial information.

The Group adopted all standards, revised standards and interpretations issued by the IFRS and CPC that were effective as at June 30, 2021.

#### Impacts of Covid-19 pandemic

In compliance with CVM Circular Letter SNC/SEP 03/2020, in view of the current scenario in Brazil due to the Covid-19 pandemic, the Company assessed the provision for expected credit losses, taking into consideration all facts and circumstances, in order to verify whether in fact there was a significant increase in credit risk or any temporary liquidity restriction.

The Company adopted the assessment of trade receivables at June 30, 2021 as the calculation basis. On this date, the Company's receivables with respect to total accumulated sales were represented by: (i) Cards (83.7%), (ii) Cash (12.9%) and others (3.4%).

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

Trade receivables at June 30, 2021 are presented below:

<b>Trade receivables</b>	<b>Jun/21</b>	<b>%</b>
Credit / debit cards	1,504,902	95.6
Popular Pharmacy	36,366	2.3
Agreements with companies – Univers	18,898	1.2
Medicine Benefit Program – PBM	13,299	0.8
Trade receivables – Checks (cash/post-dated)	924	0.1
Trade receivables – Apps/Marketplace	562	0.0
Trade receivables – Manipulaê	3	0.0
Expected credit losses	(838)	0.0
<b>Total</b>	<b>1,574,116</b>	<b>100.0</b>

Regarding trade receivables items with greater representation, it is worth emphasizing that: (i) Credit / debit cards (95.6%) are concentrated on card administrators (Getnet, Cielo and Rede), where, of this amount, the Company should receive 69.7% in July 2021, and the remaining amount is substantially scheduled to be received in August, September, October, November and December 2021; and (ii) for the Popular Pharmacy Program (2.3%), there are no indicators that would justify any adjustment to the provision in Management's understanding, since no impact has been noted, such as the increase in default or in the average term of receipts.

Accordingly, Management assessed and concluded that there was no significant increase in credit risk regarding Trade Receivables that could justify any adjustment to the provision for expected credit losses, as well as the need for any additional disclosure, at this time, regarding the impact of the Covid-19 pandemic on the Company's receivables.

Despite the social distancing measures imposed by the Government in virtually all Brazilian states, in Management's assessment, there was no significant impact on sales indicating structural problems that could impact the accounting estimates with respect to: recoverability of financial assets (cash and cash equivalents, financial investments), realization of inventories, realization of deferred taxes, provisions for employee benefits, recoverability of indirect taxes, covenants, renegotiation of lease agreements, revaluation of assets, e-commerce revenue and taxes on profit.

Up to June 30, 2021, 102 drugstores were opened and 27 drugstores were closed (240 drugstores were opened and 11 drugstores were closed in 2020). All drugstore closures were carried out to optimize our drugstore portfolio, with positive expectations of return. The Covid-19 pandemic had no significant impact on the Company's expansion plan.

In accordance with CVM Ruling 859/2020, which addresses amendments to NBC TG 06 (R3) – Leases, Covid-19-related rent concessions – the Company has assessed that the benefits arising from lease discounts obtained on some properties are specific events and have not resulted in changes in the terms of lease agreements (Note 21).

### 3. New accounting procedures, amendments to and interpretations of standards

#### New accounting procedures

There are no accounting standards, guidance or pronouncements that became effective for the first time as from the quarter ended June 30, 2021.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### Standards issued but not yet effective

The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company's interim financial information are disclosed below. The Company intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.

#### (a) NBC TG 11 (R2), CPC 50 / IFRS 17 – Insurance contracts

In May 2017, the IASB issued IFRS 17 - Insurance Contracts (standard not yet issued by CPC in Brazil, but which will be coded as CPC 50 - Insurance Contracts and will replace NBC TG 11 (R2)- Insurance Contracts), a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. The core of IFRS 17 is the general model, supplemented by:

- (i) A specific adaptation for contracts with direct participation features (the variable fee approach);
- (ii) A simplified approach (the premium allocation approach) mainly for short-duration contracts.

IFRS 17 is effective for reporting periods beginning on or after January 1, 2023, with comparative figures required. Early application is permitted, provided the entity also applies IFRS 9 and IFRS 15 on or before the date it first applies IFRS 17. Management understands that this standard is not applicable to the Company's interim financial information.

#### (b) NBC TG 26 (R5) / IAS 1: Presentation of Financial Statements

Classification of Liabilities as current or non-current

In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1, corresponding to NBC TG 26 (R5) to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:

What is meant by a right to defer settlement?

- (i) That a right to defer must exist at the end of the reporting period;
- (ii) That classification is unaffected by the likelihood that an entity will exercise its deferral right; and
- (iii) That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification.

The amendments are effective for reporting periods beginning on or after January 1, 2023 and must be applied retrospectively. The Company is currently assessing the impact the amendments would have on current practice and whether existing loan agreements could require renegotiation, however, up to this moment, Management concludes that these amendments did not have significant impacts on the interim financial information.

#### (c) Amendment to IFRS 3 - Reference to the Conceptual Framework

This Amendment to IFRS 3 - Business Combination is effective for periods beginning January 1, 2022, aiming to clarify some alterations regarding the conceptual framework, without significant changes. Management is assessing possible impacts to the Company.

#### (d) Amendment to IAS 16 – Property, Plant and Equipment: Proceeds before intended use

This Amendment to IFRS 16, which will become effective as from January 1, 2022, prohibits entities deducting the cost of an item of property, plant and equipment from any proceeds from selling items produced while bringing that asset to the location and conditions necessary for it to be able of operating in the manner intended by Management. Instead, the Company should recognize in profit or loss for the year the proceeds from selling such items and the costs of producing those items, when incurred. Management is assessing possible impacts to the Company.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### (e) Amendment to IAS 37/ NBC TG 25 – Onerous Contracts: Costs of Fulfilling a Contract

This Amendment to IAS 37 / NBC TG 25 will become effective as from January 1, 2022, whose main changes aim at specifying that the 'cost of fulfilling' a contract comprises 'costs that relate directly to the contract'. The costs that relate directly to a contract may be incremental costs and an allocation of other costs directly related to the performance of a contract. Management periodically assesses its contracts and sets up possible provisions when identified.

## 4. Significant accounting practices

The accounting practices adopted for preparing this interim financial information are consistent with those disclosed in Note 4 to the financial statements for the year ended December 31, 2020, disclosed on March 9, 2021.

## 5. Cash and cash equivalents

Cash and cash equivalents items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Cash and banks	111,114	116,076	112,924	117,167
Investment fund	-	-	2,495	2,174
Automatic investments <sup>(i)</sup>	13,648	11,871	19,395	13,145
Bank Deposit Certificates - CDB <sup>(ii)</sup>	28,970	53,716	39,315	53,716
Debentures held under repurchase agreements <sup>(iii)</sup>	88,356	673,594	92,556	694,155
<b>Total</b>	<b>242,088</b>	<b>855,257</b>	<b>266,685</b>	<b>880,357</b>

(i) Refers to a short-term fixed income fund with short-term investments and automatic redemptions.

(ii) Investments in bank deposit certificate have daily liquidity and grace period of 30 days.

(iii) Refers to a fixed income investment with income linked to the variation of the Interbank Deposit Certificate - CDI, backed by publicly offered debentures issued by companies, with commitment of repurchase by the Bank and resale by the Group, according to the conditions previously established in which financial institutions that negotiated these securities guarantee credit risk, of low risk to the Group, immediate liquidity and without loss of income.

The financial investments are distributed at the banks Banco do Brasil, Banrisul, Bradesco, Caixa Econômica, Daycoval, Itaú, Safra and Santander.

The Group's exposure to interest rate risks on financial investments is disclosed in Note 24 a.

## 6. Trade receivables

Trade receivables items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Trade receivables	1,579,370	1,376,516	1,778,584	1,559,908
(-) Expected credit losses	(838)	(646)	(2,880)	(2,069)
(-) Adjustment to present value	(4,416)	(2,069)	(5,034)	(2,405)
<b>Total</b>	<b>1,574,116</b>	<b>1,373,801</b>	<b>1,770,670</b>	<b>1,555,434</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

The aging of trade receivables is presented below:

Maturities	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Not yet due	1,577,380	1,372,587	1,763,873	1,545,854
Overdue:				
Between 1 and 30 days	1,292	2,954	6,399	6,565
Between 31 and 60 days	262	537	2,930	2,214
Between 61 and 90 days	83	60	1,062	969
Between 91 and 180 days	353	378	2,512	3,038
Between 181 and 360 days	-	-	1,808	1,268
(-) Expected credit losses	(838)	(646)	(2,880)	(2,069)
(-) Adjustment to present value	(4,416)	(2,069)	(5,034)	(2,405)
<b>Total</b>	<b>1,574,116</b>	<b>1,373,801</b>	<b>1,770,670</b>	<b>1,555,434</b>

Days sales outstanding, represented by credit and debit cards and partnerships with companies and the Government, are approximately 42 days (40 days in Dec/2020), term that is considered part of the normal conditions inherent in Group's operations. A substantial portion of the amounts overdue for more than 31 days are represented by collection through special plans and Medicine Benefit Programs – PBMs.

The changes in expected credit losses are presented below:

Changes in expected losses	Parent Company	Consolidated
At January 1 <sup>st</sup> , 2020	(1,250)	(3,430)
Additions	(3,231)	(5,532)
Reversals	1,013	3,184
Losses	2,412	2,504
At June 30, 2020	<b>(1,056)</b>	<b>(3,274)</b>
Additions	(10,720)	(12,895)
Reversals	2,142	3,763
Losses	8,988	10,337
At December 31, 2020	<b>(646)</b>	<b>(2,069)</b>
Additions	(2,533)	(4,920)
Reversals	791	2,265
Losses	1,550	1,844
<b>At June 30, 2021</b>	<b>(838)</b>	<b>(2,880)</b>

Trade receivables are classified as financial assets at amortized cost and are therefore measured as described in Note 4(d) – Impairment to the interim financial information for the six-month period ended June 30, 2021.

## 7. Inventories

Inventory items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Goods for resale	4,495,678	4,139,133	4,630,708	4,251,814
Consumables	13,627	6,317	13,627	6,317
(-) Provision for inventory losses	(33,450)	(28,196)	(33,450)	(28,196)
(-) Adjustment to present value	(7,491)	(4,412)	(7,752)	(4,527)
<b>Total inventory</b>	<b>4,468,364</b>	<b>4,112,842</b>	<b>4,603,133</b>	<b>4,225,408</b>

## Notes to the parent company and consolidated interim financial information

### June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

Changes in the provision for expected losses on goods are as follows:

<b>Changes in expected losses on goods</b>	<b>Parent Company</b>	<b>Consolidated</b>
At January 1 <sup>st</sup> , 2020	(13,116)	(13,116)
Additions	(26,604)	(26,604)
Write-offs	6,014	6,014
At June 30, 2020	<b>(33,706)</b>	<b>(33,706)</b>
Additions	(12,772)	(12,772)
Write-offs	18,282	18,282
At December 31, 2020	<b>(28,196)</b>	<b>(28,196)</b>
Additions	(8,663)	(8,663)
Write-offs	3,409	3,409
<b>At June 30, 2021</b>	<b>(33,450)</b>	<b>(33,450)</b>

For the six-month period ended June 30, 2021, cost of goods sold recognized in the statement of income was R\$ 7,507,593, Note 21, (R\$ 6,209,473 – Jun/2020) for the Parent Company and R\$ 8,046,287 (R\$ 6,657,672 – Jun/2020) for the Consolidated accounts, including the amount of the write-offs of goods inventories recognized as losses for the period amounting to R\$ 91,053 (R\$ 69,415 – Jun/2020) for the Parent Company and R\$ 91,753 (R\$ 69,923 – Jun/2020) for the Consolidated accounts.

The effect of the recognition, reversal or write-off of the provision for inventory losses is included in cost of sales in the statement of income.

## 8. Recoverable taxes

<b>Recoverable taxes items</b>	<b>Parent Company</b>		<b>Consolidated</b>	
	<b>Jun/21</b>	<b>Dec/20</b>	<b>Jun/21</b>	<b>Dec/20</b>
<b>Taxes on profit recoverable</b>				
Withholding Income Tax (IRRF)	2,214	1,255	2,412	1,255
Corporate Income Tax (IRPJ)	2,925	214	9,502	7,162
Social Contribution on Net Profit (CSLL)	199	23	2,569	2,535
<b>Subtotal</b>	<b>5,338</b>	<b>1,492</b>	<b>14,483</b>	<b>10,952</b>
<b>Other recoverable taxes</b>				
Value Added Tax on Sales and Services (ICMS) – credit balance (i)	44,577	43,710	48,003	48,396
ICMS – Refund of ICMS withheld in advance (ii)	10,122	10,543	10,122	10,543
ICMS on acquisitions of fixed assets	82,923	92,583	82,923	92,583
Social Integration Program (PIS)	10,818	427	11,500	1,120
Social Contribution on Revenue (COFINS)	50,572	2,706	53,219	5,623
Social Investment Fund (FINSOCIAL) - 1982 - securities issued to cover court-ordered debts	561	561	561	561
National Institute of Social Security (INSS)	-	3,301	-	3,301
<b>Subtotal</b>	<b>199,573</b>	<b>153,831</b>	<b>206,328</b>	<b>162,127</b>
<b>Total</b>	<b>204,911</b>	<b>155,323</b>	<b>220,811</b>	<b>173,079</b>
Current assets	82,239	59,288	91,047	61,531
Non-current assets	122,672	96,035	129,764	111,548

(i) The ICMS credits amounting to R\$ 44,577 and R\$ 10,122 (R\$ 43,710 and R\$ 10,543 - Dec/2020) for the Parent Company and R\$ 48,003 and R\$ 10,122 (R\$ 48,396 and R\$ 10,543 - Dec/2020) for the Consolidated accounts are the result of applying different ICMS rates and of refunds of ICMS-ST (the Substitute Taxpayer Regime) on goods receiving and shipping operations carried out by the Company's distribution centers in the states of Pernambuco and Rio Grande do Sul, in order to supply their branches located in other Brazilian states. The respective tax credits have been progressively consumed in the last months, mainly due to goods that are not under the substitute taxpayer regime.



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### Final and unappealable – Exclusion of ICMS from the PIS and COFINS tax bases – Ordinary proceeding distributed by Drogasil S.A. in April 1986

On March 15, 2017, the Federal Supreme Court (STF) concluded the judgment on the merits of Appeal to Supreme Court No. 574,706, with general repercussion effects, thereby entitling taxpayers to the right of excluding ICMS from the PIS and COFINS tax bases.

The Company has a lawsuit filed in 1986 to discuss the right to exclude the ICMS from the PIS and Finsocial calculation basis, for which a final and unappealable decision was rendered and the lawsuit was returned to the court of origin in May 2019. The effects of this ruling also apply to Cofins since the proceeding acknowledges Finsocial succession by Cofins.

It is worth remembering that the criteria for calculating the credits and the modulation of the effects of the decision of the aforementioned appeal are still awaiting the judgment of the appeal for clarification filed by the General Prosecution Unit of the National Treasury in RE 574,706. The aforementioned decision is essential for the calculations, as the decision rendered related to the Company's lawsuit did not consider the merits related to which ICMS amount should be excluded from the PIS/Cofins calculation basis (the amount separately stated in the invoice, the forecast amount or the calculated amount).

Therefore, in order to assure greater legal certainty for the purpose of recovering credits from past periods, the Company opted to momentarily adopt the criterion determined by the Brazilian Federal Revenue under the terms of Cosit Private Letter Ruling 13/18 and Normative Instruction (IN) 1,911/19, having determined credits in the amount of R\$ 4,809, which were fully offset up to December 2020. As these amounts correspond to the period from 2013 to 2017, the principal (R\$ 3,503) was recorded in the non-recurring result and the monetary restatement (R\$ 1,306) in the finance income (costs) for the year ended December 31, 2019.

On May 13, 2021, the Federal Supreme Court (STF) partially accepted the appeals for clarification filed by the Federal Government, determining that the ICMS amount to be excluded from the PIS and COFINS calculation basis is the one separately stated on the invoice, but the matter should only be effective beginning March 15, 2017, date of the judgment on the merits of RE 574,706/PR, except for the lawsuits and administrative proceedings filed until said date (session held by videoconference - Resolution 672/2020/STF).

Once the ICMS amount separately stated on the invoice was considered as the calculation criteria, the Company recorded the additional amount of R\$ 58,044 in the non-recurring result in May 2021 (Note 22), of which R\$ 42,025 refers to the principal amount and R\$ 16,019 to the monetary adjustment.

### Undue payment of social security contributions on payroll discounts

A review of the payments related to social security contribution on the payroll made in the last five years was performed and it was identified an undue payment of the contributions on amounts discounted from the payroll that would qualify as not subject to tax levy or as exemption based on favorable court decisions that defend that the discounts on the payroll for purposes of co-participation of employees in benefits exempt from social security contribution (employer portion) should also not be subject to any social security taxation. Accordingly, based on the analyses and opinions prepared by our lawyers and advisors, we determined an amount of tax credit of R\$ 32,728, which was fully offset up to March 2021.



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### Expected realization of credits

The expected realization of amounts classified in current and non-current assets is as follows:

Expected realization	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
In the next 12 months	82,239	59,288	91,047	61,531
Between 13 and 24 months	45,998	23,870	45,998	23,870
Between 25 and 36 months	32,118	23,868	39,210	36,497
Between 37 and 48 months	21,998	23,868	21,998	26,752
Between 49 and 60 months	22,558	24,429	22,558	24,429
<b>Total</b>	<b>204,911</b>	<b>155,323</b>	<b>220,811</b>	<b>173,079</b>

## 9. Investments

### 9.1 Business combinations and goodwill

#### (a) Business combination – 4Bio Medicamentos S.A.

In 2015, the Company acquired a 55% equity interest in 4Bio Medicamentos S.A. ("4Bio") and obtained its control on October 1, 2015.

The agreement establishes the granting of call and put options for all the remaining shares, corresponding to 45% of the total, which continued to be held by the founding stockholder. On September 24, 2019, the Company and the Equity Investment Fund Kona ("Kona"), holder of the shares of the founding stockholder, as agreed, signed an amendment to the original purchase and sale agreement changing the period of exercise of the call options held by the Company and of the put options held by Kona, related to the remaining 45% of 4Bio, adopting the following criterion: (i) 1<sup>st</sup> call and put options of shares, equivalent to 30% of the capital, will be exercisable between January 1, 2021 and June 30, 2021, having as reference the average of adjusted EBITDA of 4Bio for the years ended December 31, 2018, 2019 and 2020; (ii) 2<sup>nd</sup> call and put options of shares, equivalent to 15% of the capital, will be exercisable after January 1st, 2024 and June 30, 2024, having as reference the average of adjusted EBITDAs of 4Bio for the years ending December 31, 2021, 2022 and 2023. It was also established that Mr. André Kina will continue as CEO of 4Bio at least until the end of 2023.

On April 22, 2021, Kona submitted to the Company the Notice of Exercise of the First Put Option of shares equivalent to 30% of the capital of subsidiary 4Bio. The shares were transferred on May 13, 2021, upon the payment of R\$ 11,884. After the exercise of the first put option, the Company became the holder of 85% of the capital of 4Bio Medicamentos S.A.

The fair value of the financial liability referring to the additional shares recorded in Parent Company and Consolidated, of R\$ 35,934 (R\$ 46,448 - Dec/20), is classified as Level 3 in the fair value hierarchy. The main fair value measurements have as reference: (i) a discount rate of 12.60% in June 2021 (12.60% - Dec/20), (ii) an average growth rate of EBITDA of 18.02% in June 2021 (18.02% - Dec/20), considering the average of the EBITDAs projected for 2018 to 2021 and the multiple provided for in contract.

The goodwill arising on acquisition of R\$ 12,907 (R\$ 12,907 – Dec/20) for the Parent Company and R\$ 25,563 (R\$ 25,563 – Dec/20) for the Consolidated accounts represents the future economic benefits expected from the business combination.

#### (b) Business combinations – Vitat Serviços em Saúde Ltda. (former "Tech.fit")

On February 18, 2021, the Company announced to its shareholders and to the market in general that it entered into an Agreement for the acquisition of 100% of the equity interest in B2U Editora S.A. ("Tech.fit").

Tech.fit is a Brazilian start-up with years of experience in developing digital platforms for the promotion of healthy habits. Its platform includes apps such as Tecnonutri, Dieta e Saúde, Workout and Cuidaí, which promote healthy eating habits

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

and physical activities through nutritional programs, training plans and access to professionals such as nutritionists, psychologists and physical educators.

On March 5, 2021, the Company received the final approval by the Administrative Council for Economic Defense (CADE) and, upon compliance with the remaining precedent conditions established in the Agreement, on April 1, 2021, the Company entered into the Closing Term and made the payments set forth in the Agreement, taking over control of Tech.fit.

On May 4, 2021, the Company changed the name of the subsidiary to Vitat Serviços em Saúde Ltda. ("Vitat"), converted the subsidiary into a privately-held limited company, also adopting the trade name "Vitat", and included in its corporate purpose: health management support activities, nursing activities, diagnostic and therapeutic complementary services, other professional, scientific, and technical activities, clinical laboratories, activities of health care professionals and human health care activities, with the purpose of accelerating the development of our Health Platform, offering customers health promotion, prevention, customized journeys and contents.

The Company adopted the balance sheet as at March 31, 2021 as the opening balance sheet for purposes of allocating the effects of the acquisition. The following table summarizes the consideration paid and the fair values of assets acquired and liabilities assumed recognized at the acquisition date.

	<u>Parent Company</u>
<b>At April 1<sup>st</sup>, 2021</b>	
Cash paid to founding shareholders	45,000
Adjustment to Purchase Price	13,072
<b>Total consideration transferred</b>	<b><u>58,072</u></b>
<b>Amounts recognized of identifiable assets acquired and liabilities assumed</b>	
Cash and cash equivalents	13,275
Trade notes receivable	2,635
Trademarks (included in intangible assets) (Note 10b) <sup>(i)</sup>	2,394
Platform (included in intangible assets) (Note 10b) <sup>(i)</sup>	16,500
Non-compete agreement (included in intangible assets) (Note 10b) <sup>(i)</sup>	4,000
Property and equipment, net (Note 10a)	228
Intangible assets, net (Note 10b)	1,106
Recoverable taxes	32
Other credits	274
Trade notes payable to suppliers	(389)
Social security and labor obligations	(599)
Tax obligations	(140)
Other obligations	(2,130)
<b>Total identifiable net assets</b>	<b><u>37,186</u></b>
Goodwill	20,886
	<b><u>58,072</u></b>

(i) The fair value of intangible assets (platform, brand and non-compete agreement) has been assessed provisionally and is subject to the completion of an independent appraisal. .

The goodwill arising from the acquisition of R\$ 20,886 represents the future economic benefits expected from the business combination. If new information obtained within one year from the acquisition date, on the facts and circumstances that existed on the date of the acquisition, indicate adjustments to the amounts mentioned above, or any additional provision that existed on that date, the acquisition recorded may be reviewed.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 9.2 Incorporation of company

#### (b) Incorporation of company – Stix Fidelidade e Inteligência S.A.

The Company together with Grupo Pão de Açúcar (“GPA”) announced the first Brazilian coalition of retailers with national companies through the creation of the company Stix Fidelidade (“Stix”). Stix was born with a platform of products and services for the accumulation and redemption of points, in order to offer discounts and advantages to the loyal customers of the two Companies, in addition to having the support in more than 3 thousand establishments across the country through the Drogasil, Droga Raia, Extra and Pão de Açúcar brands.

The Stix Fidelidade program focuses on offering valuable and affordable benefits to participants in a wide range of segments, building customer loyalty and generating value for the companies that will integrate its platform. The program was launched in October 2020, for customers who make their purchases at Droga Raia, Drogasil, Extra and Pão de Açúcar stores, accumulating Stix points.

Stix Fidelidade has its shareholding structure represented by 66.77% of GPA and 33.33% of the Company and it is an autonomous company, with a Board of Directors formed by members appointed by the shareholders.

On February 29, 2020, the Company made a capital contribution in the amount of R\$ 3,289 and on February 28, 2021, it made a capital contribution in the amount of R\$ 6,508, maintaining its proportional ownership interest.

#### (b) Incorporation of company - RD Ventures Fundo de Investimento em Participações - Multiestratégia

On October 22, 2020, the Company incorporated the private equity investment fund as a closed-end fund, pursuant to CVM Instruction 578 of August 30, 2016, as amended (“CVM Instruction 578”), to CVM Instruction 579 of August 30, 2016 and to Code ABVCAP/ANBIMA of Regulations and Best Practices, as well as other applicable legal and regulatory provisions, with the name RD Ventures Fundo de Investimento em Participações – Multiestratégia (“FIP RD Ventures”).

FIP RD Ventures is managed by Paraty Capital Ltda., a company headquartered at Rua dos Pinheiros, 870, conjunto 133, Pinheiros, in the city of São Paulo, state of São Paulo, registered at the National Registry of Legal Entities (CNPJ/ME) under No. 18.313.996/0001-50, duly authorized by the Brazilian Securities Commission (“CVM”) to manage securities portfolio.

On December 30, 2020, the Company made a capital contribution in the amount of R\$ 4,500 and on March 10, 2021 it made a capital contribution in the amount of R\$ 8,000.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 9.3 Composition and changes in investments

At June 30, 2021 and December 31, 2020, the Company's investment balance is presented below:

Investee	Main activity	Jun/21		Dec/20	
		Direct interest (%)	Parent Company	Direct interest (%)	Parent Company
4Bio	Retail of special medicines Platform of products and services	85%	112,671	55%	73,768
Stix Fidelidade (i)	for the accumulation and redemption of points	33%	(1,043)	33%	(4,578)
RD Ventures FIP	Private equity investment fund	100%	11,576	100%	4,498
Vitat	Supporting health management and promoting healthy habits	100%	57,060	-	-
<b>Total</b>			<b>180,264</b>		<b>73,688</b>

(i) The provision for losses on investments is recorded in "Other provisions".

Changes in investment balances presented in the individual interim financial information are shown below:

Changes in investments	Parent Company				Total
	4BIO Aidion, private label Subsidiary	stix Joint venture	RD VENTURES Subsidiary	vitat Subsidiary	
At January 1 <sup>st</sup> , 2020	60,263	-	-	-	60,263
Capital contribution	-	3,289	-	-	3,289
Equity in the results of subsidiaries	2,759	-	-	-	2,759
Restricted share compensation plan – 4Bio	(49)	-	-	-	(49)
<b>At June 30, 2020</b>	<b>62,973</b>	<b>3,289</b>	<b>-</b>	<b>-</b>	<b>66,262</b>
Capital contribution	-	-	4,500	-	4,500
Equity in the results of subsidiaries	10,794	(7,867)	(2)	-	2,925
Restricted share compensation plan – 4Bio	1	-	-	-	1
<b>At December 31, 2020</b>	<b>73,768</b>	<b>(4,578)</b>	<b>4,498</b>	<b>-</b>	<b>73,688</b>
<b>Classified as provision for losses on investments (i)</b>	<b>-</b>	<b>(4,578)</b>	<b>-</b>	<b>-</b>	<b>(4,578)</b>
<b>Classified as investments</b>	<b>73,768</b>	<b>-</b>	<b>4,498</b>	<b>-</b>	<b>78,266</b>
At January 1 <sup>st</sup> , 2021	73,768	(4,578)	4,498	-	73,688
Capital contribution	-	6,508	8,000	58,072	72,580
Equity in the results of subsidiary	4,919	(3,001)	(922)	(1,012)	(16)
Restricted share compensation plan – 4Bio	(39)	-	-	-	(39)
Adjustment in percentage of interest	34,023	28	-	-	34,051
<b>At June 30, 2020</b>	<b>112,671</b>	<b>(1,043)</b>	<b>11,576</b>	<b>57,060</b>	<b>180,264</b>
<b>Classified as provision for losses on investments (i)</b>	<b>-</b>	<b>(1,043)</b>	<b>-</b>	<b>-</b>	<b>(1,043)</b>
<b>Classified as investments</b>	<b>112,671</b>	<b>-</b>	<b>11,576</b>	<b>57,060</b>	<b>181,307</b>

(i) The provision for losses on investments is recorded in "Other Provisions".

For the purpose of calculating the equity in subsidiaries and joint ventures, the Company adjusts the assets, liabilities and the respective changes in the result. At 4Bio they are adjusted based on the purchase price allocation determined on the acquisition date. The table below shows the effects on profit (loss) for the year/period of subsidiaries and joint ventures for the purposes of determining the equity in results of subsidiaries for the six-month period ended June 30, 2021 and the year ended December 31, 2020:

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

**Parent Company**

	<b>4BIO</b> <small>Aidion, privetage</small>	<b>stix</b>	<b>RD</b> <b>VENTURES</b>	<b>vitat</b>	<b>Total</b>
<b>Changes in investments</b>					
Profit (loss) for the year	3,045	-	-	-	<b>3,045</b>
Amortization of surplus arising from the business combination	(286)	-	-	-	<b>(286)</b>
<b>Equity in the results of subsidiaries at 6/30/2020</b>	<b>2,759</b>	-	-	-	<b>2,759</b>
Profit (loss) for the year	11,021	(7,867)	(2)	-	<b>3,152</b>
Amortization of surplus arising from the business combination	(227)	-	-	-	<b>(227)</b>
<b>Equity in the results of subsidiaries at 12/31/2020</b>	<b>13,553</b>	<b>(7,867)</b>	<b>(2)</b>	-	<b>5,684</b>
Profit (loss) for the period	4,991	(3,001)	(922)	(1,012)	<b>56</b>
Amortization of surplus arising from the business combination	(72)	-	-	-	<b>(72)</b>
<b>Equity in the results of subsidiaries at 06/30/2021</b>	<b>4,919</b>	<b>(3,001)</b>	<b>(922)</b>	<b>(1,012)</b>	<b>(16)</b>

**Parent Company**

	<b>4BIO</b> <small>Aidion, privetage</small>	<b>stix</b>	<b>RD</b> <b>VENTURES</b>	<b>vitat</b>	<b>Jun/21</b>
<b>Adjusted equity</b>					
Investment at book value	98,161	(1,043)	11,576	13,280	<b>121,974</b>
Allocation of the purchase price (surplus of assets)	2,570	-	-	22,894	<b>25,464</b>
Deferred income tax liability on allocation adjustments	(874)	-	-	-	<b>(874)</b>
Restricted share compensation plan	(93)	-	-	-	<b>(93)</b>
<b>Total adjusted equity</b>	<b>99,764</b>	<b>(1,043)</b>	<b>11,576</b>	<b>36,174</b>	<b>146,471</b>
Goodwill based on expected future profitability	<b>12,907</b>	-	-	<b>20,886</b>	<b>33,793</b>
<b>Investment balance</b>	<b>112,671</b>	<b>(1,043)</b>	<b>11,576</b>	<b>57,060</b>	<b>180,264</b>

**Parent Company**

	<b>4BIO</b> <small>Aidion, privetage</small>	<b>stix</b>	<b>RD</b> <b>VENTURES</b>	<b>Dec/20</b>
<b>Adjusted equity</b>				
Investment at book value	59,147	(4,578)	4,498	<b>59,067</b>
Allocation of the purchase price (surplus of assets)	2,679	-	-	<b>2,679</b>
Deferred income tax liability on allocation adjustments	(911)	-	-	<b>(911)</b>
Restricted share compensation plan	(54)	-	-	<b>(54)</b>
<b>Total adjusted equity</b>	<b>60,861</b>	<b>(4,578)</b>	<b>4,498</b>	<b>60,781</b>
Goodwill based on expected future profitability	12,907	-	-	<b>12,907</b>
<b>Investment balance</b>	<b>73,768</b>	<b>(4,578)</b>	<b>4,498</b>	<b>73,688</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

**10. Property and equipment and intangible assets**

a) Property and equipment

Property and equipment is broken down as follows:

		Parent Company					
		Jun/21			Dec/20		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	32,124	32,124	-	32,124
Buildings	2.5 - 2.7	69,837	(27,798)	42,039	69,837	(26,886)	42,951
Furniture, fittings and facilities	7.4 - 10	1,155,623	(492,671)	662,952	1,096,992	(443,290)	653,702
Machinery and equipment	7.1 - 15.8	753,779	(401,443)	352,336	705,530	(361,320)	344,210
Vehicles	20 - 23.7	76,275	(42,008)	34,267	73,711	(38,306)	35,405
Leasehold improvements	13 - 20	1,475,054	(733,270)	741,784	1,435,389	(689,570)	745,819
<b>Total</b>		<b>3,562,692</b>	<b>(1,697,190)</b>	<b>1,865,502</b>	<b>3,413,583</b>	<b>(1,559,372)</b>	<b>1,854,211</b>

		Consolidated					
		Jun/21			Dec/20		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	32,124	32,124	-	32,124
Buildings	2.5 - 2.7	69,837	(27,798)	42,039	69,837	(26,886)	42,951
Furniture, fittings and facilities	7.4 - 10	1,157,844	(493,779)	664,065	1,098,912	(444,070)	654,842
Machinery and equipment	7.1 - 15.8	758,513	(403,941)	354,572	709,103	(362,736)	346,367
Vehicles	20 - 23.7	76,622	(42,221)	34,401	74,058	(38,499)	35,559
Leasehold improvements	13 - 20	1,478,401	(735,271)	743,130	1,438,562	(691,185)	747,377
<b>Total</b>		<b>3,573,341</b>	<b>(1,703,010)</b>	<b>1,870,331</b>	<b>3,422,596</b>	<b>(1,563,376)</b>	<b>1,859,220</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

Changes in the Parent Company's property and equipment are as follows:

	Jan 1 <sup>st</sup> , 2020	Additions	Disposals and write-offs	(Provision for) / Reversal of drugstore closures	Jun/20	Additions	Disposals and write-offs	(Provision for) / Reversal of drugstore closures	Dec/20	Additions	Disposals and write-offs	(Provision for) / Reversal of drugstore closures	Jun/21
<b>Changes in cost</b>													
Land	35,646	-	-	-	35,646	-	(3,522)	-	32,124	-	-	-	32,124
Buildings	71,422	-	-	-	71,422	-	(1,585)	-	69,837	-	-	-	69,837
Furniture, fittings and facilities	967,400	59,537	(4,314)	957	1,023,580	87,043	(9,979)	(3,652)	1,096,992	62,508	(6,870)	2,993	1,155,623
Machinery and equipment	597,668	52,426	(4,077)	-	646,017	64,108	(4,595)	-	705,530	52,557	(4,308)	-	753,779
Vehicles	68,061	4,237	-	-	72,298	3,822	(2,409)	-	73,711	3,287	(723)	-	76,275
Leasehold improvements	1,330,927	113,561	(65,887)	1,722	1,380,323	176,247	(115,786)	(5,395)	1,435,389	145,186	(109,158)	3,637	1,475,054
<b>Total</b>	<b>3,071,124</b>	<b>229,761</b>	<b>(74,278)</b>	<b>2,679</b>	<b>3,229,286</b>	<b>331,220</b>	<b>(137,876)</b>	<b>(9,047)</b>	<b>3,413,583</b>	<b>263,538</b>	<b>(121,059)</b>	<b>6,630</b>	<b>3,562,692</b>
<b>Changes in accumulated depreciation</b>													
Land	-	-	-	-	-	-	-	-	-	-	-	-	-
Buildings	(25,216)	(951)	-	-	(26,167)	(941)	222	-	(26,886)	(912)	-	-	(27,798)
Furniture, fittings and facilities	(361,231)	(46,772)	3,919	(368)	(404,452)	(49,661)	9,124	1,699	(443,290)	(52,548)	4,299	(1,132)	(492,671)
Machinery and equipment	(288,631)	(39,565)	3,871	-	(324,325)	(41,371)	4,376	-	(361,320)	(43,867)	3,744	-	(401,443)
Vehicles	(31,308)	(3,823)	-	-	(35,131)	(3,959)	784	-	(38,306)	(4,422)	720	-	(42,008)
Leasehold improvements	(591,403)	(136,119)	65,370	(1,265)	(663,417)	(144,577)	114,838	3,586	(689,570)	(145,826)	103,596	(1,470)	(733,270)
<b>Total</b>	<b>(1,297,789)</b>	<b>(227,230)</b>	<b>73,160</b>	<b>(1,633)</b>	<b>(1,453,492)</b>	<b>(240,509)</b>	<b>129,344</b>	<b>5,285</b>	<b>(1,559,372)</b>	<b>(247,575)</b>	<b>112,359</b>	<b>(2,602)</b>	<b>(1,697,190)</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

Changes in the Consolidated property and equipment are as follows:

	Jan 1 <sup>st</sup> , 2020	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Jun/20	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Dec/20	Business combination	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Jun/21
<b>Changes in cost</b>														
Land	35,646	-	-	-	35,646	-	(3,522)	-	32,124	-	-	-	-	32,124
Buildings	71,422	-	-	-	71,422	-	(1,585)	-	69,837	-	-	-	-	69,837
Furniture, fittings and facilities	969,119	59,662	(4,313)	957	1,025,425	87,120	(9,981)	(3,652)	1,098,912	275	62,552	(6,870)	2,993	1,157,862
Machinery and equipment	600,255	52,673	(4,077)	-	648,851	64,847	(4,595)	-	709,103	889	52,812	(4,308)	-	758,496
Vehicles	68,408	4,237	-	-	72,645	3,822	(2,409)	-	74,058	-	3,287	(723)	-	76,622
Leasehold improvements	1,333,498	113,744	(65,887)	1,722	1,383,077	176,666	(115,786)	(5,395)	1,438,562	174	145,186	(109,158)	3,637	1,478,401
<b>Total</b>	<b>3,078,348</b>	<b>230,316</b>	<b>(74,277)</b>	<b>2,679</b>	<b>3,237,066</b>	<b>332,455</b>	<b>(137,878)</b>	<b>(9,047)</b>	<b>3,422,596</b>	<b>1,338</b>	<b>263,837</b>	<b>(121,059)</b>	<b>6,630</b>	<b>3,573,342</b>
<b>Changes in accumulated depreciation</b>														
Land	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Buildings	(25,216)	(951)	-	-	(26,167)	(941)	222	-	(26,886)	-	(912)	-	-	(27,798)
Furniture, fittings and facilities	(361,850)	(46,851)	3,919	(368)	(405,150)	(49,744)	9,125	1,699	(444,070)	(237)	(52,639)	4,299	(1,132)	(493,779)
Machinery and equipment	(289,592)	(39,775)	3,871	-	(325,496)	(41,615)	4,375	-	(362,736)	(777)	(44,172)	3,744	-	(403,941)
Vehicles	(31,460)	(3,843)	-	-	(35,303)	(3,980)	784	-	(38,499)	-	(4,442)	720	-	(42,221)
Leasehold improvements	(592,495)	(136,363)	65,370	(1,265)	(664,753)	(144,856)	114,838	3,586	(691,185)	(95)	(146,118)	103,596	(1,470)	(735,272)
<b>Total</b>	<b>(1,300,613)</b>	<b>(227,783)</b>	<b>73,160</b>	<b>(1,633)</b>	<b>(1,456,869)</b>	<b>(241,136)</b>	<b>129,344</b>	<b>5,285</b>	<b>(1,563,376)</b>	<b>(1,109)</b>	<b>(248,283)</b>	<b>112,359</b>	<b>(2,602)</b>	<b>(1,703,011)</b>



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

b) Intangible assets

Intangible assets are broken down as follows:

	Average annual amortization rates (%)	Parent Company					
		Jun/21			Dec/20		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Points of sale	17 - 23.4	262,937	(177,993)	<b>84,944</b>	271,276	(171,884)	<b>99,392</b>
Software license	20	298,588	(125,676)	<b>172,912</b>	255,240	(105,344)	<b>149,896</b>
Goodwill on business acquisition - Vison Ltda	(i)	22,275	(2,387)	<b>19,888</b>	22,275	(2,387)	<b>19,888</b>
Goodwill on business acquisition - Raia S.A.	(i)	780,084	-	<b>780,084</b>	780,084	-	<b>780,084</b>
Trademarks	(i)	178,996	(1,346)	<b>177,650</b>	177,835	(995)	<b>176,840</b>
Customers portfolio	6.7 - 25	41,700	(39,247)	<b>2,453</b>	41,700	(39,017)	<b>2,683</b>
<b>Total</b>		<b>1,584,580</b>	<b>(346,649)</b>	<b>1,237,931</b>	<b>1,548,410</b>	<b>(319,627)</b>	<b>1,228,783</b>

	Average annual amortization rates (%)	Consolidated					
		Jun/21			Dec/20		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Points of sale	17 - 23.4	262,939	(177,992)	<b>84,947</b>	271,278	(171,883)	<b>99,395</b>
Software license and systems implementation	20	303,913	(127,788)	<b>176,125</b>	259,418	(107,033)	<b>152,385</b>
Goodwill on business acquisition - Vison Ltda	(i)	22,275	(2,387)	<b>19,888</b>	22,275	(2,387)	<b>19,888</b>
Goodwill on business acquisition - Raia S.A.	(i)	780,084	-	<b>780,084</b>	780,084	-	<b>780,084</b>
Goodwill on business acquisition - 4Bio S.A.	(i)	25,563	-	<b>25,563</b>	25,563	-	<b>25,563</b>
Goodwill on business acquisition - Vitat	(i)	20,886	-	<b>20,886</b>	-	-	-
Platform (Note 9.1b)	20	16,500	-	<b>16,500</b>	-	-	-
Non-compete agreement (Note 9.1b)	20	4,000	-	<b>4,000</b>	-	-	-
Trademarks	(i)	188,137	(7,072)	<b>181,065</b>	182,904	(6,149)	<b>176,755</b>
Customers portfolio (Raia S.A.)	6.7 - 25	41,700	(39,247)	<b>2,453</b>	41,700	(39,017)	<b>2,683</b>
Customer relationship (4Bio S.A.)	20	7,928	(3,137)	<b>4,791</b>	7,928	(2,972)	<b>4,956</b>
<b>Total</b>		<b>1,673,925</b>	<b>(357,623)</b>	<b>1,316,302</b>	<b>1,591,150</b>	<b>(329,441)</b>	<b>1,261,709</b>

(i) Indefinite useful life

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

Changes in the Company's intangible assets are as follows:

	Jan 1 <sup>st</sup> , 2020	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Jun/20	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Dec/20	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Jun/21
<b>Changes in cost</b>													
Points of sale	288,139	16,164	(19,939)	1,000	285,364	11,085	(24,407)	(766)	271,276	7,518	(16,172)	315	262,937
Software license	205,506	37,933	(14,857)	4	228,586	43,333	(16,684)	5	255,240	49,645	(6,278)	(19)	298,588
Goodwill on business acquisition – Vison	22,275	-	-	-	22,275	-	-	-	22,275	-	-	-	22,275
Goodwill on business acquisition – Raia	780,084	-	-	-	780,084	-	-	-	780,084	-	-	-	780,084
Trademarks	176,553	577	-	-	177,130	780	(75)	-	177,835	2,015	(854)	-	178,996
Customers portfolio	41,700	-	-	-	41,700	-	0	-	41,700	-	-	-	41,700
<b>Total</b>	<b>1,514,257</b>	<b>54,674</b>	<b>(34,796)</b>	<b>1,004</b>	<b>1,535,139</b>	<b>55,198</b>	<b>(41,166)</b>	<b>(761)</b>	<b>1,548,410</b>	<b>59,178</b>	<b>(23,304)</b>	<b>296</b>	<b>1,584,580</b>
<b>Changes in accumulated depreciation</b>													
Points of sale	(171,093)	(23,113)	19,788	(850)	(175,268)	(21,995)	24,314	1,065	(171,884)	(20,848)	15,288	(549)	(177,993)
Software license	(90,012)	(22,201)	14,856	(3)	(97,360)	(24,411)	16,427	-	(105,344)	(27,474)	7,132	10	(125,676)
Goodwill on business acquisition – Vison	(2,387)	-	-	-	(2,387)	-	-	-	(2,387)	-	-	-	(2,387)
Goodwill on business acquisition – Raia	-	-	-	-	-	-	-	-	-	-	-	-	-
Trademarks	(293)	(351)	-	-	(644)	(351)	-	-	(995)	(351)	-	-	(1,346)
Customers portfolio	(38,557)	(230)	-	-	(38,787)	(230)	-	-	(39,017)	(230)	-	-	(39,247)
<b>Total</b>	<b>(302,342)</b>	<b>(45,895)</b>	<b>34,644</b>	<b>(853)</b>	<b>(314,446)</b>	<b>(46,987)</b>	<b>40,741</b>	<b>1,065</b>	<b>(319,627)</b>	<b>(48,903)</b>	<b>22,420</b>	<b>(539)</b>	<b>(346,649)</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

Changes in the consolidated intangible assets are as follows:

	Jan 1 <sup>st</sup> , 2020	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Jun/20	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Dec/20	Business combinations	Additions	Disposals and write- offs	(Provision for) / Reversal of drugstore closures	Jun/21
<b>Changes in cost</b>														
Points of sale	288,139	16,164	(19,938)	1,000	285,365	11,085	(24,406)	(766)	271,278	-	7,518	(16,172)	315	262,939
Software license	208,238	38,444	(14,857)	4	231,829	44,268	(16,684)	5	259,418	-	50,792	(6,278)	(19)	303,913
Goodwill on business acquisition – Vison	22,275	-	-	-	22,275	-	-	-	22,275	-	-	-	-	22,275
Goodwill on business acquisition – Raia	780,084	-	-	-	780,084	-	-	-	780,084	-	-	-	-	780,084
Goodwill on business acquisition – 4Bio	25,563	-	-	-	25,563	-	-	-	25,563	-	-	-	-	25,563
Goodwill on business acquisition – Vitat	-	-	-	-	-	-	-	-	-	-	20,886	-	-	20,886
Platform	-	-	-	-	-	-	-	-	-	-	16,500	-	-	16,500
Non-compete agreement	-	-	-	-	-	-	-	-	-	-	4,000	-	-	4,000
Trademarks	181,622	577	-	-	182,199	780	(75)	-	182,904	1,678	4,409	(854)	-	188,137
Customers portfolio - Raia	41,700	-	-	-	41,700	-	-	-	41,700	-	-	-	-	41,700
Customer relationship - 4Bio	7,928	-	-	-	7,928	-	-	-	7,928	-	-	-	-	7,928
<b>Total</b>	<b>1,555,549</b>	<b>55,185</b>	<b>(34,795)</b>	<b>1,004</b>	<b>1,576,943</b>	<b>56,133</b>	<b>(41,165)</b>	<b>(761)</b>	<b>1,591,150</b>	<b>1,678</b>	<b>104,105</b>	<b>(23,304)</b>	<b>296</b>	<b>1,673,925</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

Changes in accumulated depreciation	Jan 1 <sup>st</sup> , 2020	Additions	Disposals and write-offs	(Provision for) / Reversal of drugstore closures	Jun/20	Additions	Disposals and write-offs	(Provision for) / Reversal of drugstore closures	Dec/20	Business combinations	Additions	Disposals and write-offs	(Provision for) / Reversal of drugstore closures	Jun/21
Points of sale	(171,092)	(23,113)	19,788	(850)	(175,267)	(21,995)	24,313	1,066	(171,883)	-	(20,848)	15,290	(549)	(177,992)
Software license	(91,064)	(22,477)	14,855	(3)	(98,689)	(24,771)	16,427	-	(107,033)	-	(27,898)	7,133	10	(127,788)
Goodwill on business acquisition – Vison	(2,387)	-	-	-	(2,387)	-	-	-	(2,387)	-	-	-	-	(2,387)
Goodwill on business acquisition – Raia	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill on business acquisition – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill on business acquisition – Vitat Platform	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-compete agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trademarks	(4,602)	(858)	-	-	(5,460)	(689)	-	-	(6,149)	(572)	(351)	-	-	(7,072)
Customers portfolio - Raia	(38,557)	(230)	-	-	(38,787)	(230)	-	-	(39,017)	-	(230)	-	-	(39,247)
Customer relationship - 4Bio	(2,406)	(283)	-	-	(2,689)	(283)	-	-	(2,972)	-	(165)	-	-	(3,137)
<b>Total</b>	<b>(310,108)</b>	<b>(46,961)</b>	<b>34,643</b>	<b>(853)</b>	<b>(323,279)</b>	<b>(47,968)</b>	<b>40,740</b>	<b>1,066</b>	<b>(329,441)</b>	<b>(572)</b>	<b>(49,492)</b>	<b>22,423</b>	<b>(539)</b>	<b>(357,623)</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### Goodwill on acquisition of companies

Goodwill on the acquisition of companies is subject to annual impairment testing.

#### Goodwill on the acquisition of Drogaria Vison Ltda.

Goodwill in the amount of R\$ 19,888 refers to the acquisition of Drogaria Vison Ltda. on February 13, 2008, which was included in the Company's operations as from June 30, 2008.

Goodwill is based on expected future profitability, pursuant to an appraisal prepared by an independent expert, and was amortized from April to December 2008. As provided for in CPC Guidance (OCPC) 02, since 2009, goodwill has no longer been amortized, but has been subject to impairment testing ever since.

#### Goodwill on the acquisition of Raia S.A.

The Company computed goodwill of R\$ 780,084 in the business combination with Raia S.A., occurred on November 10, 2011, which is based on expected future profitability resulting from the positive difference between the balances of assets assigned and those received.

#### Goodwill on the acquisition of 4Bio Medicamentos S.A.

The Company computed goodwill of R\$ 25,563 arising from the business combination with 4Bio Medicamentos S.A., occurred on October 1, 2015, of which the balance was supplemented by the final adjustment of the price at March 31, 2016 of R\$ 2,040, which is based on expected future profitability arising from the difference between the balance of assets assigned and those received.

#### Goodwill on the acquisition of Vitat Serviços em Saúde Ltda.

The Company computed goodwill of R\$ 20,886 in the business combination with Vitat Negócios em Saúde Ltda (former B2U Editora S.A.), occurred on April 1<sup>st</sup>, 2021, of which the balance was supplemented by the final price adjustment as of May 31, 2021 of R\$ 13,072, which is based on expected future profitability resulting from the positive difference between the balances of assets assigned and those received.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 11. Employees benefits

#### (a) Profit sharing program

The Group has a profit sharing program intended mainly to measure the performance of employees during the period. On a monthly basis, a liability and an expense for profit sharing are recognized in the statement of income based on estimates of achievement of operating targets and specific objectives established and approved by Management. The recognition as liabilities is made in the account of salaries and social charges and in the statement of income the recognition is made in the account of selling expenses and general and administrative expenses (Note 21).

#### (b) Other benefits

Other short-term benefits are also granted to employees, such as life insurance, health and dental care, housing allowance, maternity leave and scholarship, which are recognized on an accrual basis and whose right is extinguished at the end of the employment relationship with the Group.

The Group does not grant post-employment benefits, severance pay benefits or other long-term benefits.

### 12. Trade payables

Trade payables items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Goods suppliers	2,399,639	2,810,531	2,560,649	2,971,215
Service providers	100,051	105,359	101,625	107,973
Materials suppliers	19,066	20,841	19,211	20,935
Assets suppliers	10,825	14,258	11,060	14,679
Adjustment to present value	(9,440)	(7,610)	(9,950)	(7,864)
<b>Total</b>	<b>2,520,141</b>	<b>2,943,379</b>	<b>2,682,595</b>	<b>3,106,938</b>

In the first half of 2021, certain suppliers have assigned Company notes, without right of subrogation. This advance on credit notes generated a financial gain to the Company in the amount of R\$ 6,170 (R\$ 8,330 - Dec/2020). In this operation, the financial institution takes into consideration the credit risk of the buyer (in this case, the Company), there is no change in the average payment period and there is no obligation that results in expenses for the Company. The Company's Management also considered the guidance in CVM Circular Letter SNC/SEP 01/2021, observing the qualitative aspects on the issue, and concluded that there are no impacts because there is no change in the conditions originally agreed regarding prices and terms, as a result of these suppliers financing transactions.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 13. Borrowings, debentures and promissory notes

(a) Breakdown

Borrowings items	Average annual long-term interest rate	Parent Company		Consolidated	
		Jun/21	Dec/20	Jun/21	Dec/20
<b>BNDES – Subloan</b>					
Ventures	TLP + 2.02% (2.02% - Dec/2020) p.a.	-	11,480	-	11,480
Ventures	SELIC + 2.42% (2.42% - Dec/2020) p.a.	-	14,483	-	14,483
Machinery, equipment and vehicles	TLP + 2.02% (2.02% - Dec/2020) p.a.	-	2,373	-	2,373
Machinery, equipment and vehicles	SELIC + 2.42% (2.42% - Dec/2020) p.a.	-	12	-	12
Other		310	547	310	547
<b>Total BNDES – Subloan</b>		<b>310</b>	<b>28,895</b>	<b>310</b>	<b>28,895</b>
<b>Debentures</b>					
1 <sup>st</sup> issue of debentures	104.75% of CDI	66,918	100,072	66,918	100,072
2 <sup>nd</sup> issue of debentures	104.50% of CDI	179,052	223,087	179,052	223,087
3 <sup>rd</sup> issue of debentures – Certificate of Real Estate Receivables	98.50% of CDI	247,454	246,104	247,454	246,104
4 <sup>th</sup> issue of debentures	106.99% of CDI	300,118	299,850	300,118	299,850
<b>Total Debentures</b>		<b>793,542</b>	<b>869,113</b>	<b>793,542</b>	<b>869,113</b>
<b>Borrowings</b>					
Direct loans Law 4,131	100.00% of CDI + 2.61%	303,658	312,628	303,658	312,628
Direct loans Law 4,131	100.00% of CDI + 3.30%	101,346	100,924	101,346	100,924
Other	100.00% of CDI + 2.95%	-	-	40,366	33,453
<b>Total Borrowings</b>		<b>405,004</b>	<b>413,552</b>	<b>445,370</b>	<b>447,005</b>
<b>Promissory Notes</b>					
1 <sup>st</sup> issue of promissory notes	100.00% of CDI + 3.00%	317,816	308,441	317,816	308,441
<b>Total Promissory Notes</b>		<b>317,816</b>	<b>308,441</b>	<b>317,816</b>	<b>308,441</b>
<b>Total</b>		<b>1,516,672</b>	<b>1,620,001</b>	<b>1,557,038</b>	<b>1,653,454</b>
Current liabilities		582,340	497,751	622,706	531,204
Non-current liabilities		934,332	1,122,250	934,332	1,122,250

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

The amounts above have the following payment flow forecast:

Payment forecast	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
2021 <sup>(i)</sup>	582,340	497,751	622,706	531,204
2022	43,020	531,286	43,020	531,286
2023	43,227	43,405	43,227	43,405
2024 and thereafter	848,085	547,559	848,085	547,559
<b>Total</b>	<b>1,516,672</b>	<b>1,620,001</b>	<b>1,557,038</b>	<b>1,653,454</b>

(i) For comparison purposes, the installments falling due, corresponding to twelve months, were considered as 2021, including six installments falling due in 2021 and six installments falling due in 2022.

### (b) Characteristics of BNDES borrowing

Borrowing from the BNDES is used for the expansion of drugstores, acquisition of machinery, equipment, vehicles and also to finance the Company's working capital.

The subloans for the Social Project, Development of Own Brand and Acquisition of National Software are grouped in the Other line. Part of the Company's borrowing from BNDES has been taken out in the form of subloans, totaling R\$ 310 (R\$ 28,895 - Dec/20), subject to the following restrictive covenants:

- (i) EBITDA margin (EBITDA/Net operating revenue): equal to or higher than 3.6%; and
- (ii) Total net debt/Total assets: equal to or lower than 20%.

Covenants are measured annually and, at December 31, 2020, the Company was in compliance with these covenants.

If these requirements were not met, the Company would have to provide BNDES with bank guarantees to ensure the performance of its obligations under the agreement.

The Group is not a party to any agreements containing non-financial covenants before BNDES.

### (c) Characteristics of the debentures and promissory notes

On April 24, 2020, the Company carried out the 1<sup>st</sup> issue of promissory notes in a single series for public distribution with restricted efforts (CVM 476), in the amount of R\$ 300,000, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 3.00% per year and payment term of 2 years. Interest payment and amortization of principal will be carried out on the maturity date. The funds were used to improve the working capital.

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
1 <sup>st</sup> issue – single series	R\$ 300,000	60	04/24/2020	2020-2022	CDI + 3.00%	R\$ 5,000

On June 17, 2019, the Company carried out the 4<sup>th</sup> issue of non-convertible, simple unsecured debentures in a single series in the total amount of R\$ 300,000 for public distribution with restricted efforts (CVM 476), with settlement on July 12, 2019, in the amount of R\$ 300,000, with remuneration of 106.99% of CDI and payment term of 8 years. Interest payments will be semi-annual and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on June 17, 2027. The funds were used to improve the working capital.

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
4 <sup>th</sup> issue – single series	R\$ 300,000	300,000	06/17/2019	2019-2027	106.99%	R\$ 1



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

On February 1, 2019, the Company approved, through the Extraordinary Meeting of the Board of Directors, the 3<sup>rd</sup> issue of non-convertible, simple unsecured debentures in a single series, in the total amount of R\$ 250,000, with remuneration of 98.5% of CDI and payment term of 7 years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on March 13, 2026. The funds raised are being used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates issued by Vert Companhia Securitizadora, which will be issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 400.

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
3 <sup>rd</sup> issue – Single Series	R\$ 250,000	250,000	03/15/2019	2019-2026	98.5%	R\$ 1

The 2<sup>nd</sup> issue of debentures was carried out on April 2, 2018 and has maturity of 60 months (April/2023).

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
2 <sup>nd</sup> issue - 9 series	R\$ 400,000	40,000	04/02/2018	2018-2023	104.5%(*)	R\$ 10

(\*) Weighted average rate of series.

The amortization of the principal related to the 2<sup>nd</sup> issue of debentures will occur in 9 semiannual consecutive installments, the first being from the 12<sup>th</sup> month after the issue. The payment of the remuneration will occur on a semiannual basis, and the first payment is due in April 2019, and others always in April and October of each year, until the due date.

The characteristics of the debentures issued in 2017 were not changed, as shown in the table below:

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
1 <sup>st</sup> issue – single series	R\$ 300,000	30,000	04/19/2017	2017-2022	104.75%	R\$ 10

The costs incurred on the issues of the Company's debentures (2017 - 1<sup>st</sup> issue, 2018 - 2<sup>nd</sup> issue, 2019 - 3<sup>rd</sup> and 4<sup>th</sup> issues) and 1<sup>st</sup> issue of promissory notes in 2020, including fees, commissions and other costs, totaled R\$ 14,572 (R\$ 14,293 - 2020) and are classified in line item of the respective debentures and promissory notes, and are being recognized over the total period of the debt. At June 30, 2021, the amount to be recognized was R\$ 6,943 (R\$ 8,505 - 2020), and is presented net in debentures and promissory notes balance.

The Company's debentures and promissory notes are conditioned to the compliance with the following covenants:

(i) Net Debt / EBTIDA: cannot exceed 3 times.

The calculation of net debt, the basis for determining the covenants calculation of Company's debentures and promissory notes, considers the balances of borrowings. As described in Note 14, the lease obligations are being presented in a separate line item in the quarterly information, and therefore, are not included in the net debt calculation.

Covenants are measured quarterly and, at June 30, 2021, the Company was in compliance with such requirements

The non-compliance with the covenants for two consecutive quarters can be considered as a default event and consequently result in early maturity.

The Group monitors clauses subject to compliance with non-financial covenants, in order to ensure that they are being complied with. The Company was in compliance with these covenants.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### (d) Characteristics of borrowings

On April 8, 2020, the Company carried out loan operation – 4131, in the amount of R\$ 100,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDIs, plus a surcharge of 3.30% per year and payment term of 2 years. Interest payments will be quarterly and amortization of principal will be carried out on the maturity date. The funds were used to improve the working capital.

On March 26, 2021, the Company carried out loan operation – 4131, in the amount of R\$ 300,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 2.61% per year and payment term of 3 years. Interest payments will be semi-annual and amortization of principal will be carried out on the maturity date. The funds were used to improve the working capital.

The transaction costs incurred in borrowings - 4131 are of 0.25% referring to the amount of R\$ 100,000, with a term of 2 years, and 0.30% referring to the amount of R\$ 300,000, with a term of 3 years, including fees, commissions and other costs, which amounted to R\$ 2,004 and are classified in line item of the respective borrowings, and are being recognized over the total period of the debt. At June 30, 2021, the amount to be recognized was R\$ 974 (R\$ 404 - Dec/2020), and is presented net in the borrowings balance.

The borrowings - 4131 are not conditioned to compliance with financial and non-financial covenants.

### (e) Reconciliation of net debt

The analysis of and the changes in net debt are presented below:

Composition and changes in net debt	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Short-term borrowings	582,340	497,751	622,706	531,204
Long-term borrowings	934,332	1,122,250	934,332	1,122,250
<b>Total debt</b>	<b>1,516,672</b>	<b>1,620,001</b>	<b>1,557,038</b>	<b>1,653,454</b>
(-) Cash and cash equivalents (Note 5)	(242,088)	(855,257)	(266,685)	(880,357)
<b>Net debt</b>	<b>1,274,584</b>	<b>764,744</b>	<b>1,290,353</b>	<b>773,097</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

	Parent Company		
	Borrowing	Cash and cash equivalents	Net debt
<b>Changes in net debt</b>			
Net debt at January 1, 2020	1,126,476	(294,863)	831,613
Funding	696,392	-	696,392
Accrued interest	30,190	-	30,190
Payment of interest	(24,621)	-	(24,621)
Amortization of principal	(116,862)	-	(116,862)
Amortization of transaction costs	1,705	-	1,705
Increase in cash and cash equivalents	-	52,881	52,881
<b>Net debt at June 30, 2020</b>	<b>1,713,280</b>	<b>(241,982)</b>	<b>1,471,298</b>
Funding	(1,105)	-	(1,105)
Accrued interest	28,801	-	28,801
Payment of interest	(15,463)	-	(15,463)
Amortization of principal	(108,383)	-	(108,383)
Amortization of transaction costs	2,871	-	2,871
Decrease in and cash equivalents	-	(613,275)	(613,275)
<b>Net debt at December 31, 2020</b>	<b>1,620,001</b>	<b>(855,257)</b>	<b>764,744</b>
Funding	299,010	-	299,010
Accrued interest	30,904	-	30,904
Payment of interest	(28,844)	-	(28,844)
Amortization of principal	(406,787)	-	(406,787)
Amortization of transaction costs	2,388	-	2,388
Increase (decrease) in cash and cash equivalents	-	613,169	613,169
<b>Net debt at June 30, 2021</b>	<b>1,516,672</b>	<b>(242,088)</b>	<b>1,274,584</b>

	Consolidated		
	Borrowing	Cash and cash equivalents	Net debt
<b>Changes in net debt</b>			
Net debt at January 1, 2020	1,126,476	(299,226)	827,250
Funding	711,420	-	711,420
Accrued interest	30,303	-	30,303
Payment of interest	(24,621)	-	(24,621)
Amortization of principal	(116,862)	-	(116,862)
Amortization of transaction costs	1,705	-	1,705
Increase in cash and cash equivalents	-	32,810	32,810
<b>Net debt at June 30, 2020</b>	<b>1,728,421</b>	<b>(266,416)</b>	<b>1,462,005</b>
Funding	16,796	-	16,796
Accrued interest	29,212	-	29,212
Payment of interest	(15,463)	-	(15,463)
Amortization of principal	(108,383)	-	(108,383)
Amortization of transaction costs	2,871	-	2,871
Decrease in and cash equivalents	-	(613,941)	(613,941)
<b>Net debt at December 31, 2020</b>	<b>1,653,454</b>	<b>(880,357)</b>	<b>773,097</b>
Funding	339,010	-	339,010
Accrued interest	31,518	-	31,518
Payment of interest	(29,616)	-	(29,616)
Amortization of principal	(439,716)	-	(439,716)
Amortization of transaction costs	2,388	-	2,388
Increase in cash and cash equivalents	-	613,672	613,672
<b>Net debt at June 30, 2021</b>	<b>1,557,038</b>	<b>(266,685)</b>	<b>1,290,353</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 14. Leases

The Group leases physical stores, distribution centers, land and real estate properties for its office space, vehicles and equipment. Operating real estate and distribution/administrative centers leases have term of 5 to 20 years, residential real estate leases have term of 2 years, and lease agreements for vehicles and equipment have term of 3 years.

Since January 1, 2019, the Company has recognized lease agreements in its balance sheet as required by NBC TG 06 (R3) / IFRS 16 as right-of-use assets and lease liabilities. In compliance with CVM guidelines contained in CVM Circular Letter 2/2019, the Company adopts, since the year ended December 31, 2019, the use of the Nominal Discount Rate for lease agreements, disregarding the Real Rate applied at the beginning of effectiveness of that standard.

Information on the Group's leases are presented below.

#### As a lessee

##### Right-of-use asset

Breakdown of Parent Company and Consolidated right-of-use:

Right-of-use asset	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Operating real estate	2,961,773	2,894,417	2,961,773	2,894,417
Residential real estate	12,722	9,380	12,925	9,459
Distribution/administrative centers	283,204	254,410	285,743	257,181
Vehicles	908	152	908	153
Equipment	-	35	-	35
<b>Total</b>	<b>3,258,607</b>	<b>3,158,394</b>	<b>3,261,349</b>	<b>3,161,245</b>

The changes in the Parent Company and Consolidated right-of-use are presented below:

	Parent Company					
	Operating real estate	Residential real estate	Distribution/administrative centers	Vehicles	Equipment	Total
<b>At 01/01/2020</b>	<b>2,749,100</b>	<b>8,980</b>	<b>271,770</b>	<b>2,662</b>	<b>92</b>	<b>3,032,604</b>
New agreements	209,956	4,227	6	45	-	214,234
Remeasurements <sup>(i)</sup>	152,651	(431)	14,302	(1,359)	(12)	165,151
Termination of agreements	(7,503)	(777)	-	(58)	-	(8,338)
Depreciation	(264,064)	(863)	(26,105)	(256)	(9)	(291,297)
<b>At 06/30/2020</b>	<b>2,840,140</b>	<b>11,136</b>	<b>259,973</b>	<b>1,034</b>	<b>71</b>	<b>3,112,354</b>
New agreements	165,994	785	11,961	(28)	-	178,712
Remeasurements <sup>(i)</sup>	209,802	137	13,794	(440)	(26)	223,267
Termination of agreements	(30,884)	(1,729)	(2,587)	(133)	-	(35,333)
Depreciation	(290,635)	(949)	(28,731)	(281)	(10)	(320,606)
<b>At 12/31/2020</b>	<b>2,894,417</b>	<b>9,380</b>	<b>254,410</b>	<b>152</b>	<b>35</b>	<b>3,158,394</b>
New agreements	148,179	5,139	-	472	-	153,790
Remeasurements <sup>(i)</sup>	253,190	369	55,484	300	4	309,347
Termination of agreements	(30,595)	(961)	-	-	(34)	(31,590)
Depreciation	(303,418)	(1,205)	(26,690)	(16)	(5)	(331,334)
<b>At 06/30/2021</b>	<b>2,961,773</b>	<b>12,722</b>	<b>283,204</b>	<b>908</b>	<b>-</b>	<b>3,258,607</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAI A Drogasil S.A.

**Notes to the parent company and consolidated interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

	Consolidated					
	Operating real estate	Residential real estate	Distribution/ administrative centers	Vehicles	Equipment	Total
<b>At 01/01/2020</b>	<b>2,749,100</b>	<b>9,101</b>	<b>275,570</b>	<b>2,662</b>	<b>92</b>	<b>3,036,525</b>
New agreements	209,956	4,227	703	45	-	214,931
Remeasurements <sup>(i)</sup>	152,651	(435)	14,062	(1,359)	(12)	164,907
Termination of agreements	(7,503)	(777)	-	(58)	-	(8,338)
Depreciation	(264,064)	(890)	(26,846)	(256)	(9)	(292,065)
<b>At 06/30/2020</b>	<b>2,840,140</b>	<b>11,226</b>	<b>263,489</b>	<b>1,034</b>	<b>71</b>	<b>3,115,960</b>
New agreements	165,994	820	11,961	(28)	-	178,747
Remeasurements <sup>(i)</sup>	209,802	110	13,794	(440)	(26)	223,240
Termination of agreements	(30,884)	(1,729)	(2,587)	(133)	-	(35,333)
Depreciation	(290,635)	(968)	(29,476)	(280)	(10)	(321,369)
<b>At 12/31/2020</b>	<b>2,894,417</b>	<b>9,459</b>	<b>257,181</b>	<b>153</b>	<b>35</b>	<b>3,161,245</b>
New agreements	148,179	5,139	-	471	-	153,789
Remeasurements <sup>(i)</sup>	253,190	529	56,078	300	4	310,101
Termination of agreements	(30,595)	(961)	(63)	-	(34)	(31,653)
Depreciation	(303,418)	(1,241)	(27,453)	(16)	(5)	(332,133)
<b>At 06/30/2021</b>	<b>2,961,773</b>	<b>12,925</b>	<b>285,743</b>	<b>908</b>	<b>-</b>	<b>3,261,349</b>

(i) The Company remeasures the right-of-use asset in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases), initially determined as short-term contracts.

**Lease liabilities**

The changes in the Parent Company and Consolidated lease liabilities are as follows:

Leases	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Operating real estate	3,226,161	3,127,787	3,226,161	3,127,787
Residential real estate	1,126	2,071	1,278	2,098
Distribution/administrative centers	339,339	299,297	342,059	302,245
Vehicles	(1,492)	(1,188)	(1,492)	(1,188)
Equipment	(50)	(17)	(50)	(17)
<b>Total</b>	<b>3,565,084</b>	<b>3,427,950</b>	<b>3,567,956</b>	<b>3,430,925</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

The changes in the Parent Company and Consolidated lease liabilities are as follows:

	Parent Company					
	Operating real estate	Residential real estate	Distribution/ administrative centers	Vehicles	Equipment	Total
<b>At 01/01/2020</b>	<b>2,882,824</b>	<b>8,401</b>	<b>286,616</b>	<b>2,711</b>	<b>103</b>	<b>3,180,655</b>
New agreements	209,956	4,227	6	45	-	214,234
Remeasurements <sup>(i)</sup>	152,651	(431)	14,302	(1,359)	(12)	165,151
Interest	100,815	409	7,359	40	2	108,625
Payments / Compensations	(328,349)	(5,361)	(21,055)	(984)	(48)	(355,797)
<b>At 06/30/2020</b>	<b>3,017,897</b>	<b>7,245</b>	<b>287,228</b>	<b>453</b>	<b>45</b>	<b>3,312,868</b>
New agreements	165,994	785	11,961	(28)	-	178,712
Remeasurements <sup>(i)</sup>	209,802	137	13,794	(440)	(26)	223,267
Interest	110,156	(141)	9,110	28	3	119,156
Payments / Compensations	(376,062)	(5,955)	(22,796)	(1,201)	(39)	(406,053)
<b>At 12/31/2020</b>	<b>3,127,787</b>	<b>2,071</b>	<b>299,297</b>	<b>(1,188)</b>	<b>(17)</b>	<b>3,427,950</b>
New agreements	148,179	5,139	-	471	-	153,789
Remeasurements <sup>(i)</sup>	253,190	369	55,484	300	4	309,347
Interest	104,623	493	9,510	42	1	114,669
Payments / Compensations	(407,618)	(6,946)	(24,952)	(1,117)	(38)	(440,671)
<b>At 06/30/2021</b>	<b>3,226,161</b>	<b>1,126</b>	<b>339,339</b>	<b>(1,492)</b>	<b>(50)</b>	<b>3,565,084</b>

	Consolidated					
	Operating real estate	Residential real estate	Distribution/ administrative centers	Vehicles	Equipment	Total
<b>At 01/01/2020</b>	<b>2,882,824</b>	<b>8,537</b>	<b>290,458</b>	<b>2,711</b>	<b>103</b>	<b>3,184,633</b>
New agreements	209,956	4,227	703	45	-	214,931
Remeasurements <sup>(i)</sup>	152,651	(435)	14,062	(1,359)	(12)	164,907
Interest	100,815	413	7,483	40	2	108,753
Payments / Compensations	(328,349)	(5,392)	(21,861)	(984)	(48)	(356,634)
<b>At 06/30/2020</b>	<b>3,017,897</b>	<b>7,350</b>	<b>290,845</b>	<b>453</b>	<b>45</b>	<b>3,316,590</b>
New agreements	165,994	751	11,961	(28)	-	178,678
Remeasurements <sup>(i)</sup>	209,802	109	13,794	(440)	(26)	223,239
Interest	110,156	(140)	9,219	28	3	119,266
Payments / Compensations	(376,062)	(5,972)	(23,574)	(1,201)	(39)	(406,848)
<b>At 12/31/2020</b>	<b>3,127,787</b>	<b>2,098</b>	<b>302,245</b>	<b>(1,188)</b>	<b>(17)</b>	<b>3,430,925</b>
New agreements	148,179	5,139	-	471	-	153,789
Remeasurements <sup>(i)</sup>	253,190	529	56,079	300	4	310,102
Interest	104,624	497	9,612	42	1	114,776
Payments / Compensations	(407,619)	(6,985)	(25,877)	(1,117)	(38)	(441,636)
<b>At 06/30/2021</b>	<b>3,226,161</b>	<b>1,278</b>	<b>342,059</b>	<b>(1,492)</b>	<b>(50)</b>	<b>3,567,956</b>

(i) The Company remeasures the lease liabilities in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases).

## Notes to the parent company and consolidated interim financial information

### June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

The maturities of lease liabilities are classified according to the following schedule:

Analysis of maturities - Lease liabilities	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Less than 1 year	571,895	501,924	573,292	503,318
<b>Current</b>	<b>571,895</b>	<b>501,924</b>	<b>573,292</b>	<b>503,318</b>
1 to 5 years	2,533,853	2,431,810	2,535,328	2,433,391
Over 5 years	459,336	494,216	459,336	494,216
<b>Non-current</b>	<b>2,993,189</b>	<b>2,926,026</b>	<b>2,994,664</b>	<b>2,927,607</b>
<b>Total</b>	<b>3,565,084</b>	<b>3,427,950</b>	<b>3,567,956</b>	<b>3,430,925</b>

Future payments to be made to the lessor may give the Group the right to be credited with PIS and COFINS. Therefore, the recorded amount of the right-of-use asset against the lease liability already includes potential future credit.

The potential right to PIS / COFINS recoverable embedded in future lease payments is presented below:

Future considerations	Parent Company / Consolidated	Potential PIS / COFINS (9.25%)
Less than 1 year	509,511	47,130
1 to 2 years	482,050	44,590
2 to 3 years	439,718	40,674
3 to 4 years	375,580	34,741
4 to 5 years	295,974	27,378
Over 5 years	573,061	53,008
<b>Total</b>	<b>2,675,894</b>	<b>247,521</b>

The right to use PIS/COFINS credits comprises only contracts whose lessor is a legal entity. The Company has lease contracts for both lessors, corporate and individual.

In compliance with CVM Circular Letter 02/2019 and NBC TG 06 (R3) / IFRS 16, justified by the fact that the Group has not applied the methodology of nominal flows due to the prohibition imposed by NBC TG 06 (R3) of future inflation projection and in order to provide additional information to users, the analysis of contract maturities and installments not yet discounted at June 30, 2021 is presented below:

Year	Parent Company			Consolidated		
	Net present value	Estimated interest (future) <sup>(i)</sup>	Amounts of installments not yet discounted	Net present value	Estimated interest (future) <sup>(i)</sup>	Amounts of installments not yet discounted
2021	311,362	109,562	420,924	312,759	109,885	422,644
2022	633,350	188,256	821,606	633,350	188,256	821,606
2023	605,592	148,170	753,762	605,592	148,170	753,762
2024	553,857	110,488	664,345	553,857	110,488	664,345
2025	466,407	77,495	543,902	466,407	77,495	543,902
2026	357,515	51,157	408,672	358,990	51,515	410,505
2027 and thereafter	637,001	70,104	707,105	637,001	70,104	707,105
<b>Total</b>	<b>3,565,084</b>	<b>755,232</b>	<b>4,320,316</b>	<b>3,567,956</b>	<b>755,913</b>	<b>4,323,869</b>

(i) The present value of the leases payable was calculated considering the projection of future fixed payments, discounted at the rate of 6.69% p.a., which was built from the basic interest rate released by the Central Bank of Brazil (Bacen).



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### Amount recognized in the statement of income

Amount recognized in the statement of income	Parent Company		Consolidated	
	Jun/21	Jun/20	Jun/21	Jun/20
Amortization of right-of-use asset	331,332	291,297	332,132	277,062
Interest on lease liabilities	114,669	108,625	114,774	53,772
Adjustment for lease write-of (contracts terminated)	(868)	794	(868)	-
Variable payments not included in the measurement of lease liabilities	21,688	13,303	21,902	7,396
Revenue on subleases of right-of-use assets	(1,388)	(1,668)	(1,388)	(1,100)
Expenses related to short-term and/or low-value leases	9,218	7,331	9,218	10,654
Discounts on property rental	(4,546)	-	(4,546)	-

#### (i) Payment of variable leases based on sales

Some operating real estate leases contain variable lease payments based on a percentage of 2% to 12% of the sales made during the period in the leased operating real estate. These payment conditions are common for stores in the country where the Group operates. Variable lease payments for the six-month period ended June 30, 2021 amounted to R\$ 2,242 (R\$ 4,087 - Jun/2020) for Parent Company and Consolidated accounts.

#### (ii) Leases fitting into exceptions and practical expedients

The lease agreements identified and that fall within the scope of exemption mainly refer to lease of printers, forklifts, cardiotech scales, power generators, electron aligners and photovoltaic plates.

The Group also leases equipment with contracts of up to one year. These leases are short-term and/or low-value leases. The Group opted not to recognize the right-of-use assets and the lease liabilities of such items.

### As a lessor

The Group subleases some of the properties to third parties. The Group has classified these leases as operating leases because they do not transfer substantially all the risks and rewards of ownership of assets.

The table below presents an analysis of maturities of lease payments, showing undiscounted lease payments to be received after the reporting date:

Undiscounted lease payments	Parent Company and Consolidated	
	Jun/21	Dec/20
Less than 1 year	997	1,846
1 to 2 years	1,847	1,675
2 to 3 years	1,356	1,280
3 to 4 years	1,025	1,025
4 to 5 years	591	591
Over 5 years	-	818
<b>Total</b>	<b>5,816</b>	<b>7,235</b>



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 15. Provision for contingencies and judicial deposits

The Company and its subsidiary are subject to legal claims (tax, civil and labor) arising in the normal course of business. Management, supported by the opinion of its legal advisors and, where applicable, by specific opinions issued by experts, assesses the probable final outcomes of ongoing litigation and determines whether or not setting up of provision for contingencies is necessary. In the case of labor contingencies, the evolution of the lawsuits and the history of losses are determining factors to reflect the best estimate.

At June 30, 2021 and December 31, 2020, the Group had the following provision and corresponding judicial deposits relating to legal proceedings:

Judicial deposits items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Labor and social security	89,268	95,942	89,268	95,942
Tax	15,488	16,996	82,891	17,185
Civil	2,112	1,713	2,112	1,713
Subtotal	<b>106,868</b>	<b>114,651</b>	<b>174,271</b>	<b>114,840</b>
(-) Corresponding judicial deposits	(9,260)	(11,183)	(66,135)	(11,183)
<b>Total</b>	<b>97,608</b>	<b>103,468</b>	<b>108,136</b>	<b>103,657</b>
Current liabilities	36,470	32,646	46,998	32,835
Non-current liabilities	61,138	70,822	61,138	70,822

Changes in the provision are as follows:

Changes in the provision	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
<b>Opening balance</b>	<b>114,651</b>	<b>111,299</b>	<b>114,840</b>	<b>111,299</b>
Additions of new lawsuits and review of estimate	23,620	55,739	90,834	55,928
Write-offs for payments	(34,918)	(81,844)	(34,918)	(81,844)
Reversals due to changes in lawsuits	239	(7,225)	239	(7,225)
Revaluation of amounts	(20)	22,392	(20)	22,392
Monetary restatement	3,296	14,290	3,296	14,290
<b>Closing balance</b>	<b>106,868</b>	<b>114,651</b>	<b>174,271</b>	<b>114,840</b>

The provision for legal claims took into consideration the best estimate of the amounts involved, for the cases in which the likelihood of loss is estimated as probable, and a portion of these proceedings is guaranteed by pledged assets.

#### Possible losses

As of June 30, 2021 and December 31, 2020, the Group has tax and civil lawsuits related to fines applied by the relevant administrative authorities, tax rate difference in interstate transfers and tax enforcements as well as of civil nature due to indemnity claims for losses and pain and suffering arising from consumer relations, involving possible loss as assessed by Management and its legal advisors in the amount of R\$ 54,099 (R\$ 52,281 - Dec/20) for Parent Company and Consolidated, of which R\$ 1,732 (R\$ 1,090 - Dec/20) corresponds to the labor/social security contingencies, R\$ 5,562 (R\$ 4,111 - Dec/20) to the civil contingencies and R\$ 46,805 (R\$ 47,081 - Dec/20) to tax contingencies.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### Judicial deposits

At June 30, 2021 and December 31, 2020, the Group had the following judicial deposit amounts, for which no corresponding provision had been set up:

Analysis of judicial deposits	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Labor and social security	15,032	15,285	15,032	15,285
Tax	10,470	10,464	13,078	10,464
Civil	2,573	3,338	2,573	3,338
(-) Corresponding judicial deposits	(3,930)	(3,334)	(3,930)	(3,334)
<b>Total</b>	<b>24,145</b>	<b>25,753</b>	<b>26,753</b>	<b>25,753</b>

### Labor contingencies

Labor claims in general relate to lawsuits filed by former employees questioning the payment of unpaid overtime and health hazard premium. The Group is also involved in proceedings arising from Raia S.A., as well as from Drogaria Onofre Ltda., which were filed by former employees of service providers claiming to have employment relationships directly with the Group, or in which the Group received a joint enforcement order for the payment of the labor rights claimed. There are also proceedings filed by professional unions for the payment of union dues, under the dispute regarding the legitimacy of the territorial base.

### Tax contingencies

These represent administrative fines, tax rate differences on interstate transfers and tax collection proceedings.

### Civil contingencies

The Group is a defendant in lawsuits regarding usual and unique matters arising in the course of its business, most of which seek indemnification for property damage and pain and suffering from consumption relations.

### Guarantees for lawsuits

The items of property and equipment were given as security for tax, social security and labor proceedings:

Guarantees for lawsuits	Parent Company/Consolidated	
	2021	2020
Furniture and facilities	12	14
Machinery and equipment	85	85
<b>Total guarantees for lawsuits</b>	<b>97</b>	<b>99</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 16. Arbitration asset/liability

The Company recognizes in non-current liabilities the obligations arising from the agreement for acquisition of Drogaria Onofre Ltda. These are obligations of the Seller with former shareholders of Onofre and settlement depends on an arbitral decision. In the agreement for acquisition of July 1, 2019, it was agreed that the financial investments and the letter of guarantee (indemnification asset) in the amounts of R\$ 197,061 and R\$ 127,037, respectively, shall remain linked to the arbitration liability as a guarantee of settlement. Accordingly, Raia Drogasil shall not be harmed by, or benefit from, this transaction as from the acquisition date until the date of its complete settlement. These guarantee amounts are recognized in the arbitration restricted asset under non-current assets.

The arbitration asset/liability is presented below:

Arbitration asset/liability items	Parent Company and Consolidated	
	Jun/21	Dec/20
<b>Arbitration restricted asset</b>		
Financial investment	210,701	207,721
Letter of guarantee/indemnification asset	135,887	134,185
	<b>346,588</b>	<b>341,906</b>
<b>Arbitration restricted liability</b>		
Obligations with former shareholders	(346,958)	(342,727)
Exclusion of operation effects	723	884
	<b>(346,235)</b>	<b>(341,843)</b>
	<b>353</b>	<b>63</b>

The net position of the arbitration asset/liability of R\$ 353 (R\$ 63 - Dec/20) represents the amount in excess for the guarantee of settlement in order to comply with the existing obligation.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

**17. Income tax and social contribution**

**(a) Income tax and social contribution paid**

At June 30, 2021 and 2020, effective income tax and social contribution are as follows:

	Parent Company		Consolidated	
	Jun/21	Jun/20	Jun/21	Jun/20
<b>Income tax and social contribution paid items</b>				
Profit before income tax and social contribution	589,734	215,440	596,821	216,843
Interest on capital and additional interest on capital proposed	(94,000)	(96,000)	(94,000)	(96,000)
<b>Taxable profit</b>	<b>495,734</b>	<b>119,440</b>	<b>502,821</b>	<b>120,843</b>
Combined tax rate (25% for income tax and 9% for social contribution)	34.00%	34.00%	34.00%	34.00%
<b>Theoretical tax expense</b>	<b>(168,550)</b>	<b>(40,610)</b>	<b>170,959</b>	<b>(41,087)</b>
Permanent additions	(12,841)	(19,971)	(25,881)	(20,073)
Equity in the results of subsidiaries	(5)	938	(1,020)	-
Reduction of taxes due to incentives (P.A.T)	3,351	1,581	3,351	1,581
Investment grant <sup>(i)</sup>	15,036	10,562	27,614	19,721
Tax loss and negative CSLL basis	-	-	(264)	(6,788)
Provisions with no deferred charges	-	-	5	-
Other (revaluation reserve + additional income tax exemption ceiling)	326	56	344	56
<b>Result of current income tax and social contribution</b>	<b>(186,191)</b>	<b>(87,967)</b>	<b>(192,025)</b>	<b>(87,967)</b>
<b>Result of deferred income tax and social contribution</b>	<b>23,508</b>	<b>40,523</b>	<b>25,215</b>	<b>41,377</b>
<b>Income tax and social contribution expense</b>	<b>(162,683)</b>	<b>(47,444)</b>	<b>(166,810)</b>	<b>(46,590)</b>
Effective tax rate <sup>(ii)</sup>	27.59%	22.02%	27.95%	21.49%

(i) Beginning on the third quarter of 2018, the Group considers as deductible, for income tax purposes the gains arising from the ICMS tax benefits in the states of Bahia, Goiás and Pernambuco, established by Supplementary Law 160/17, agreement ICMS CONFAZ 190/17, and the amendment to Law 12,973/2014. The amount recognized in the six-month period ended June 30, 2021 was R\$ 44,224 (R\$ 31,065 - Jun/2020).

(ii) Based on the best estimate made up to this moment, the average annual effective rate will be 26.25% and, therefore, we do not expect significant variations in relation to the real rate calculated for the quarter. In case of any event that may cause changes to the estimated annual percentage, the amounts recognized related to expense on tax on profit and social contribution for the interim period will be adjusted in subsequent periods.

**(b) Deferred income tax and social contribution assets**

Deferred income tax and social contribution assets amounting to R\$ 328,124 (R\$ 315,938 – Dec/20) for the Parent Company and R\$ 366,023 (R\$ 352,198 – Dec/20) for the Consolidated accounts arose from temporarily non-deductible expenses that may be carried forward indefinitely, with estimated realization as disclosed in item (c) below.

Deferred income tax and social contribution liabilities amounting to R\$ 377,346 (R\$ 388,710 - Dec/20) for the Parent Company and R\$ 378,934 (R\$ 390,366 - Dec/20) for the Consolidated accounts relate to tax charges on the remaining balances of: (i) the revaluation reserve; (ii) surplus value PPA (Purchase Price Allocation) Raia; and (iii) gain on bargain purchase.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

For the six-month periods ended June 30, 2021 and 2020, deferred income and social contribution were as follows:

	Balance sheet				Statement of income			
	Parent Company		Consolidated		Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20	Jun/21	Jun/20	Jun/21	Jun/20
<b>Temporary differences</b>								
Revaluation at fair value of land and buildings	(6,756)	(6,798)	(6,756)	(6,798)	-	-	-	-
Amortization of the goodwill on future profitability	(245,089)	(245,025)	(245,089)	(245,025)	64	353	64	353
Non-deductible intangible assets - merger of Raia	(53,881)	(53,959)	(53,881)	(53,959)	(78)	(78)	(78)	(78)
Non-deductible intangible assets - acquisition of 4Bio	-	-	(1,588)	(1,657)	-	-	(68)	(269)
Gain on bargain purchase – acquisition of Onofre	(71,620)	(82,928)	(71,620)	(82,928)	(11,308)	(11,308)	(11,308)	(11,308)
Tax losses to be offset against future taxable profits	-	-	32,319	34,615	-	-	2,296	-
Adjustment to present value	838	(384)	964	(317)	(1,222)	(762)	(1,281)	(700)
Adjustment to fair value	5,980	5,514	5,980	5,514	(466)	(822)	(466)	(822)
Provision for inventory losses	11,373	9,587	11,373	9,587	(1,786)	(7,001)	(1,786)	(7,001)
Provision for sundry obligations	74,494	76,995	74,615	77,012	2,501	7,166	2,397	7,154
Provision for employee profit sharing	62,239	62,481	62,590	62,871	241	1,625	280	1,848
Provision for contingencies	54,051	56,684	54,051	56,684	2,634	(2,043)	2,634	(2,043)
Expected credit losses	1,242	1,079	6,195	2,227	(162)	(10)	(3,968)	(868)
Lease (depreciation x consideration)	100,281	87,124	100,310	87,148	(13,157)	(23,699)	(13,162)	(23,699)
Other adjustments	17,626	16,858	17,626	16,858	(769)	(3,944)	(769)	(3,944)
<b>Deferred income tax and social contribution expense (benefit)</b>	-	-	-	-	<b>(23,508)</b>	<b>(40,523)</b>	<b>(25,215)</b>	<b>(41,377)</b>
<b>Deferred tax liabilities, net</b>	<b>(49,222)</b>	<b>(72,772)</b>	<b>(12,911)</b>	<b>(38,168)</b>				
Reflected in the balance sheet as follows:								
Deferred tax assets	328,124	315,938	328,124	315,938				
Deferred tax liabilities	377,346	(388,710)	(378,934)	(390,366)				
<b>Deferred tax liabilities, net</b>	<b>(49,222)</b>	<b>(72,772)</b>	<b>(50,810)</b>	<b>(74,428)</b>				
<b>Deferred tax assets – Parent Company – 4Bio</b>	-	-	<b>37,899</b>	<b>36,261</b>				
<b>Reconciliation of deferred tax assets (liabilities), net</b>								
<b>At the beginning of the period</b>	(72,772)	(142,810)	(38,168)	(123,987)				
Expense recognized in the statement of income	23,508	69,949	25,215	85,730				
Realization of deferred tax recognized in equity	42	89	42	89				
<b>Balance at the end of the period</b>	<b>(49,222)</b>	<b>(72,772)</b>	<b>(12,911)</b>	<b>(38,168)</b>				

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### (c) Estimated recovery of income tax and social contribution credits

The projections of future taxable profits are based on estimates relating to the Group's performance, the behavior of the market in which the Group operates and certain economic aspects, among other factors. Actual amounts may differ from these estimates. According to projections, the tax credit will be recovered according to the following schedule:

Recovery forecast	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
2021 <sup>(i)</sup>	130,274	111,563	150,397	113,207
2022	49,011	56,630	58,707	56,630
2,023	34,793	33,761	41,257	44,146
2024	62,798	17,081	64,414	27,466
2025 and thereafter	51,248	96,903	51,248	110,749
<b>Total</b>	<b>328,124</b>	<b>315,938</b>	<b>366,023</b>	<b>352,198</b>
Deferred tax assets on temporary differences, recorded net in liabilities	328,124	315,938	328,124	315,938
Deferred tax assets on tax losses in subsidiaries	-	-	37,899	36,261

(i) For comparison purposes, the installments falling due, corresponding to twelve months, were considered as 2021, including six installments falling due in 2021 and six installments falling due in 2022

### (d) Uncertainty over IRPJ and CSLL treatment

The Company has four discussions in the administrative stage with the Brazilian Federal Revenue referring to the disallowance for tax amortization of goodwill arising from acquisitions of companies in the amount of R\$ 37,635, which, according to internal and external assessment of legal advisors, will probably be accepted in decisions of higher courts (probability of acceptance higher than 50%); for this reason, the Company did not record any IRPJ/CSLL liabilities in connection with these proceedings.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

**18. Earnings per share**

Basic earnings per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of common shares outstanding during the year. Diluted earnings per share are calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potential common diluted shares.

Basic and diluted earnings for the six-month period ended June 30, 2020 includes the application of the stock split, approved at the Extraordinary General Meeting held on September 15, 2020, in the proportion of five common shares to each share of the same type. Accordingly, basic earnings increased from 329,623 to 1,648,115 and diluted earnings increased from 331,091 to 1,655,455.

The following table presents profit and stock information used for calculating basic and diluted earnings per share:

<b>Earnings per share items</b>	<b>Parent Company / Consolidated</b>	
	<b>Jun/21</b>	<b>Jun/20</b>
<b>Basic</b>		
Profit for the period	427,051	167,996
Weighted average number of common shares	1,649,216	1,648,115
<b>Basic earnings per share - R\$</b>	<b>0.25894</b>	<b>0.10193</b>
<b>Diluted</b>		
Profit for the period	427,051	167,996
Weighted average number of common shares adjusted for dilution effect	1,653,427	1,655,455
<b>Diluted earnings per share - R\$</b>	<b>0.25828</b>	<b>0.10148</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 19. Equity

#### (a) Capital

At June 30, 2021, the fully paid-up capital amounted to R\$ 2,500,000 (R\$ 2,500,000 - Dec/20), represented by 1,651,930,000 common registered book-entry shares with no par value, of which 1,083,178,147 were outstanding common shares (1,072,442,905 common shares - Dec/20).

Pursuant to the Company's bylaws, it is authorized to increase its capital up to the limit of 2,000,000,000 common shares, subject to the approval of the Board of Directors.

At the Extraordinary General Meeting held on September 15, 2020, the Company approved a stock split, in the proportion of 5 common shares to each share of the same type existing on September 18, 2020, with no change to its capital. Accordingly, the number of shares went from 330,386,000 to 1,651,930,000 common registered book-entry shares with no par value.

At June 30, 2021, the Company's ownership interest was as follows:

Ownership interest	Number of shares		Interest (%)	
	Jun/21	Dec/20	Jun/21	Dec/20
Controlling stockholders	566,981,498	577,007,615	34.32	34.93
Shares outstanding	1,083,178,147	1,072,442,905	65.57	64.92
Treasury shares	1,770,355	2,479,480	0.11	0.15
<b>Total</b>	<b>1,651,930,000</b>	<b>1,651,930,000</b>	<b>100.00</b>	<b>100.00</b>

The ownership interest of the controlling stockholders is represented by the families Pipponzi, Pires Oliveira Dias and Galvão and by the Holding Pragma.

The change in the number of outstanding shares of the Company is as follows:

Changes	Shares outstanding
At December 31, 2019	214,036,654
Stock split	856,146,616
(Purchase)/sale of restricted shares, net	2,259,635
<b>At December 31, 2020</b>	<b>1,072,442,905</b>
(Purchase)/sale of restricted shares, net	10,735,242
<b>At June 30, 2021</b>	<b>1,083,178,147</b>

At June 30, 2021, the Company's common shares were quoted at R\$ 24.71 (closing quote) (R\$ 25.04 at December 31, 2020).

#### (b) Tax incentive reserve

These refer to ICMS tax benefits obtained in the states of Bahia, Goiás and Pernambuco, as regulated by Complementary Law 160/17, ICMS CONFAZ 190/17 agreement and amendment to Law 12,973/2014. Set up in accordance with the provisions of article 195-A of the Brazilian Corporate Law (as amended by Law 11,638/07), this reserve receives the portion of government subsidy recognized in profit for the period, as a deduction from sales taxes and allocated to it from the retained earnings account, accordingly, they are not included in the calculation basis of the minimum mandatory dividend.



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### (c) Treasury shares

On August 6, 2019, the Board of Directors authorized the Company to repurchase, over a period of 365 days, its own registered common shares with no par value to be held in treasury and subsequently sold, however they were not purchased. The changes in treasury shares in the six-month period ended June 30, 2021 are summarized below:

Changes in treasury shares	Parent Company	
	Number of shares	Amount of shares
<b>At December 31, 2019</b>	<b>729,434</b>	<b>38,141</b>
Shares delivered to executives related to the 3 <sup>rd</sup> tranche of the 2016 grant, 2 <sup>nd</sup> tranche of the 2017 grant and 1 <sup>st</sup> tranche of the 2018 grant.	(219,992)	(11,141)
Shares delivered to executives related to the 1 <sup>st</sup> tranche of 2018, 2 <sup>nd</sup> tranche of 2017 and 3 <sup>rd</sup> tranche of 2016 of 4Bio.	(853)	(45)
Shares delivered to executives related to the grants of 2017, 2018, 2019 and 2020.	(63,465)	(673)
Stock split	2,034,356	-
<b>At December 31, 2020</b>	<b>2,479,480</b>	<b>26,282</b>
Shares delivered to executives related to the 3 <sup>rd</sup> tranche of the 2017 grant, 2 <sup>nd</sup> tranche of the 2018 grant and 1 <sup>st</sup> tranche of the 2019 grant	(702,260)	(7,444)
Shares delivered to executives related to the 1 <sup>st</sup> tranche of 2019, 2 <sup>nd</sup> tranche of 2018 and 3 <sup>rd</sup> tranche of 2017 of 4Bio.	(6,865)	(73)
<b>At June 30, 2021</b>	<b>1,770,355</b>	<b>18,765</b>

At June 30, 2021, the market value of the treasury shares, having as reference the quotation of R\$ 24.71 per share (R\$ 25.04 at December 31, 2020), corresponds to R\$ 43,745 (R\$ 62,086 - Dec/20).

### (d) Restricted share plan

#### Long-Term Incentive Program

Since March 2014, the Company offers its officers the Long-Term Incentive Program with Restricted Shares (the "Restricted Share Plan"), which aims to offer an opportunity to receive variable remuneration provided that the officer remains for a predetermined period in the Company.

The maximum number of shares that may be delivered as a result of the exercise of the Plan is limited to 3% of the Company's Capital Stock during the entire term of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary will be equivalent to the average share price on B3 (weighted by the volume of trades) in the last thirty trading sessions preceding the grant.

As stated in the Restricted Share Plan, a portion of their annual variable remuneration (profit-sharing), will be paid to the officer in cash and the remaining balance shall be paid only in Company shares ("incentive stock").

If the officer decides to use a portion of the total amount of the variable remuneration paid in cash to buy Company shares ("own shares") on the stock exchange, the Company will offer the officer an equal number of shares purchased on the stock exchange.

At its discretion, the Company may grant to this officer more Company shares, using as reference the number of own shares acquired by the officer on the stock exchange.

The shares offered to the officer through the Restricted Share Plan may not be sold, assigned or transferred to third parties for a period of four years from the date of the grant. Every year, from the second, third and fourth anniversary of the grant date, the officers will acquire the right to receive a third of their restricted stock. The portion not exercised within the

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

established terms and conditions will be automatically considered extinguished seven years after the respective grant date.

### Performance shares

At a meeting of the Board of Directors on October 22, 2020, the granting of restricted shares was approved under the terms of the Restricted Share Granting Plan - Performance Shares ("Plan"), approved at the Extraordinary General Meeting of the Company held on September 15, 2020.

The purpose of the Plan is: (a) to foster the expansion, success and fulfillment of the corporate purposes of the Company and the companies under its control; (b) to align the interests of Beneficiaries with the interests of shareholders; and (c) to encourage Beneficiaries to stay in the Company or companies under its control. The Plan will be managed by the Board of Directors, and may have an advisory committee created or appointed by the Board of Directors to advise it in this respect. Beneficiaries will be chosen and elected by the Board of Directors at each new grant.

The maximum number of shares that may be delivered as a result of exercising the Plan is limited to 2% of the Company's Capital on the date of approval of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary will equivalent to the average share price in B3 (weighted by the volume of trades) in the ninety trading sessions prior to January 1 of the year in which the grant occurs.

The definitive transfer of the Restricted Shares will be subject to the fulfillment of a four-year grace period from the grant date and, at the end of the grace period, the participant must be linked to the Company so that the grants are not canceled. Restricted Shares that have not yet completed the grace period will become due and will be transferred to the holders, their estate or heirs in the event of death, permanent disability or retirement. The Plan provides that the liquidation must occur through the transfer of shares, however, in the event that the Company does not have treasury shares at the time of liquidation and / or upon inability to acquire shares on the market, the Board of Directors may choose to settle the delivery of the Restricted Shares in cash.

### Changes in restricted shares

The changes of the restricted shares are summarized below:

Changes in restricted shares	Jun/21		Dec/20	
	Shares	Amount	Shares	Amount
Opening balance	1,261,394	27,206	397,329	21,977
Granted shares for the period	702,910	4,392	1,148,375	18,217
Value of the shares at the delivery date	(709,125)	(6,141)	(284,310)	(12,988)
<b>Closing balance</b>	<b>1,255,179</b>	<b>25,457</b>	<b>1,261,394</b>	<b>27,206</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### Position of the restricted share plan

Below is a breakdown of the assumptions that govern each grant plan:

Grants	Grant date	Number of shares granted <sup>(i)</sup>	Date on which they will become exercisable	Period of restriction to share transfer	Fair value of shares on grant date <sup>(i)</sup>
<b>Long-Term Incentive Program</b>					
2018 - 3 <sup>rd</sup> tranche	03/01/2018	154,620	02/28/2022	02/28/2022	R\$ 15.84
2019 - 2 <sup>nd</sup> tranche	03/01/2019	334,855	02/28/2022	02/28/2022	R\$ 12.77
2019 - 3 <sup>rd</sup> tranche	03/01/2019	334,695	02/28/2023	02/28/2023	R\$ 12.77
2020 - 1 <sup>st</sup> tranche	03/01/2020	352,982	02/28/2022	02/28/2022	R\$ 24.89
2020 - 2 <sup>nd</sup> tranche	03/01/2020	352,982	02/28/2023	02/28/2023	R\$ 24.89
2020 - 3 <sup>rd</sup> tranche	03/01/2020	352,977	02/28/2024	02/28/2024	R\$ 24.89
2021 - 1 <sup>st</sup> tranche	03/01/2021	274,596	02/28/2023	02/28/2023	R\$ 22.72
2021 - 2 <sup>nd</sup> tranche	03/01/2021	274,596	02/28/2024	02/28/2024	R\$ 22.72
2021 - 3 <sup>rd</sup> tranche	03/01/2021	274,596	02/28/2025	02/28/2025	R\$ 22.72
<b>Performance share</b>					
2020 - 1 <sup>st</sup> tranche	01/01/2020	350,421	01/01/2024	01/01/2025	R\$ 13.19
2021 - 1 <sup>st</sup> tranche	01/01/2021	302,990	02/01/2025	01/01/2026	R\$ 13.19

(i) After the application of the stock split effect, approved in the EGM held on September 15, 2020.

## 20. Net sales revenue

Breakdown of net revenue	Parent Company			
	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20
Sales revenue	5,887,873	11,521,597	4,434,449	9,364,328
Service revenue	16,442	33,168	10,175	18,150
<b>Gross sales revenue</b>	<b>5,904,315</b>	<b>11,554,765</b>	<b>4,444,624</b>	<b>9,382,478</b>
Taxes on sales	(284,102)	(563,175)	(189,180)	(382,729)
Returns, rebates and other	(53,151)	(97,327)	(34,278)	(68,692)
<b>Net sales revenue</b>	<b>5,567,062</b>	<b>10,894,263</b>	<b>4,221,166</b>	<b>8,931,057</b>

Breakdown of net revenue	Consolidated			
	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20
Sales revenue	6,226,223	12,188,971	4,711,736	9,909,964
Service revenue	18,939	35,699	10,136	18,229
<b>Gross sales revenue</b>	<b>6,245,162</b>	<b>12,224,670</b>	<b>4,721,872</b>	<b>9,928,193</b>
Taxes on sales	(315,153)	(624,864)	(212,057)	(427,956)
Returns, rebates and other	(61,745)	(111,490)	(40,041)	(80,591)
<b>Net sales revenue</b>	<b>5,868,264</b>	<b>11,488,316</b>	<b>4,469,774</b>	<b>9,419,646</b>

Taxes on sales primarily comprise ICMS at rates predominantly between 17% and 18%, for goods not subject to the tax substitute (ST) regime, service tax at 5%, and PIS (1.65%) and COFINS (7.60%) for goods not subject to the one-time taxation regime (Law 10,147/00).

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)



### 21. Information on the nature of expenses recognized in the statement of income

The Group presented its statement of income using a classification based on the function of expenses. Information on the nature of these expenses is recorded in the statement of income as follows:

Nature of expenses	Parent Company			
	2 <sup>nd</sup>		2 <sup>nd</sup>	
	Quarter/21	Jun/21	Quarter/20	Jun/20
Costs of inventories sold (Note 7)	(3,799,202)	(7,507,592)	(2,920,832)	(6,209,473)
Personnel expenses	(690,236)	(1,326,888)	(578,135)	(1,148,595)
Occupancy expenses <sup>(i)</sup>	(75,567)	(156,903)	(64,647)	(141,287)
Depreciation and amortization <sup>(ii)</sup>	(310,454)	(611,102)	(273,943)	(550,675)
Discounts on property rental <sup>(iii)</sup>	4,546	6,419	9,371	9,371
Service provider expenses <sup>(iv)</sup>	(82,530)	(162,627)	(78,872)	(140,125)
Expenses on card operator fees	(73,755)	(144,347)	(56,243)	(115,499)
Other <sup>(v)</sup>	(166,408)	(318,842)	(138,084)	(262,788)
<b>Total</b>	<b>(5,193,606)</b>	<b>(10,221,882)</b>	<b>(4,101,385)</b>	<b>(8,559,071)</b>
<b>Classified in the statement of income as:</b>				
Function of expenses	2 <sup>nd</sup>		2 <sup>nd</sup>	
	Quarter/21	Jun/21	Quarter/20	Jun/20
Costs of sales and services	(3,801,860)	(7,510,250)	(2,920,832)	(6,209,473)
Selling	(1,192,978)	(2,328,510)	(1,019,249)	(2,039,551)
General and administrative	(198,768)	(383,122)	(161,304)	(310,047)
<b>Total</b>	<b>(5,193,606)</b>	<b>(10,221,882)</b>	<b>(4,101,385)</b>	<b>(8,559,071)</b>
Nature of expenses	Consolidated			
	2 <sup>nd</sup>		2 <sup>nd</sup>	
	Quarter/21	Jun/21	Quarter/20	Jun/20
Costs of inventories sold (Note 7)	(4,068,088)	(8,046,287)	(3,149,652)	(6,657,673)
Personnel expenses	(703,288)	(1,349,948)	(587,314)	(1,166,743)
Occupancy expenses <sup>(i)</sup>	(76,031)	(157,783)	(65,068)	(142,128)
Depreciation and amortization <sup>(ii)</sup>	(311,471)	(613,199)	(275,143)	(553,062)
Discounts on property rental <sup>(iii)</sup>	4,546	6,419	9,371	9,371
Service provider expenses <sup>(iv)</sup>	(84,007)	(165,995)	(79,577)	(141,536)
Expenses on card operator fees	(74,286)	(145,340)	(56,679)	(116,422)
Other <sup>(v)</sup>	(173,633)	(331,117)	(142,535)	(273,992)
<b>Total</b>	<b>(5,486,258)</b>	<b>(10,803,250)</b>	<b>(4,346,597)</b>	<b>(9,042,185)</b>
<b>Classified in the statement of income as:</b>				
Function of expenses	2 <sup>nd</sup>		2 <sup>nd</sup>	
	Quarter/21	Jun/21	Quarter/20	Jun/20
Costs of sales and services	(4,071,213)	(8,049,412)	(3,149,652)	(6,657,673)
Selling	(1,209,285)	(2,357,584)	(1,031,431)	(2,065,774)
General and administrative	(205,760)	(396,254)	(165,514)	(318,738)
<b>Total</b>	<b>(5,486,258)</b>	<b>(10,803,250)</b>	<b>(4,346,597)</b>	<b>(9,042,185)</b>

(i) These refer to expenses on property rental, condominium fees, electricity, water, communication and municipal real estate tax (IPTU).

(ii) Depreciation and amortization totaled R\$ 611,102 in the 1<sup>st</sup> half of 2021 (R\$ 550,675 - Jun/2020) for the Parent Company, of which R\$ 561,489 (R\$ 507,671 - Jun/2020) correspond to the Sales area and R\$ 49,613 (R\$ 43,004 - Jun/2020) to the Administrative area, and R\$ 613,199 (R\$ 553,062 Jun/2020) in the Consolidated, of which R\$ 562,211 (R\$ 508,223 - Jun/2020) correspond to the Sales area and R\$ 50,988 (R\$ 44,839 - Jun/2020) to the Administrative area. These amounts are presented

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)



net of PIS and COFINS credits on the lease right-of-use, which resulted in an expense reduction in the amount of R\$ 16,709 (R\$ 13,742 - Jun/2020).

(iii) Due to the Covid-19 pandemic, the Company obtained discounts on payments related to the expenses from the lease of some properties. There were no changes in the term of the agreements, so there was no requirement to remeasure those lease agreements.

(iii) These refer mostly to expenses on transportation, materials, other administrative expenses, maintenance of assets, advertising and publicity.

(v) Due to the Covid-19 pandemic, the Company increased the hiring of service providers to intensify cleaning services in drugstores and meet the greater demand of delivery services and increased the hiring of temporary staff to work in drugstores and distribution centers.

### 22. Other operating (income)/expenses, net

At June 30, 2021, other operating income/ (expenses) totaled R\$ 69,449 (R\$ 13,508 referring to expenses in June 2020) for the Consolidated accounts. These amounts comprise non-recurring expenses and revenues, as presented below:

Nature of revenues / (expenses)	Parent Company			
	2 <sup>nd</sup>		2 <sup>nd</sup>	
	Quarter/21	Jun/21	Quarter/20	Jun/20
Write-off of property and equipment and intangible assets due to the drugstores closure.	(5,295)	(4,413)	959	(794)
Donations	(310)	(3,603)	(25,890)	(25,890)
Consulting and advisory expenses	-	-	(8,022)	(8,314)
Losses on Popular Pharmacy Program	-	-	(252)	(11,948)
Provision for inventory losses from previous periods	-	-	(16)	(119)
Revaluations - judicial deposits	548	548	-	-
Recognition of INSS credits from 2016 to 2019	303	1,141	31,059	31,059
Adjustment of provision for labor risks - Selic rate	-	3,410	-	-
Refund of ICMS-ST on 2020 sales <sup>(i)</sup>	44	13,706	-	-
Exclusion of ICMS from PIS/COFINS calculation basis (Note 8)	58,044	58,044	-	-
Credits from prior periods, mainly from PIS and COFINS	-	-	1,088	1,108
Other	(221)	294	7	1,448
<b>Total</b>	<b>53,113</b>	<b>69,127</b>	<b>(1,067)</b>	<b>(13,450)</b>

Nature of revenues / (expenses)	Consolidated			
	2 <sup>nd</sup>		2 <sup>nd</sup>	
	Quarter/21	Jun/21	Quarter/20	Jun/20
Write-off of property and equipment and intangible assets due to the drugstores closure.	(5,295)	(4,413)	959	(794)
Donations	(310)	(3,603)	(25,890)	(25,890)
Consulting and advisory expenses	(216)	(267)	(8,075)	(8,407)
Losses on Popular Pharmacy Program	-	-	(252)	(11,948)
Provision for inventory losses from previous periods	-	-	(16)	(119)
Revaluations - judicial deposits	548	548	-	-
Recognition of INSS credits from 2016 to 2019	303	1,141	31,059	31,059
Adjustment of provision for labor risks - Selic rate	-	3,410	-	-
Refund of ICMS-ST on 2020 sales <sup>(i)</sup>	44	14,323	-	-
Exclusion of ICMS from PIS/COFINS calculation basis (Note 8)	58,052	58,052	-	-
Credits from prior periods, mainly from PIS and COFINS	-	-	1,088	1,108
Other	(226)	258	57	1,066
<b>Total</b>	<b>52,900</b>	<b>69,449</b>	<b>(1,050)</b>	<b>(13,508)</b>

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)



(I) ICMS in the substitute taxpayer regime (ICMV-ST), which implies the prepayment of ICMS of the whole commercial chain at the time the goods leave the industrial establishment or the importer, or at the time it enters the state. Its refund is a right of the taxpayer that made sales in which the taxable event of the prepayment of ICMS-ST was not confirmed, generating the right to the refund of this amount by the State Tax Authorities. The process of refund requires the proof, using tax documents and digital files, of the operations made that generated for the Company the right to refund. Only after its approval by the State Tax Authorities and/or compliance with the specific record-keeping and reporting obligations that aim that proof, credits can be used by the Company, which occurs in periods subsequent to their generation.

### 23. Finance income and costs

	Parent Company			
	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20
<b>Finance income</b>				
Present Value Adjustment	10,360	16,646	10,279	21,722
Short-term investment yields	1,138	4,153	1,769	2,235
Interest on intercompany loans	963	1,730	458	1,083
Monetary gains	265	615	509	744
Discounts obtained	190	358	985	3,105
<b>Total finance income</b>	<b>12,916</b>	<b>23,502</b>	<b>14,000</b>	<b>28,889</b>
<b>Finance costs</b>				
Interest on leases	(55,202)	(108,849)	(52,633)	(104,363)
Present Value Adjustment	(18,784)	(30,452)	(13,320)	(35,228)
Charges on debentures and promissory notes	(11,287)	(19,416)	(11,064)	(21,984)
Amortization of transaction costs	(6,908)	(13,263)	(860)	(1,360)
Interest on payables to subsidiary's shareholder	(695)	(1,371)	(1,226)	(2,418)
Interest, charges and bank fees	(159)	(1,060)	(190)	(383)
Charges on borrowings	(109)	(394)	(6,720)	(8,205)
Monetary gains	(202)	(455)	(357)	(804)
<b>Total finance costs</b>	<b>(93,346)</b>	<b>(175,260)</b>	<b>(86,370)</b>	<b>(174,745)</b>
<b>Finance income (costs)</b>	<b>(80,430)</b>	<b>(151,758)</b>	<b>(72,370)</b>	<b>(145,856)</b>
	Consolidated			
	2 <sup>nd</sup> Quarter/21	Jun/21	2 <sup>nd</sup> Quarter/20	Jun/20
<b>Finance income</b>				
Present Value Adjustment	11,677	18,759	11,550	24,381
Short-term investment yields	1,248	4,273	1,769	2,235
Monetary gains	318	705	545	875
Discounts obtained	198	374	1,009	3,135
Other finance income	50	92	63	169
<b>Total finance income</b>	<b>13,491</b>	<b>24,203</b>	<b>14,936</b>	<b>30,795</b>



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

	2 <sup>nd</sup> Quarter/21		2 <sup>nd</sup> Quarter/20	
	Jun/21	Jun/21	Jun/20	Jun/20
<b>Finance costs</b>				
Interest on leases <sup>(i)</sup>	(55,258)	(108,961)	(52,696)	(104,491)
Present Value Adjustment	(19,992)	(32,406)	(14,265)	(37,403)
Charges on debentures and promissory notes	(11,287)	(19,416)	(11,064)	(21,984)
Amortization of transaction costs	(6,908)	(13,263)	(860)	(1,360)
Interest on payables to subsidiary's shareholder	(695)	(1,371)	(1,226)	(2,418)
Interest, charges and bank fees	(261)	(1,188)	(252)	(544)
Charges on borrowings	(109)	(394)	(6,720)	(8,205)
Discounts granted to customers	(292)	(324)	(69)	(164)
Monetary gains	(847)	(1,573)	(668)	(1,337)
<b>Total finance costs</b>	<b>(95,649)</b>	<b>(178,896)</b>	<b>(87,820)</b>	<b>(177,906)</b>
<b>Finance income (costs)</b>	<b>(82,158)</b>	<b>(154,693)</b>	<b>(72,884)</b>	<b>(147,111)</b>

(i) Interest on leases is shown net of PIS and COFINS.

## 24. Financial instruments and risk management policy

### Financial instruments by category

Financial instruments items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
<b>Assets</b>				
<u>At amortized cost</u>				
Cash and cash equivalents (Note 5)	242,088	855,257	266,685	880,357
Trade receivables (Note 6)	1,574,116	1,373,801	1,770,670	1,555,434
Other receivables	282,654	322,448	229,361	270,475
Judicial deposits (Note 15)	24,145	25,753	26,753	25,753
Arbitration restricted asset (Note 16)	346,588	341,906	346,588	341,906
<b>Total assets</b>	<b>2,469,591</b>	<b>2,919,165</b>	<b>2,640,057</b>	<b>3,073,925</b>
<b>Liabilities</b>				
<u>Liabilities at fair value through profit or loss</u>				
Payables to subsidiary's shareholder (Note 9)	35,934	46,448	35,934	46,448
<b>Subtotal</b>	<b>35,934</b>	<b>46,448</b>	<b>35,934</b>	<b>46,448</b>
<b>Other liabilities</b>				
Trade payables	2,520,141	2,943,379	2,682,595	3,106,938
Borrowing (Note 13)	1,516,672	1,620,001	1,557,038	1,653,454
Other payables	311,436	170,622	322,804	175,873
Leases payable	3,565,084	3,427,950	3,567,956	3,430,925
Arbitration liability (Note 16)	346,235	341,843	346,235	341,843
<b>Subtotal</b>	<b>8,259,568</b>	<b>8,503,795</b>	<b>8,476,628</b>	<b>8,709,033</b>
<b>Total liabilities</b>	<b>8,295,502</b>	<b>8,550,243</b>	<b>8,512,562</b>	<b>8,755,481</b>

### Financial risk management

The Company applied the requirements of NBC TG 40 (R3) and also considered the guidance in CVM Circular Letter SNC/SEP 01/2021, observing qualitative and quantitative aspects of risk management, concluded that there are no material impacts that require disclosure of additional information in the interim financial information.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)



The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Group's risk management program focuses on the unpredictability of financial and operational markets and seeks to minimize potential adverse effects on the Group's financial performance.

The Board of Directors provides principles for overall risk management, as well as written policies covering specific areas, such as interest rate risk, credit risk, use of non-derivative financial instruments and investment of surplus cash.

### (a) Market risk

#### Foreign exchange risk

All of the asset and liability operations of the Group are denominated in Brazilian reais; therefore, the Company is not exposed to foreign exchange risk.

#### Derivative financial instruments

The Group does not operate with derivative instruments, except in specific situations. At June 30, 2021, the Group did not have any derivative financial transactions.

### (b) Interest rate risk

Most of the BNDES transactions are entered into based on the TLP + interest and on the SELIC rate. Other borrowings of the Company are linked to the CDI + bank spread. Financial investments are entered into based on the CDI variations, which does not result in higher interest rate risk since these variations are not significant. Management understands that there is a low risk of significant changes in profit or loss or in cash flows.

### (b) Credit risk

Credit risk arises from financial assets, i.e. cash and cash equivalents, short-term investments and trade receivables.

Cash and cash equivalents and short-term investments are maintained with sound financial institutions.

The risk ratings of the cash equivalents are in accordance with the main risk rating agencies, according to the table below:

Risk rating	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
<b>Rating - National scale</b>				
brAAA	77,197	468,469	83,072	490,077
brAA+	34,708	249,124	45,180	249,163
brA	9,501	15,497	9,504	15,497
(*) n/a - Cash and automatic investments	120,682	122,167	126,434	123,446
(*) n/a - Investment funds	-	-	2,495	2,174
<b>Total - National scale</b>	<b>242,088</b>	<b>855,257</b>	<b>266,685</b>	<b>880,357</b>

(\*) Not applicable, since there is no risk rating for cash, automatic investments and investment funds.

The granting of credit on sales of goods follows a policy that aims at minimizing defaults. At June 30, 2021, credit sales represented 56% (54% - Dec/2020) for the Parent Company and 58% (56% - Dec/2020) for the Consolidated accounts of which 94% (94% - Dec/2020) for the Parent Company and 87% (86% - Dec/2020) for the Consolidated accounts related to credit card sales which, based on the history of losses, posed an extremely low risk. The remaining 6% (6% - Dec/2020) for the Parent Company and 13% (14% - Dec/2020) for the Consolidated accounts are credits from PBMs and special plans that pose a low risk, due to customer selectivity.



## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### (c) Liquidity risk

The Group's management continuously monitors forecasts of the Company's liquidity requirements, in order to ensure that it has sufficient cash to meet operational needs. The Group invests its surplus cash in financial assets with appropriate maturities to provide the liquidity necessary to honor its obligations.

### (d) Sensitivity analysis

The table below presents a sensitivity analysis of financial instruments that are exposed to losses.

The most probable scenario, according to the assessment made by Management, is based on an increase of 0.5% in the interest rate. Two further scenarios are presented in order to show a 25% and 50% deterioration in the risk variables considered (scenarios II and III).

Operation	Parent Company			
	Notional amount	Effect on profit or loss and equity		
		Scenario I (probable)	Scenario II - 25%	Scenario III - 50%
Short term investments - CDI	130,974	655	819	982
<b>Revenue</b>		<b>655</b>	<b>819</b>	<b>982</b>
Borrowings - CDI	1,516,672	(7,583)	(9,479)	(11,375)
REFIS (SELIC)	1,156	(6)	(7)	(9)
<b>Expense</b>		<b>(7,589)</b>	<b>(9,486)</b>	<b>(11,384)</b>
<b>Effect on profit or loss</b>		<b>(6,934)</b>	<b>(8,667)</b>	<b>(10,402)</b>

Operation	Consolidated			
	Notional amount	Effect on profit or loss and equity		
		Scenario I (probable)	Scenario II - 25%	Scenario III - 50%
Short term investments - CDI	153,761	769	961	1,153
<b>Revenue</b>		<b>769</b>	<b>961</b>	<b>1,153</b>
Borrowings - CDI	1,557,038	(7,785)	(9,731)	(11,678)
REFIS (SELIC)	1,156	(6)	(7)	(9)
<b>Expense</b>		<b>(7,791)</b>	<b>(9,738)</b>	<b>(11,687)</b>
<b>Effect on profit or loss</b>		<b>(7,022)</b>	<b>(8,777)</b>	<b>(10,534)</b>

The risk of variations in the TLP on BNDES operations which could result in material losses for the Group is not considered as probable by management.

### (e) Capital management

The Group's objective relating to capital management is to maintain the Group's investment capacity, thus allowing it to grow its business and provide proper returns for stockholders.

The Group has adopted a policy of not leveraging its capital structure with borrowings, except for long-term credit facilities from BNDES (FINEM), debentures and promissory notes at interest rates that are commensurate with the Group's profit levels.

Accordingly, this ratio corresponds to the net debt expressed as a percentage of total capital. The net debt, in turn, corresponds to total borrowings less cash and cash equivalents. The total capital is calculated through the sum of the equity, as shown in the individual and consolidated balance sheet, and the net debt, as presented below:

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

Capital management items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Short- and long-term borrowings	1,516,672	1,620,001	1,557,038	1,653,454
(-) Cash and cash equivalents	(242,088)	(855,257)	(266,685)	(880,357)
<b>Net debt</b>	<b>1,274,584</b>	<b>764,744</b>	<b>1,290,353</b>	<b>773,097</b>
Equity attributable to the stockholders of the parent company	4,665,461	4,363,126	4,665,461	4,363,126
Noncontrolling interests	-	-	31,428	62,495
Total equity	4,665,461	4,363,126	4,696,889	4,425,621
<b>Total capital</b>	<b>5,940,045</b>	<b>5,127,870</b>	<b>5,987,242</b>	<b>5,198,718</b>
<b>Gearing ratio</b>	<b>21.46</b>	<b>14.91</b>	<b>21.55</b>	<b>14.87</b>

As described in Note 14, as from January 1, 2019, the Group recognized in its balance sheet the obligations associated with the lease agreements where it has control. Considering the balance of lease liabilities at the balance sheet dates in the capital management calculation, the gearing ratio of the Company and the Group would be as follows:

Adjusted net debt with lease liabilities	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Net debt	1,274,584	764,744	1,290,353	773,097
Lease liabilities	3,565,084	3,427,950	3,567,956	3,430,925
<b>Adjusted net debt</b>	<b>4,839,668</b>	<b>4,192,694</b>	<b>4,858,309</b>	<b>4,204,022</b>
Total equity	4,665,461	4,363,126	4,696,889	4,425,621
<b>Total adjusted capital</b>	<b>9,505,129</b>	<b>8,555,820</b>	<b>9,555,198</b>	<b>8,629,643</b>
<b>Adjusted gearing ratio (%)</b>	<b>50.92</b>	<b>49.00</b>	<b>50.84</b>	<b>48.72</b>

### (f) Fair value estimation

The carrying values of financial investments in the balance sheet approximate their fair values since the remuneration rates are based on the CDI variation. The carrying values of trade receivables and payables are measured at amortized cost and are recorded at their original amount, less the provision for impairment and present value adjustment, when applicable. The carrying values are assumed to approximate their fair values, taking into consideration the realization of these balances and settlement terms not exceeding 60 days.

Borrowings are classified as financial liabilities not measured at fair value and are carried at amortized cost and according to contractual conditions. The fair values of the borrowings approximate their carrying values since they refer to financial instruments with rate that approximate market rates. The estimated fair values are:

Fair value estimation	Parent Company				Consolidated			
	Carrying amount		Fair value		Carrying amount		Fair value	
	Jun/21	Dec/20	Jun/21	Dec/20	Jun/21	Dec/20	Jun/21	Dec/20
BNDES	310	28,895	310	28,889	310	28,894	310	28,889
Debentures and promissory notes	1,111,358	1,177,554	1,111,358	1,177,554	1,111,358	1,177,554	1,111,358	1,177,554
Other	405,004	413,552	405,004	413,553	445,370	447,006	445,370	447,006
<b>Total</b>	<b>1,516,672</b>	<b>1,620,001</b>	<b>1,516,672</b>	<b>1,619,996</b>	<b>1,557,038</b>	<b>1,653,454</b>	<b>1,557,038</b>	<b>1,653,449</b>

For disclosure purposes, the fair value of financial liabilities is estimated by discounting future contractual cash flow at the interest rates available in the market that are available to the Group for similar financial instruments. The effective interest rates at the balance sheet dates are usual market rates and their fair value does not significantly differ from the balances in the accounting records.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

At June 30, 2021, the Group had no material assets and liabilities measured at fair value at Level 1 and Level 2 in the fair value hierarchy. The following table presents the changes in Level 3 instruments for the six-month period ended June 30, 2021:

	Parent Company/Consolidated	
	Payables to subsidiary's shareholder	
	Jun/21	Jun/20
<b>Changes in payables to subsidiary's shareholder</b>		
Balance at January 1 <sup>st</sup>	46,448	42,113
( - ) Payment for the exercise of the 1 <sup>st</sup> Call Option of shares	(11,884)	-
Expenses recognized in the statement of income:	1,370	1,192
At June 30	35,934	43,305
<b>Total expenses for the period recognized in the statement of income</b>	<b>1,370</b>	<b>1,192</b>
<b>Changes in unrealized expenses for the period included in the statement of income</b>	<b>1,370</b>	<b>1,192</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

**25. Transactions with related parties**

(a) Transactions with related parties consist of transactions with the Company's stockholders and persons connected to them:

Related parties	Relationship	Parent Company		Consolidated		Parent Company		Consolidated	
		Assets				Transacted amount			
		Jun/21	Dec/20	Jun/21	Dec/20	Jun/21	Jun/20	Jun/21	Jun/20
<b>Receivables</b>									
Special plans <sup>(i)</sup>									
Regimar Comercial S.A.	Stockholder/Family	10	9	10	9	37	38	37	38
Heliomar Ltda.	Stockholder/Board Member	2	1	2	1	8	12	8	12
Rodrigo Wright Pipponzi (Editora Mol Ltda.)	Stockholder/Family	-	-	-	-	-	-	-	-
Natura Cosméticos S.A. <sup>(ii)</sup>	Stockholder/Related party	121	112	121	112	698	693	698	693
4Bio Medicamentos S.A. <sup>(v)</sup>	Subsidiary	43	42	43	42	154	141	154	141
<b>Subtotal</b>		<b>176</b>	<b>164</b>	<b>176</b>	<b>164</b>	<b>897</b>	<b>884</b>	<b>897</b>	<b>884</b>
<b>Other receivables from related parties</b>									
Commercial agreements									
Natura Cosméticos S.A. <sup>(ii)</sup>	Stockholder/Related party	1	57	1	57	97	197	97	197
Advances to suppliers		-	-	-	-	-	-	-	-
Cfly Consultoria e Gestão Empresarial Ltda. <sup>(iii)</sup>	Family	247	231	247	231	-	-	-	-
Ribeiro Filho, Pires Oliveira Dias e Freire – Advogados <sup>(iv)</sup>	Stockholder/Family	45	-	45	-	-	-	-	-
Loan and other receivables									
4Bio Medicamentos S.A. <sup>(v)</sup>	Subsidiary	59,881	57,993	-	-	1,983	1,336	-	-
ZTO Tecn. e Ser. de Infor. na Int. Ltda. (Manipulaê) <sup>(x)</sup>	Subsidiary	-	-	3,000	-	-	-	3,000	-
<b>Subtotal</b>		<b>60,174</b>	<b>58,281</b>	<b>3,293</b>	<b>288</b>	<b>2,080</b>	<b>1,533</b>	<b>3,097</b>	<b>197</b>
<b>Total receivables from related parties</b>		<b>60,350</b>	<b>58,445</b>	<b>3,469</b>	<b>452</b>	<b>2,977</b>	<b>2,417</b>	<b>3,994</b>	<b>1,081</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

**Notes to the parent company and consolidated  
interim financial information**

**June 30, 2021**

**(All amounts in thousands of reais unless otherwise stated)**

Related parties	Relationship	Parent Company		Consolidated		Parent Company		Consolidated	
		Liabilities				Transacted amount			
		Jun/21	Dec/20	Jun/21	Dec/20	Jun/21	Jun/20	Jun/21	Jun/20
<b>Payables</b>									
Rentals <sup>(vi)</sup>									
Heliomar Ltda.	Stockholder/Board Member	25	26	25	26	78	122	78	122
Antonio Carlos Pipponzi	Stockholder/Board Member	8	8	8	8	26	48	26	48
Rosalia Pipponzi Raia	Stockholder/Board Member	8	8	8	8	26	48	26	48
Cristiana Almeida Pipponzi	Stockholder/Board Member	3	3	3	3	9	16	9	16
André Almeida Pipponzi	Stockholder/Board Member	3	3	3	3	9	16	9	16
Marta Almeida Pipponzi	Stockholder/Board Member	3	2	3	2	9	16	9	16
<b>Subtotal</b>		<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>157</b>	<b>266</b>	<b>157</b>	<b>266</b>
Service providers									
Zurcher, Ribeiro Filho, Pires Oliveira Dias e Freire Advogados <sup>(iv)</sup>	Stockholder/Family	-	1	-	1	966	2,725	966	2,725
Rodrigo Wright Pipponzi (Editora Mol Ltda.) <sup>(vii)</sup>	Stockholder/Family	1,093	923	1,093	923	3,436	4,809	3,436	4,809
Cfly Consultoria e Gestão Empresarial Ltda. <sup>(iii)</sup>	Family	278	195	278	195	323	1,157	323	1,157
Cristina Ribeiro Sobral Sarian (Anthea Consultoria Empresarial) <sup>(ix)</sup>	Stockholder/Alternate Board Member	-	49	-	49	-	250	-	250
Cesar Nivaldo Gon (CI&T IOT Comercio de HardWare e Software Ltda e CI&T Softwares S.A) <sup>(xi)</sup>	Stockholder/Board Member	11	-	11	-	32	-	32	-
Stix Fidelidade e Inteligência S.A. <sup>(ix)</sup>	Joint venture	2,335	-	2,335	-	-	-	-	-
<b>Subtotal</b>		<b>3,717</b>	<b>1,168</b>	<b>3,717</b>	<b>1,168</b>	<b>4,757</b>	<b>8,941</b>	<b>4,757</b>	<b>8,941</b>
Goods suppliers									
Natura Cosméticos S.A. <sup>(ii)</sup>	Stockholder/Related party	-	-	-	-	-	-	-	-
<b>Subtotal</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total payables to related parties</b>		<b>3,767</b>	<b>1,218</b>	<b>3,767</b>	<b>1,218</b>	<b>4,914</b>	<b>9,207</b>	<b>4,914</b>	<b>9,207</b>

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

Transactions with related parties, basically purchases and sales of products, were carried out at prices, terms and conditions usual in the market.

(i) Refer to sales made by agreements whose transactions are executed into under commercial conditions equivalent to those practiced with other companies.

(ii) Purchase and sale of Natura Cosméticos S.A.'s products, which will be sold across the national territory and Raia Drogasil will receive a percentage on the products sold. Some members of the controlling block of Natura Cosméticos S.A. indirectly own shares of Raia Drogasil.

(iii) Provision of services of aircraft operation to the owner Raia Drogasil S.A., which will pay the operator a monthly remuneration for the services of operational advisory, compliance, finance, maintenance coordination and maintenance technical control.

(iv) Transaction related to legal advisory.

(v) During 2016, 2017 and 2019 loan transactions between Raia Drogasil S.A. (Lender) and 4Bio Medicamentos S.A. (Borrower) were carried out in the amounts of R\$ 14,000, R\$ 20,100 and R\$ 12,000, respectively. All loan agreements are monetarily restated by 110% of the CDI, and mature in December 2021.

Other receivables comprises commissions on Raia Drogasil S.A. referrals (R\$ 343), recognized in "other receivables".

(vi) Transactions related to rental of commercial properties for the implementation of drugstores.

(vii) These balances and transactions relate to service agreements for the development, creation and production of marketing materials for the institutional sales area, and the design of the Company's internal magazine.

(viii) The balances and transactions refer to the agreement for provision of consulting services in the healthcare and sustainability sectors.

(ix) Transactions related to trade receivables and trade payables referring to the STIX points program.

(x) Transactions with loans between the subsidiary FIP RD Ventures (lender) and ZTO Tecnologia e Servicos de Informacao na Internet Ltda. (borrower) in monthly amounts of R\$ 300 for July/2020 and R\$ 675 for August, September, and December 2020 and January 2021, respectively.

(xi) Transactions related to IT information technology consulting services, being a contract entered into in March 2020 with CI&T Comércio de Hardware e Software Ltda. and another in November 2020 with CI&T Softwares S.A., with the object of consultancy for digital transformation and squads.

Moreover, we inform that there are no additional transactions other than the amounts presented above and that the category of the related parties corresponds to the entity's key management personnel.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### (b) Key management compensation

Key management includes the Officers, Directors and members of the Supervisory Board. The compensation paid or payable for services rendered is as follows:

Compensation items	Parent Company		Consolidated	
	Jun/21	Jun/20	Jun/21	Jun/20
Share-based payment	7,719	6,275	8,380	6,438
Bonuses and social charges	4,099	5,694	4,099	5,694
<b>Subtotal bonuses and social charges</b>	<b>11,818</b>	<b>11,969</b>	<b>12,479</b>	<b>12,132</b>
Fees and social charges	10,986	9,980	12,403	11,358
Fringe benefits	169	206	169	206
<b>Total</b>	<b>22,973</b>	<b>22,155</b>	<b>25,051</b>	<b>23,696</b>

The Company applied the requirements of NBC TG 05 (R3) - Related-Party Disclosures and also considered the guidance in CVM Circular Letter SNC/SEP 01/2021, observing qualitative aspects of related-party transaction, and concluded that there are no material impacts that require disclosure of additional information in the interim financial information.

## 26. Insurance coverage

The Company has adopted a policy of taking out insurance coverage at amounts deemed sufficient to cover any losses on assets or civil liability attributed to it taking into consideration the nature of its activities and the guidance of its insurance consultants.

The Group had the following insurance:

Insurance items	Parent Company		Consolidated	
	Jun/21	Dec/20	Jun/21	Dec/20
Inventory loss risks	307,616	382,074	335,364	454,152
Permanent assets	319,789	444,453	328,049	455,058
Loss of profits	64,837	63,020	218,827	166,333
Civil liability risks	38,424	38,424	40,000	40,000

## 27. Non-cash transactions

At June 30, 2021, the main transactions that did not involve the Group's cash were:

- (i) the restatement of the financial liability arising from payables to subsidiary's shareholder (Note 09);
- (ii) part of the compensation of key management personnel associated with the restricted share plan (Note 25);
- (iii) the installment purchase of property and equipment items in the amount of R\$ 10,825 (R\$ 14,258 - Dec/ 2020);
- (iv) recognition of lease liability with a balancing item in right-of-use asset, which additions of new agreements in the amount of R\$ 153,787 (R\$ 393,646 – Dec/2020), remeasurements of R\$ 310,102 (R\$ 388,146 – Dec/2020) and termination of agreements in the amount of (R\$ 7,489) (R\$ 43,671 – Dec/2020).

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Notes to the parent company and consolidated interim financial information

June 30, 2021

(All amounts in thousands of reais unless otherwise stated)

### 28. Events after the reporting period

#### (a) Acquisition of equity interest - Dr. Cuco Desenvolvimento de Software Ltda

On August 6, 2021, the Company entered into an agreement to acquire all the equity interest of Dr. Cuco Desenvolvimento de Software Ltda ("Dr. Cuco") for the amount of R\$ 15,000. Little adherence to the treatment prescribed by the doctors is considered as one of the main health problems all over the world, especially with regard to the asymptomatic chronic diseases. RD understands that the technology and expertise developed by Cuco will be crucial to support our customers in order to fully adhere to the treatment prescribed by the doctor. The acquisition of Cuco, therefore, is in line with RD's desire of becoming, until 2030, the group that most contributes to a healthier society in Brazil

The completion of the acquisition is subject to the fulfillment of some suspensive conditions, including the approval of the transaction by the Brazilian Antitrust Enforcement Agency ("CADE").

#### (b) Share buyback program

At the Board of Directors' meeting held on August 10, 2021, the acquisition of up to 3,000,000 (three million) common shares issued by the Company was authorized to be held in treasury and subsequently sold or cancelled, without capital reduction ("Buyback Program").

The purpose of the Buyback Program is to acquire shares issued by the Company to be held in treasury in order to meet (i) the Long-Term Incentive Program with Restricted Shares, approved at the Company's Extraordinary General Meeting held on April 23, 2014, (ii) the Restricted Shares Grant Plan ("Performance Shares") approved at the Company's Extraordinary General Meeting held on September 15, 2020 and (iii) the payment of any acquisitions of equity interests that may be made by the Company in operations of this nature. Share purchases may be carried out at B3 S.A. – Brasil, Bolsa, Balcão, for a period of up to eighteen months, as of August 20, 2021.



(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIÁ Drogasil S.A.

## Comments on business projection performance

---

In this section, pursuant to CVM Instruction 480/09, we compare the store opening projections for the Company with the data on drugstore openings actually conducted every year, until the end of the current year. The projections for 2016 and 2017 were disclosed to the market on July 28, 2016, the projections for 2018 and 2019 were disclosed on November 9, 2017, the projections for 2020 were disclosed on October 3, 2019 and the projections for 2021 and 2022 were disclosed on September 29, 2020.

<b>YEAR</b>	<b>PRIOR PROJECTION</b>	<b>CURRENT PROJECTION</b>	<b>ACTUAL ACCUMULATED</b>
2016	165 openings	200 openings	212 openings
2017	195 openings	200 openings	210 openings
2018		240 openings	240 openings
2019		240 openings	240 openings
2020		240 openings	240 openings
2021		240 openings	102 openings <sup>1</sup>
2022		240 openings	

<sup>1</sup> For 2021, accumulated up to 6/30/2021.

On July 28, 2016, we revised the prior projection of 165 openings in 2016 and 195 openings in 2017 to 200 drugstore openings for both years. The Company has ended 2020 with 240 store openings and reiterates the projections of 240 openings per year for 2021 and 2022.

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

## **Report on special review - without exceptions**

---

**A free translation from Portuguese into English of Independent Auditor's Review Report on Individual and Consolidated Interim Financial Information prepared in Brazilian currency in accordance with the rules issued by Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information Form (ITR)**

---

## **Independent auditor's report on review of interim financial statements**

The Shareholders and Officers

**Raia Drogasil S.A.**

São Paulo – SP

### **Introduction**

We have reviewed the accompanying individual and consolidated interim financial information of Raia Drogasil S.A. ("Company"), contained in the Quarterly Information Form (ITR) for the quarter ended June 30, 2021, comprising the statement of financial position as of June 30, 2021 and the related statements of profit or loss and of comprehensive income for the three and six-month periods the ended, and of changes in equity and cash flows for the six-month period then ended, including the explanatory notes.

Management is responsible for preparation of the individual and consolidated interim financial information in accordance with Accounting Pronouncement NBC TG 21 – Interim Financial Reporting, and IAS 34 – Interim Financial Reporting, issued by the Federal Accounting Counsel ("CFC") and International Accounting Standards Board (IASB), respectively, as well as for the fair presentation of this information in conformity with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of the Quarterly Information Form (ITR). Our responsibility is to express a conclusion on this individual and consolidated interim financial information based on our review.

### **Scope of review**

We conducted our review in accordance with Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion on the individual and consolidated interim financial information**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual and consolidated interim financial information included in the Quarterly Information Form referred to above was not prepared, in all material respects, in accordance with NBC TG 21 and IAS 34 applicable to the preparation of Quarterly Information Form (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).

### **Other matters**

#### *Statements of value added*

The abovementioned quarterly information includes the individual and consolidated statements of value added (SVA) for the six-month period ended June 30, 2021, prepared under Company's Management responsibility

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 6/30/2021 - RAIA Drogasil S.A.

**Report on special review - without exceptions**

---

and presented as supplementary information by IAS 34. These statements have been subject to review procedures performed together with the review of the quarterly information with the objective to conclude whether they are reconciled to the interim financial information and the accounting records, as applicable, and if its format and content are in accordance with the criteria set forth by NBC TG 09 – Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that they were not prepared, in all material respects, consistently with the overall individual and consolidated interim financial information.

São Paulo, August 10, 2021.

ERNST & YOUNG  
Auditores Independentes S.S.  
CRC-2SP034519/O-6

Patricia Nakano Ferreira  
Accountant CRC-1SP234620/O-4

---

To the Board of Directors and Stockholders

Raia Drogasil S.A.

The Company's Supervisory Board, in exercising its duties and legal responsibilities, has examined the Quarterly Information (ITR) for the quarter ended June 30, 2021 and, based on the examinations performed and on clarifications provided by management, and also considering the favorable Report on Special Review without exceptions, issued by the independent auditor Ernst & Young Auditores Independentes, the Supervisory Board members concluded that the documents above are fairly presented, in all material respects.

São Paulo, August 10, 2021.

---

Gilberto Lério  
Supervisory Board Member

---

Mário Antonio Luiz Corrêa  
Supervisory Board Member

---

Paulo Sérgio Buzaid Tohmé  
Supervisory Board Member

---

Antônio Edson Maciel dos Santos  
Supervisory Board Member

**Officers' representation on quarterly information  
June 30, 2021**

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the Quarterly Information (ITR) for the quarter ended June 30, 2021.

São Paulo, August 10, 2021.

---

Marcilio D'Amico Pousada  
Chief Executive Officer

---

Eugênio De Zagottis  
Officer

---

Antonio Carlos Coelho  
Officer and Technical Responsible  
CRC 1SP166428/O-9

---

Marcello De Zagottis  
Officer

---

Fernando Kozel Varela  
Officer

---

Renato Cepollina Raduan  
Officer

---

Maria Susana de Souza  
Officer

---

Bruno Wright Pipponzi  
Officer

(A free translation of the original in Portuguese)

Quarterly information (ITR) - 3/31/2021- RAIA Drogasil S.A.

### **Opinions and Representations / Officers' Representation on Independent Auditor's Report**

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the conclusions expressed in the favorable Special Review Report without exceptions issued by the independent auditors for the quarter ended June 30, 2021.

São Paulo, August 10, 2021.

---

Marcilio D'Amico Pousada  
Chief Executive Officer

---

Eugênio De Zagottis  
Officer

---

Antonio Carlos Coelho  
Officer and Technical Responsible  
CRC 1SP166428/O-9

---

Marcello De Zagottis  
Officer

---

Fernando Kozel Varela  
Officer

---

Renato Cepollina Raduan  
Officer

---

Maria Susana de Souza  
Officer

---

Bruno Wright Pipponzi  
Officer